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Abstract: Zusammenfassung Multiple Sklerose (MS) ist eine Autoimmunerkrankung des zentralen Ner-
vensystems (ZNS). Untersuchungen des Mausmodells für MS, namentlich Experimentelle autoimmune
Enzephalomyelitis (EAE), konnten zeigen, dass autoreaktive CD4+ T-Zellen eine herausragende Rolle
in der Entwicklung von EAE spielen. Jedoch ist bisher unklar, ob Selbstantigene des Myelins über den
klassischen MHC Klasse II Prozessierungsweg, Autophagie oder LC3-assoziierte Phagozytose (LAP) de-
gradiert und gegenüber CD4+ T-Zellen präsentiert werden. Mit Bezug auf LAP konnte gezeigt werden,
dass extrazelluläres Material über diesen Weg abgebaut werden kann und zudem nimmt die Anzahl von
LC3+ Vesikeln in Microglia-Zellen am Höhepunkt der EAE zu. Basierend auf diesen Daten haben wir
angenommen, dass die Präsentation von Autoantigenen durch LAP die Aktivierung von autoreaktiven
T-Zellen unterstützt. Um diese Hypothese zu bestätigen, haben wir den Einfluss von Atg5-Defizienz in
CD11c+ Zellen auf die Entwicklung der EAE untersucht. Wir haben gezeigt, dass die Defizienz von
Atg5 in CD11c+ Zellen keine Rolle bei der Entwicklung von aktiver EAE spielt und dass dieses Ergeb-
nis davon unabhängig ist, ob MOG-Peptid oder MOG-Protein zur Induktion der Krankheit verwendet
worden ist. Überraschenderweise resultierte die Induktion der adoptiven Transfer-EAE darin, dass EAE-
Symptome in Atg5-defizienten Mäusen nahezu abwesend waren, während Atg5-Kontroll Mäuse normale
EAE-Symptome entwickelt haben. Um diese gegensätzlichen Ergebnisse besser verstehen zu können,
wurden MOG-spezifische T-Zellen mit primären Atg5+ oder Atg5- CD11c+ Zellen, in der Gegenwart
von MOG-Peptid, MOG-Protein oder Kugeln, welche mit MOG-Protein beschichtet waren, co-kultiviert.
Hierbei ergab die Messung der Proliferation von T-Zellen, dass T Zellen in der Gegenwart von Atg5-
CD11c+ Zellen mehr proliferieren als in der Gegenwart von Atg5+ CD11c+ Zellen. Um die Antigen-
präsentation weitergehend zu untersuchen, wurden sowohl Atg5+ als auch Atg5- BM-DCs generiert, die
mit Kugeln inkubiert wurden, welche MOG-Protein, Pam3CSK4 oder MOG-Protein plus Pam3CSK4
beschichtet waren. Bei diesen Untersuchungen konnten keine LC3-assoziierten Phagosomen erkannt wer-
den und somit keine Rückschlüsse über die Rolle von LAP während der Prozessierung von extrazel-
lulären Autoantigenen gezogen werden. Weitere in vitro und in vivo Experimente werden notwendig
sein, um die unterschiedlichen Ergebnisse in der aktiven und adoptiven Transfer-EAE erklären zu kön-
nen. Zum einen müssten die T-Zell- und Antigenpräsentierende Zellinfiltrate in das ZNS am Höhepunkt
der Krankheit untersucht werden. Diese Untersuchungen könnten darüber Aufschluss geben, welche
Zellen das ZNS infiltrieren und welche Effektorfunktionen diese besitzen. Darüber hinaus könnte der
Antigenprozessierungsweg untersucht werden, indem LAP durch bekannte Faktoren, wie beispielsweise
TLR-Stimulierung, FcR-Bindung oder mit der Verwendung von “eat me” Signalen, ausgelöst wird. Alle
Experimente zusammengenommen, könnten somit neue Einblicke dahin gehend ermöglichen, über welchen
Prozessierungsweg extrazelluläre Autoantigene verarbeitet werden und wie CD4+ autoreaktive T-Zellen
dazu aktiviert werden, EAE oder MS zu induzieren. Summary Multiple sclerosis (MS) is an autoimmune
disease of the central nervous system (CNS). The commonly used mouse model for MS, namely experi-
mental autoimmune encephalomyelitis (EAE), revealed that the main driving forces in the development
of EAE are autoreactive CD4+ T cells. The exact antigen processing route of how myelin self-antigens
are processed and presented has not been described yet and the classical MHC class II pathway, the
autophagy pathway and LC3- associated phagocytosis (LAP) are potential degradation pathways that
might lead to MHC class II presentation of myelin antigen. It has recently been shown that extracellular
material can be degraded by LAP and previous studies of our laboratory indicate that the presence of
LC3+ vesicles in microglia increases at the peak of EAE. Based on these data, we hypothesized that
LAP-dependent presentation of autoantigens facilitates the activation of autoreactive T cells. To address
this question, we investigated whether autophagy deficiency in CD11c+ cells influences the development
of EAE. We demonstrated that Atg5-deficiency in CD11c+ cells does not play a role in active EAE,
neither triggered by MOG peptide nor MOG protein. Surprisingly, induction of adoptive transfer EAE
via the adoptive transfer of autoreactive CD4+ T cells resulted in the almost complete absence of EAE
symptoms in Atg5-deficient mice whereas Atg5 control mice developed EAE symptoms. In order to better
understand these findings, in vitro experiments to study the role of Atg5 in antigen presentation were per-
formed. A co-culture experiment in which MOG peptide-specific T cell receptor transgenic T cells from
2D2 mice were co-cultured with splenic Atg5+ or Atg5- CD11c+ cells in the presence of MOG peptide,
MOG protein or beads coated with MOG protein was performed. Checking for T cell proliferation, it
was shown that T cells in the presence of Atg5- CD11c+ proliferated more than in the presence of Atg5+
CD11c+ cells. In an alternative approach to investigate antigen processing pathways in antigen present-
ing cells (APCs), bone marrow-derived dendritic cells (BM-DCs) were generated from Atg5-deficient and
Atg5 control mice and incubated with beads coated with MOG protein, the TLR agonist Pam3CSK4
or MOG protein with Pam3CSK4. Screening for LC3+ vesicles that might be an indication for LAP,
did not yield any unambigous LC3- associated phagosomes. Conclusively, further in vitro and in vivo
investigations are necessary to identify the mechanism that leads to the absence of EAE symptoms in
Atg5-deficient mice in adoptive transfer EAE, but not in active EAE. Firstly, T cell and APC infiltrates
into the CNS at peak of disease need to be examined. These experiments would offer valuable clues
which cells infiltrate and which effector functions they fulfill. With regard to in vitro studies, antigen
processing and presentation characteristics could be studied by inducing LAP by known factors such as
TLR stimulation, Fc receptor (FcR) engagement or “eat me” signals. In conclusions, our findings would
give newly insights of how extracellular self-antigen is processed and how CD4+ autoreactive T cells are
triggered to induce EAE, or even MS.
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Zusammenfassung 
 
 1 
Zusammenfassung 
Multiple Sklerose (MS) ist eine Autoimmunerkrankung des zentralen Nervensystems (ZNS). 
Untersuchungen des Mausmodells für MS, namentlich Experimentelle autoimmune 
Enzephalomyelitis (EAE), konnten zeigen, dass autoreaktive CD4+ T-Zellen eine herausragende 
Rolle in der Entwicklung von EAE spielen. Jedoch ist bisher unklar, ob Selbstantigene des Myelins  
über den klassischen MHC Klasse II Prozessierungsweg, Autophagie oder LC3-assoziierte 
Phagozytose (LAP) degradiert und gegenüber CD4+ T-Zellen präsentiert werden. Mit Bezug auf 
LAP konnte gezeigt werden, dass extrazelluläres Material über diesen Weg abgebaut werden kann 
und zudem nimmt die Anzahl von LC3+ Vesikeln in Microglia-Zellen am Höhepunkt der EAE zu. 
Basierend auf diesen Daten haben wir angenommen, dass die Präsentation von Autoantigenen durch 
LAP die Aktivierung von autoreaktiven T-Zellen unterstützt. 
Um diese Hypothese zu bestätigen, haben wir den Einfluss von Atg5-Defizienz in CD11c+ Zellen 
auf die Entwicklung der EAE untersucht. Wir haben gezeigt, dass die Defizienz von Atg5 in 
CD11c+ Zellen keine Rolle bei der Entwicklung von aktiver EAE spielt und dass dieses Ergebnis 
davon unabhängig ist, ob MOG-Peptid oder MOG-Protein zur Induktion der Krankheit verwendet 
worden ist. Überraschenderweise resultierte die Induktion der adoptiven Transfer-EAE darin, dass 
EAE- Symptome in Atg5-defizienten Mäusen nahezu abwesend waren, während Atg5-Kontroll 
Mäuse normale EAE-Symptome entwickelt haben. Um diese gegensätzlichen Ergebnisse besser 
verstehen zu können, wurden MOG-spezifische T-Zellen mit primären Atg5+ oder Atg5- CD11c+ 
Zellen, in der Gegenwart von MOG-Peptid, MOG-Protein oder Kugeln, welche mit MOG-Protein 
beschichtet waren, co-kultiviert. Hierbei ergab die Messung der Proliferation von T-Zellen, dass T 
Zellen in der Gegenwart von Atg5- CD11c+ Zellen mehr proliferieren als in der Gegenwart von 
Atg5+ CD11c+ Zellen. Um die Antigenpräsentation weitergehend zu untersuchen, wurden sowohl 
Atg5+ als auch Atg5- BM-DCs generiert, die mit Kugeln inkubiert wurden, welche MOG-Protein, 
Pam3CSK4 oder MOG-Protein plus Pam3CSK4 beschichtet waren. Bei diesen Untersuchungen 
konnten keine LC3-assoziierten Phagosomen erkannt werden und somit keine Rückschlüsse über 
die Rolle von LAP während der Prozessierung von extrazellulären Autoantigenen gezogen werden. 
Weitere in vitro und in vivo Experimente werden notwendig sein, um die unterschiedlichen 
Ergebnisse in der aktiven und adoptiven Transfer-EAE erklären zu können. Zum einen müssten die 
T-Zell- und Antigenpräsentierende Zellinfiltrate in das ZNS am Höhepunkt der Krankheit 
untersucht werden. Diese Untersuchungen könnten darüber Aufschluss geben, welche Zellen das 
ZNS infiltrieren und welche Effektorfunktionen diese besitzen. Darüber hinaus könnte der 
Antigenprozessierungsweg untersucht werden, indem LAP durch bekannte Faktoren, wie 
beispielsweise TLR-Stimulierung, FcR-Bindung oder mit der Verwendung von “eat me” Signalen, 
ausgelöst wird. Alle Experimente zusammengenommen, könnten somit neue Einblicke dahin 
gehend ermöglichen, über welchen Prozessierungsweg extrazelluläre Autoantigene verarbeitet 
werden und wie CD4+ autoreaktive T-Zellen dazu aktiviert werden, EAE oder MS zu induzieren. 
Summary 
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Summary 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). The 
commonly used mouse model for MS, namely experimental autoimmune encephalomyelitis (EAE), 
revealed that the main driving forces in the development of EAE are autoreactive CD4+ T cells. 
The exact antigen processing route of how myelin self-antigens are processed and presented has not 
been described yet and the classical MHC class II pathway, the autophagy pathway and LC3-
associated phagocytosis (LAP) are potential degradation pathways that might lead to MHC class II 
presentation of myelin antigen. It has recently been shown that extracellular material can be 
degraded by LAP and previous studies of our laboratory indicate that the presence of LC3+ vesicles 
in microglia increases at the peak of EAE. Based on these data, we hypothesized that LAP-
dependent presentation of autoantigens facilitates the activation of autoreactive T cells. 
To address this question, we investigated whether autophagy deficiency in CD11c+ cells influences 
the development of EAE. We demonstrated that Atg5-deficiency in CD11c+ cells does not play a 
role in active EAE, neither triggered by MOG peptide nor MOG protein. Surprisingly, induction of 
adoptive transfer EAE via the adoptive transfer of autoreactive CD4+ T cells resulted in the almost 
complete absence of EAE symptoms in Atg5-deficient mice whereas Atg5 control mice developed 
EAE symptoms. In order to better understand these findings, in vitro experiments to study the role 
of Atg5 in antigen presentation were performed. A co-culture experiment in which MOG peptide-
specific T cell receptor transgenic T cells from 2D2 mice were co-cultured with splenic Atg5+ or 
Atg5- CD11c+ cells in the presence of MOG peptide, MOG protein or beads coated with MOG 
protein was performed. Checking for T cell proliferation, it was shown that T cells in the presence 
of Atg5- CD11c+ proliferated more than in the presence of Atg5+ CD11c+ cells. In an alternative 
approach to investigate antigen processing pathways in antigen presenting cells (APCs), bone 
marrow-derived dendritic cells (BM-DCs) were generated from Atg5-deficient and Atg5 control 
mice and incubated with beads coated with MOG protein, the TLR agonist Pam3CSK4 or MOG 
protein with Pam3CSK4. Screening for LC3+ vesicles that might be an indication for LAP, did not 
yield any unambigous LC3-associated phagosomes. 
Conclusively, further in vitro and in vivo investigations are necessary to identify the mechanism that 
leads to the absence of EAE symptoms in Atg5-deficient mice in adoptive transfer EAE, but not in 
active EAE. Firstly, T cell and APC infiltrates into the CNS at peak of disease need to be examined. 
These experiments would offer valuable clues which cells infiltrate and which effector functions 
they fulfill. With regard to in vitro studies, antigen processing and presentation characteristics could 
be studied by inducing LAP by known factors such as TLR stimulation, Fc receptor (FcR) 
engagement or “eat me” signals. 
In conclusions, our findings would give newly insights of how extracellular self-antigen is 
processed and how CD4+ autoreactive T cells are triggered to induce EAE, or even MS. 
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1 Introduction 
1.1 The Immune System 
The body harbours a plethora of diverse effector cells and molecules that function in the body’s 
defence against pathogens and other exogenous factors that might cause damage to their host. The 
entire system consisting of effector cells and molecules is called the immune system. Immunity 
describes the capability of the body to protect itself against these exogenous and damaging factors. 
The immune system can be divided into two arms: the innate and adaptive immune system. The 
innate immune system is defined as the „first line of defense“ and is mainly based on physical 
barriers, such as the skin, toxic molecules and phagocytic cells that phagogcytose and eliminate the 
pathogenic invader. The innate immune response is initiated immediately after an infection and acts 
in response to molecular patterns, which are found in pathogens or indicate cell damage. 
Nevertheless, it is irreplaceable to instruct the adaptive immune response. The adaptive immune 
system, on the other hand, is highly specific against exogenous pathogenic factors and does own 
„memory“ functions. This memory function allows the immune system to respond faster and more 
efficiently when encountering a thread for a second time. Generally, a substance that is able to 
generate an adaptive immune response is named antigen (antibody generating) (term coined by Paul 
Ehrlich around 1900). 
The adaptive immune response is executed by a class of leukocytes called lymphocytes and one 
distinguishes humoral (antibody-mediated) and cellular immune responses, which are mediated by 
two classes of lymphocytes, namely B cells and T cells, respectively. During the humoral immune 
response, B cells recognize an antigen by means of their B cell receptor (BCR) that leads to the 
activation of the B cell and, eventually, to the release of antibodies into extracellular fluids such as 
blood, tear fluid or breast milk. While circulating, antibodies bind their specific antigen, which 
originally caused the release of this antibody. The binding of the antibody to the antigen might 
result in the neutralization or inactivation of the antigen by binding to structures that otherwise 
might interact with cell surface structures of the host. Additionally, the antibody binding might 
initiate the destruction of the invader since it facilitates the uptake of it by cells of the innate 
immune system. 
The main players of the cellular immune system are lymphocytes called T cells that develop in the 
thymus, which is a lymphoepithelial organ. T cells recognize their specific antigen with a T cell 
receptor (TCR) and can be further subdivided into cytotoxic T cell lymphocytes (CTL) and T helper 
(Th) cells. Based on their unique expression of the co-receptor molecules CD8 and CD4, CTLs are 
also known as CD8+ T cells and Th cells as CD4+ T cells, respectively. CD8+ T cells have the 
capability to kill cancer cells, infected cells or otherwise defect cells in order to maintain integrity of 
the host. On the other hand, once CD4+ T cells recognize an antigen, they secrete high amounts of 
inflammatory cytokines in order to activate B cells and macrophages and, hence, destroy the 
Introduction 
 
 4 
invading pathogen. As mentioned above, T cells recognize their antigen by a TCR. In order to do 
so, the antigen needs to be presented by an antigen presenting molecule named major 
histocompatibility (MHC) molecule that is present on antigen presenting cells (APCs). 
An APC is a cell type that is able to process protein antigens and dissect them into small peptide 
fragments. These antigenic fragments are bound to MHC molecules and displayed as a 
peptide:MHC complex on the cell surface. The peptide:MHC complex is recognized by T cells by 
means of their TCR and this interaction leads to the activation of the T cell. 
Principally, there are two different types of MHC molecules, namely, MHC class I and class II 
molecules. MHC class I molecules are present on most nucleated cells and present peptides from 
cytosolic proteins to CD8+ T cells. On the other hand, MHC class II molecules bind peptides that 
are derived from extracellular material and are recognized by CD4+ T cells. MHC class II molecules 
are mainly restricted to dendritic cells (DCs), macrophages and B cells which form the group of 
professional APCs. Professional APCs are most efficient in uptake, processing and presenting of 
exogenous antigen and constitutively express MHC class II molecules. The expression of co-
stimulatory molecules is another feature that defines professional APCs. Contrary, non-professional 
APCs are less efficient in antigen uptake and processing and do not constitutively present MHC 
class II molecules, but their expression can be triggered by cytokine stimulation. The group of non-
professional APCs includes the following cells: fibroblasts, thymic epithelial cells, glial cells, 
pancreatic β-cells and vascular endothelial cells. 
The close interaction between the innate and adaptive immune system and the resulting immune 
response with cytokine secretion, antigen capture and presentation as well as pathogen elimination 
ensures the durability and survival of the host. 
 
1.2 Autoimmunity 
Autoimmunity is described as an immune reaction that is directed against antigens that originated 
from or produced by the host – so-called self-antigens. Thus, in the case of autoimmunity, the 
body’s own immune system is not able to distinguish between self and non-self-antigens. This 
disequilibrium might lead to a strong immune response against various host tissues mediated via 
self-molecules. This, in turn, might cause severe damage of the affected organ possibly instigating 
the manifestation of an autoimmune disease. 
 
1.2.1 Autoimmune Diseases 
Autoimmune diseases are caused by an immune reaction against self-antigens and might lead to 
severe tissue damage of the affected organ. Amongst the most prevalent autoimmune diseases are 
systemic lupus erythematosus (SLE), type 1 diabetes mellitus and rheumatoid arthritis (RA) as well 
as multiple sclerosis (MS). Briefly, in SLE autoantibodies and autoreactive T cells target self-DNA, 
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chromatin-associated proteins and ubiquitous ribonucleoproteins resulting in phenotypes such as 
glomerulonephritis, vasculitis or skin rash (Teresa Bailey et al., 2011). In type 1 diabetes mellitus 
the body produces autoreactive T cells against antigens of the pancreatic islets which results in the 
destruction of insulin-producing pancreatic β-cells and, thus, in depletion of this hormon (Atkinson, 
2012). A third example for an autoimmune disease is RA during which autoreactive T cells against 
the capsule around the joints (synovium) are formed. This results in an inflammation and 
destruction of joints and, finally, in arthritis (Imboden, 2009). In MS, autoreactive T and B cells are 
directed against self-antigens of the central nervous system (CNS). Sclerotic plaques are formed and 
the myelin layer around the axons is disrupted which leads to loss of myelin and scarring. 
Clinically, patients may present variable symptoms dependent on the locations of the lesions within 
the CNS. Typical manifestations include loss of sensitivity or alteration in sensation, muscle 
weakness, very pronounced reflexes, muscle spasms, or difficulties with coordination and balance 
(ataxia) (Sospedra and Martin, 2005). 
 
1.2.2 Origin and Causes of Autoimmunity 
The immune system comprises a diversity of different effector mechanisms to eliminate a wide 
range of pathogens and it is, under physiological conditions, able to distinguish between self and 
non-self antigens. In order to develop such a self-tolerance, the immune system needs to 
discriminate autoreactive from non-autoreactive lymphocytes. Principally, there are two 
mechanisms that lead to self-tolerance: central and peripheral tolerance. 
 
1.2.2.1  Principle Mechanisms of Central Tolerance 
Central tolerance develops in the thymus via negative selection and subsequent deletion of 
thymocytes that recognize self-antigen. The process of negative selection takes place during the 
entire development of lymphocytes and is located to the cortex and medulla of the thymus. Thymic 
epithelial cells express and present self-antigens on their cell surface. Alternatively, self-antigen is 
transported to the thymus where local APCs process and present these self-antigens for the 
aforementioned selection process. A developing lymphocyte that recognizes a self-peptide:MHC 
complex with its TCR too strongly will be eliminated by programmed cell death (apoptosis). The 
deletion of a T cell that is reactive to a self-peptide:MHC complex thereby decreases the likelihood 
of releasing an autoreactive T cell into the periphery, where it might cause damage by being 
activated (Hogquist et al., 2005). 
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1.2.2.2  Principle Mechanisms of Peripheral Tolerance 
Autoreactive lymphocytes can be eliminated during the process of central tolerance as elucidated 
above. If self-antigens are neither produced nor transported to the primary lymphoid organs or the 
process of central tolerance was incomplete, self-reactive lymphocytes need to be kept in check by 
peripheral tolerance. Freshly matured self-reactive lymphocytes that leave the primary lymphoid 
organs and might encounter their self-antigen will be eliminated. The main three mechanisms of 
inducing peripheral tolerance are: cell death by apoptosis, inducing an anergic state of the 
lymphocytes that renders them unresponsive to self-peptide:MHC complexes or suppression by 
regulatory T cells (Treg). Tregs comprise a subset of CD4+ T cells their main function being to 
suppress the activation of an immune response, regulation of lymphocyte homeostasis and induction 
of immune tolerance by, among other mechanisms, the secretion of interleukin (IL)-10, 
transforming growth factor (TGF)-β and IL-35 (Walker and Abbas, 2002). 
Next to these regulatory cell functions, morphological characteristics, namely immunological 
privileged areas in the body that cannot be accessed by immune cells, contribute to the reduction of 
autoimmunity. Sites of immune privilege are not drained by the lymphatic system and include for 
example the brain and the eye (Wekerle and Sun, 2010). 
 
1.2.2.3  Triggers of Autoimmune Diseases 
Autoimmune diseases are rather complex and various mechanisms have been described for the 
development of the disorders. Accordingly, a wide range of triggers that are potential causes of 
autoimmune diseases are currently under discussion. Genetic as well as environmental factors may 
contribute to the pathogenesis of autoimmune diseases and are explained by using the example of 
MS in the following section. 
 
1.2.3 Multiple Sclerosis 
MS is a demyelinating autoimmune disorder that mainly affects young adults. The name of this 
disease is attributed to the fact that hard (sclerotic) lesions are formed in the white matter of the 
brain. As a neurological disease that is characterized by local demyelination in the CNS, MS is 
believed to be an autoimmune reaction against various antigens of the myelin sheath that surrounds 
the axon. Typical brain antigens affected are myelin basic protein (MBP), proteolipid protein (PLP) 
and myelin oligodendrocyte glycoprotein (MOG). The immune response results in severe damage 
of the myelin sheath and, based on this damage, electrical signals cannot be conducted properly 
anymore and the affected conductivity might result in a variety of neurological symptoms (Sospedra 
and Martin, 2005). 
Depending on the course of disease, MS can be classified into two main categories: relapsing 
remitting and primary progressive MS. Relapsing remitting MS is defined as the occurrence of 
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exacerbating symptoms and complete remission of symptoms and can result in a relatively mild 
degree of disability. This type of MS eventually develops into secondary progressive MS that is 
defined by changing from a relapsing and remitting disease course into a steady and gradual 
worsening of disease symptoms. This shift in symptoms typically appears 15 to 20 years after first 
being diagnosed with MS. On the other hand, primary progressive MS is characterized by lack of 
remission and a continuous progression of disability (Lublin and Reingold, 1996). 
 
1.2.3.1  Etiology of MS 
The exact etiology of MS is still unknown, but there is evidence that the underlying cause of the 
condition is based on immunopathogenic processes and that both genetic and environmental factors 
contribute to the pathogenesis of MS. An interrelationship of both factors is likely. 
 
Genetic Predisposition and Hereditary Factors 
With regard to the cause of MS, some individuals show a clear genetic predisposition. Amongst all 
genes that are associated with a higher susceptibility to autoimmune diseases, the human leukocyte 
antigen (HLA) haplotype is known to confer the highest genetic risk in developing MS. The 
strongest genetic risk factor is the HLA-DRB1*1501 allele (Schmidt et al., 2007). Additionally, 
other HLA-DRB1 alleles, namely DR3 (DRB1*0301) and DR4 (DRB1*0405, DQA1*0301 and 
DQB1*0302) are associated with a relative higher risk rate of roughly threefold in heterozygous 
individuals and an elevated risk rate by sixfold in homozygous individuals (Ascherio et al., 2012). 
The correlation between the HLA haplotype and MS can be explained by use of the two following 
models. Firstly, the susceptibility to an autoimmune disease is dependent on the efficiency of the 
MHC molecule to present an autoantigen to an autoreactive T cell. This means in turn that a 
defective MHC molecule might have the ability to present self-antigens in a superior way and, thus, 
might lead to the unintended activation of autoreactive T cells. Secondly, the correlation between 
the MHC haplotype and the susceptibility to autoimmune diseases might go back to the role of 
MHC molecules in the establishment of the TCR repertoire. According to this hypothesis, during 
the process of negative selection, MHC molecules loaded with self-antigen might promote the 
positive selection of self-reactive thymocytes instead of inducing their elimination. Association to 
MHC class I alleles (Cree et al., 2010) and other non-MHC regions have been also described 
(International Multiple Sclerosis Genetics Consortium (IMSGC) et al., 2013), but are less well 
defined. 
The search for other, unrelated HLA haplotype genes that may confer the risk of MS is ongoing. 
The gene CYP27B1 that encodes for 25-hydroxyvitamin D-1α hydroxlyase has been associated 
with an increase in risk to develop MS (Ramagopalan et al., 2011). And based on further genetic 
approaches, such as genome-wide association studies and genome projects, more MS susceptibility 
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loci have been identified. These loci include, amongst others, IL-2 receptor α, IL-7 receptor α, 
CLEC16A, IRF8, IL12A and others (Qiu et al., 2013). 
In parallel, demographic studies have shown that women show a higher risk of developing 
autoimmunity than men (Voskuhl and Gold, 2012). Furthermore, a high degree of heritability of 
autoimmune disease was established in studies of twins and siblings and it was shown that the risk 
of suffering from MS is lower in Hispanic, black and Asian populations than in Caucasian 
populations (Wallin et al., 2004). 
 
Geographical and Environmental Factors 
The geographical distribution of autoimmune diseases shows a regular pattern with regard to 
continents, countries and ethnic groups in that the incidence of MS decreases form north to south in 
the northern hemisphere and the opposite way around in the southern hemisphere (so-called latitude 
gradient) (Acheson et al., 1960). This is in line with studies that showed that autoimmunity is less 
common in developing countries than in industrial countries. Deeper insights into genetics and 
environmental factors were gained by immigration studies. In these studies the movement of people 
from areas where MS is very common to areas where it is less common and vice versa were 
conducted (Gale and Martyn, 1995). The tracking of migration of people from high MS risk to low 
MS risk regions revealed that the risk of suffering from MS decreases the younger the age of the 
migrant.  This relation suggests a connection between MS risk and environmental factors (Gale and 
Martyn, 1995; McLeod et al., 2011). Additional epidemiological and clinical studies have revealed 
that there is a negative correlation between the occurrence of certain infections in early childhood, 
the socio-economic status and the development MS. This correlation is described by the hygiene 
hypothesis (Bach, 2002). 
Another environmental factor that contributes to MS is the level of vitamin D and the amount of sun 
light exposure. In this context, a negative correlation between vitamin D level and MS incidence 
was shown (van der Mei et al., 2001). Furthermore, smoking of cigarettes increases the risk of 
suffering from MS enormously when comparing ever smokers to never smokers (Hernán et al., 
2005; Riise et al., 2003; Sundström et al., 2008). All these environmental factors were also 
reviewed by (Ascherio and Munger, 2007; Milo and Kahana, 2010; Shapira et al., 2010). 
 
Pathogenic Factors that Contribute to MS 
The role of infectious and viral triggers in MS etiology and pathology is still under debate. But there 
are studies that describe the connection between pathogens and MS and which try to explain how 
infections might trigger autoimmune responses in MS. Viruses that have been described to be 
associated with MS are: Herpesviruses such as Varicalle-zoster virus (VZV), human herpesvirus-6 
(HHV-6) and Epstein-Barr virus (EBV) as well as the human endogenous retroviruses (HERVs) 
(Kakalacheva et al., 2011). 
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Amongst all viruses being described to be associated with triggering MS, EBV is the most 
promising candidate. EBV is an orally transmitted virus (“kissing disease”) and immediately infects 
the recipient. While EBV infection of children is generally asymptomatic, EBV infection during 
adolescence or adulthood often results in the clinical illness infectious mononucleosis (IM) that is 
characterized by fever, lymphadenopathy, pharyngitis and fatigue. Epidemiological studies have 
linked symptomatic infectious mononucleosis and MS and associated EBV infection with the 
development of MS. This assumption is based on results showing a strong interconnection between 
infectious mononucleosis and MS with regard to age, geographical location and socioeconomic 
status. Furthermore, an elevated serum level of antibodies against a mixture of EBV nuclear 
antigens was associated with an increased risk for developing MS (Ascherio and Munger, 2010; 
Kakalacheva et al., 2011). 
Potential molecular mechanisms of how pathogens might induce autoimmunity include: bystander 
activation, adjuvant effect, superantigen activation, molecular mimicry, epitope spreading and viral 
support of autoreactive cell survival and are illustrated in Figure 1.1. 
 
 
 
Figure 1.1: Molecular mechanisms of pathogen-induced autoimmunity. (A) bystander activation, (B) adjuvant effect, 
(C) superantigen activation, (D) molecular mimicry, (E) epitope spreading and (F) viral support of autoreactive cell 
survival. Figure from (Kakalacheva et al., 2011). 
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Bystander activation of autoreactive lymphocytes is facilitated via infectious factors (Figure 1.1A). 
During the process of an infection, an immune response is caused that leads to the release of 
immune mediators and co-stimulatory molecules. These inflammatory conditions might influence 
noninvolved lymphocytes (so-called bystanders) that are not antigen specific. Especially under 
conditions when tissue is affected and destroyed, a high number of self-antigen is released and 
presented by APCs to self-reactive lymphocytes that are then activated in a so-called bystander 
activation process (Fujinami et al., 2006; McCoy et al., 2006). 
Another aspect of how autoreactive lymphocytes could be activated is the adjuvant effect (Figure 
1.1B). Generally, the activation of APCs by binding of pathogen associated molecular patterns 
(PAMPs) by pattern recognition receptors (PRRs) leads to the activation of APCs and the release of 
pro-inflammatory mediators. If an autoreactive T cell interacts with a self-peptide:MHC molecule 
simultaneously, the inflammatory mediators might function as an adjuvant and might lead to the 
activation of these autoreactive T cells. 
Furthermore, superantigens might play a role in the development of autoimmunity (Figure 1.1C). A 
superantigen is an antigen that can direct the binding of an MHC class II molecule to a TCR by 
binding to non-polymorphic regions of the MHC class II molecule and the conserved regions of the 
TCR Vβ domain without a specifically bound peptide. This event results in the crosslinking of those 
two molecules and, potentially, to the unspecific activation of T cells. In this context, one of the 
best-known superantigens is staphylococcal enterotoxin (Brocke et al., 1993). 
Another mechanism of pathogen-induced immunity is termed molecular mimicry (Figure 1.1D). 
Pathogens express proteins or carbohydrates that resemble the host’s own structures. Under 
inflammatory conditions these self-mimicking structures might be presented to autoreactive T cells 
and induce their activation. As mentioned earlier, there are some immunological privileged areas in 
the body that cannot be accessed by immune cells. During an infection or a severe trauma, these cell 
or tissue barriers can be disrupted and self-material that is sequestered under normal conditions now 
becomes accessible to autoreactive lymphocytes and might lead to their activation. This entire 
process is called epitope spreading and is illustrated in Figure 1.1E (Fujinami et al., 2006; McCoy et 
al., 2006). 
Furthermore, a viral infection activates APCs and induces the upregulation of MHC and co-
stimulatory molecules. This might cause the conversion into an effector state and might support the 
survival of autoreactive lymphocytes (Figure 1.1F). 
 
1.2.3.2  Pathogenesis of MS 
Disregarding the potential and ultimate trigger of MS, proinflammatory conditions lead to an 
immune response in the CNS and a certain sequence of pathogenic steps (Hemmer et al., 2002; 
Sospedra and Martin, 2005; Steinman, 2009). A short overview of these steps is illustrated in Figure 
1.2. 
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The presumed initial step in the pathogenesis of MS is the activation of autoreactive T cells and B 
cells in the periphery. The activation is caused by antigen that is either released from the CNS into 
the circulation or an alternative activation process by cross-reactive foreign antigens. After 
activation of autoreactive lymphocytes in the periphery, the cells start to proliferate. The second 
step includes the transmigration of these clonally expanded cells through the blood brain barrier 
(BBB) into the brain parenchyma. The pro-inflammatory cytokines and chemokines that are 
produced by infiltrating immune cells, promote the activation of CNS-resident cells such as 
microglia and astrocytes and the recruitment of further immune cells. Once present in the CNS, T 
cells and B cells encounter their specific antigen that is either presented by APCs or naturally 
occurring in the tissue, respectively. Activated CD8+ T cells induce damage to cells that present 
self-peptide:MHC complexes on their surfaces and CD4+ T cells release inflammatory cytokines 
after encountering their specific antigen on MHC class II molecules. Additionally, plasma cells 
release myelin-specific antibodies that bind their antigen and lead to opsonization of cells and, in a 
next step, to damage of the myelin sheath. Attracted by inflammatory cytokines, macrophages are 
also recruited to the CNS, where they release further immune mediators and phagocytose target 
cells leading to a high level of CNS tissue damage. 
 
 
Figure 1.2: Pathogenesis of MS. The pathogenesis of MS can be subdivided into the following steps: Activation of 
autoreactive lymphocytes in the periphery, transmigration of autoreactive lymphocytes into the CNS, release of pro-
inflammatory cytokines and chemokines, recruitment of resident cells and further immune cells, reactivation of 
autoreactive lymphocytes and destruction of CNS tissue in the inflammatory stage. Figure from (Hemmer et al., 2002). 
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1.2.3.3  Animal Model for MS 
A murine animal model that is used to study the mechanistic basis of autoimmune demyelinating 
diseases and to test therapeutic approaches is called experimental autoimmune encephalomyelitis 
(EAE) (Gold et al., 2006) and was first described by Olitsky and Yager 65 years ago (Olitsky and 
Yager, 1949). EAE is an antigen-induced animal model and can be actively induced by the injection 
of CNS antigens in combination with Complete Freund’s Adjuvant (CFA) which is an oil-based 
adjuvant containing mycobacteria. CNS antigens can be applied in form of homogenate of the CNS 
(Brown and McFarlin, 1981), in form of brain antigens such as MBP (Fritz et al., 1983), PLP 
(Trotter et al., 1987) or MOG (Mendel et al., 1995) or, alternatively, with peptides representing the 
major encephalitogenic regions of MBP (MBP84–104), PLP (PLP139–151 or PLP178–191), or MOG (MOG 
35-55 or MOG92–106). It is noted that MOG35-55 is highly encephalitogenic in C57BL/6 mice – the 
genetic background that was used in this study. In addition to self-antigen and CFA, Pertussis toxin 
(PTx) which, originally, is an exotoxin produced by the bacterium Bordetella pertussis and causes 
whooping cough, is necessary to induce EAE. The true role of PTx is still under discussion, but PTx 
was described to facilitate immune cell entry into the CNS (Kerfoot et al., 2004). Furthermore, PTx 
is also known to break T cell tolerance and to promote clonal expansion and cytokine production by 
T cells (Kamradt et al., 1991; Shive et al., 2000; Waldner et al., 2004). 
In the EAE mouse model clinical disease symptoms arise 10 to 15 days after immunization. Initial 
disease symptoms are a flaccid, limp tail and paralysis of hind legs with progression of symptoms to 
the front legs and a potential culmination in a completely moribund state. This disease course 
describes the classic EAE model and reflects the preferential targeting of inflammation to the spinal 
cord and to some extent to the cerebellum. 
In contrast to active induction of EAE, EAE can also be induced by adoptive transfer of 
autoreactive T cells. In the adoptive transfer EAE model, donor mice are primed and autoreactive T 
cells are isolated from these donors. In a next step, the autoreactive T cells are expanded in vitro in 
the presence of neuroantigen and are then adoptively transferred to syngeneic naïve recipient mice. 
The first adoptive transfer experiment was done with rats. In these experiments, lymph node cells 
from rats that had been immunized with spinal cord homogenate were transferred into naïve mice 
that then developed EAE symptoms (Paterson, 1960). Over time it could be shown that antigen-
specific T cells are actually responsible for transfering the disease (Ben-Nun et al., 1981) and, in a 
next step, it was shown that MHC class II-restricted CD4+ T cells that are either MBP (Zamvil et 
al., 1985) or MOG-specific (Bettelli et al., 2003) can induce disease in recipient mice. All these 
experiments clearly showed that CD4+ T cells mainly mediate EAE. 
Spontaneous development of EAE in wildtype mice is not known. But there are TCR transgenic 
mice that spontaneously develop EAE without the administration of neuroantigen or adjuvant 
(Goverman et al., 1993; Krishnamoorthy et al., 2006; Pöllinger et al., 2009). 
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1.2.3.4  Pathogenesis of EAE 
The main pathogenic steps of EAE are similar to the ones believed to be essential for MS (chapter 
1.2.3.2). As mentioned above, normal wildtype mice do not develop spontaneous EAE. Thus, in 
order to induce EAE, peripheral myelin-specific CD4+ T cells that escaped tolerogenic mechanisms, 
need to be primed in the periphery by injection of CNS antigen with adjuvant. In a next step, the 
activated CD4+ T cells expand in the peripheral lymphoid organs and migrate to the CNS. In the 
CNS, the BBB is most likely broken down by the application of PTx (Kerfoot et al., 2004) and 
allows T cell entry into the CNS where they need to be reactivated by local APCs that present 
myelin peptide. The subsequent secretion of pro-inflammatory cytokines and the expression of co-
stimulatory molecules initiate a cascade of events that triggers the recruitment of macrophages to 
the site of inflammation. Macrophages are known to secrete pro-inflammatory mediators such as 
tumor necrosis factor (TNF)-α and IL-1, which support the infiltration of T cells, B cells and 
macrophages. Consequently, an inflammatory milieu is provided and due to the neuroinflammatory 
response, CNS damage is caused and focal plaques of demyelination are formed. 
 
1.3 Basic Principles of Antigen Processing and Presentation 
Antigen processing is an intracellular procedure that converts proteins from the extracellular space 
or cytosol into peptides. These peptides are loaded onto MHC molecules to be presented to T cells. 
There are two classical pathways of antigen processing and presentation: the MHC class I pathway 
for the processing and presentation of cytosolic proteins and the MHC class II pathway for 
processing and presentation of extracellular proteins (Figure 1.3). 
 
1.3.1 MHC Class I Antigen Presentation Pathway 
In every cell endogenous messenger RNA (mRNA) or even mRNA that originates from pathogens 
that reside in the cytosol are translated constantly. During this process not only correctly folded 
proteins are synthesized, but also a high amount of misfolded proteins that are called defective 
ribosomal products (DRiPs) (Li et al., 2011a). Additionally, short-lived, old or excessive proteins 
need to be removed from the cell to ensure a functional environment. All these targets are 
immediately recognized and labeled with multiple ubiquitin units (poly-ubiquitination) and are then 
directly targeted to the proteasome where they are proteolysed into small peptide fragments 
(Pickart, 2001). The peptide fragments are transported into the endoplasmatic reticulum (ER) by 
transporters called transporters associated with antigen processing-1 and -2 (TAP1 and TAP2) for 
loading onto MHC class I molecules (Abele and Tampé, 2004). 
In parallel, within the ER, the polymorphic heavy chain and a light chain called β2-microglobulin 
(β2m) subunit are assembled to form the MHC class I:β2m complex. Until a peptide has been 
loaded to the complex, the MHC class I:β2m complex is stabilized by the ER chaperone proteins 
Introduction 
 
 14 
calreticulin, ERp57, protein disulfide isomerase (PDI) and tapasin. Tapasin also functions as an 
adaptor protein between the assembled MHC class I molecule and the TAP transporter (Wearsch 
and Cresswell, 2008). Generally, the binding groove of the MHC class I molecule accommodates 
peptides of 8–9 amino acids. 
Once the peptide fragments have arrived in the ER and the MHC class I molecule has been 
assembled, peptides are loaded onto MHC class I molecules and are guided to leave the ER to 
present the peptide:MHC class I complex on the cell surface. In case peptides and MHC class I 
molecules are not assembled successfully, they are returned to the cytosol for subsequent 
degradation (Blum et al., 2013; Neefjes et al., 2011). 
 
Figure 1.3: The basic principles of MHC class I and MHC class II antigen presentation. (A) MHC class I pathway: 
proteins in the cytosol are targeted by poly-ubiquitinylation and are proteolytically degraded within the proteasome. 
Degraded peptides are transported from the cytosol to the ER where the peptide:MHC class I complex is assembled. The 
peptide:MHC class I complex is transported to the cell surface and presented to CD8+ T cells. (B) MHC class II pathway: 
extracellular proteins are taken up by APCs and are processed in endosomal and lysosomal vesicles. In the MHC class II 
loading compartment, processed peptides are associated with MHC class II molecules. The peptide:MHC class II complex 
is displayed on the cell surface and presented to CD4+ T cells. Figure from (Neefjes et al., 2011). 
 
1.3.2 MHC Class II Antigen Presentation Pathway 
Extracellular antigens are taken up by APCs by phagocytosis. The emerging phagosomes, or early 
endosomes, fuse with lysosomal vesicles which results in the stepwise acidification of the 
endosome and, thereby, in the activation of proteases (Huotari and Helenius, 2011). The cysteine 
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proteases cathepsin S and L are the most important proteases in the degradation process of vesicular 
antigens (Watts, 2001). Before cargo is degraded to peptide fragments within the lysosome, the 
enzyme gamma-interferon inducible lysosomal thiol reductase (GILT) facilitates the unfolding of 
the proteins by reducing intramolecular disulfide bonds and, thus, making the endocytosed protein 
accessible for further enzymatic processing (Phan et al., 2000). 
The transmembrane α- and β-chains of the MHC class II molecules are assembled in the ER like 
normal glycoproteins. The unspecific binding of peptides to the MHC class II molecule is prevented 
by the occupation of the binding groove by the invariant chain (Ii). An additional role of the 
invariant chain is to guide the transfer of the MHC class II molecule from the ER to the MHC class 
II loading compartment (MIIC). MIICs are late endosomal compartments where loading of the 
MHC class II molecule with peptide fragments is performed. On the way from the ER to the MIICs 
the pH within the vesicle constantly decreases. Under these conditions the invariant chain is cleaved 
off and only the class II-associated invariant chain peptide (CLIP) stays with the MHC class II 
molecule (Busch et al., 2000). Within the MIIC, the MHC class II molecule is associated with a 
molecule called HLA-DM (H2-M in mice), which prevents aggregation of MHC class II molecules 
and ensures stability of the molecule. Furthermore, HLA-DM catalyzes the removal of the CLIP 
fragment as well as the loading of a peptide antigen derived from a protein degraded in the 
endosomal pathway (Schulze and Wucherpfennig, 2012). The appropriate length of such a peptide 
antigen is 10 to 16 amino acids. In B cells, thymic epithelial cells and certain DC subsets, the HLA-
DM molecule can be bound by a HLA-DO molecule (H2-O in mice), which modulates the activity 
of HLA-DM (Guce et al., 2013). Once the peptide:MHC class II complex is assembled, it is 
transported to the cell surface where the peptide cargo is presented to CD4+ T cells. (Blum et al., 
2013; Neefjes et al., 2011) 
 
1.3.3 Cross Presentation Pathways 
Cross presentation is an antigen presentation pathway in which extracellular antigens are presented 
on MHC class I molecules and that is most prominent in DCs. Generally, cells have the ability to 
capture extracellular antigen by phagocytosis. But in the context of cross-presentation, the 
phagosome does not enter the MHC class II antigen presentation pathway (chapter 1.3.2), but the 
so-called cytosolic or vacuolar pathway. If the phagosome enters the cytosolic pathway, the antigen 
is first exported to the cytosol. In the cytosol the antigen is degraded by proteasomal degradation 
and then transported into the ER or into the phagosome where the antigenic peptide fragments are 
loaded onto MHC class I molecules by either ER loading or phagosomal loading, respectively. 
Alternatively, in the vacuolar pathway, the phagosomal cargo is directly degraded in the phagosome 
and loaded onto MHC class I molecules for antigen presentation (Joffre et al., 2012). 
On the other hand, it could also be shown that intracellular protein can be presented by MHC class 
II molecules. In this context, it was shown that self-antigens originated from the cell surface and the 
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endosomal network are presented on MHC class II molecules (Chicz et al., 1993; Hunt et al., 1992), 
but also molecules of cytoplasmic or nuclear origin could be detected in other studies (Dengjel et 
al., 2005; Dongre et al., 2001). Even though the underlying mechanism of presentation of self-
antigen via MHC class II molecules is not perfectly clear, there is evidence that macroautophagy 
might play a role in delivering these molecules to the MHC class II loading compartment (Dörfel et 
al., 2005; Nimmerjahn et al., 2003; Paludan et al., 2005). The role of macroautophagy in antigen 
presentation will be discussed in more detail in chapter 1.3.5. 
 
1.3.4 Presentation of Non-Protein Antigens to Subsets of T Cells 
Non-protein antigens that are presented by APCs include lipids and glycolipids, small 
phosphorylated proteins and alkyl amines. Lipids and glycolipids are displayed by the non-classical 
MHC molecule CD1 (Moody and Porcelli, 2003). CD1 is an MHC class I-like molecule and is 
mainly expressed on cells specialized for antigen presentation. The antigen bound to CD1 
molecules is recognized by natural killer T cells (NKT cells). NKT cells are a T cell subset defined 
by expressing markers characteristic for both natural killer (NK) cells and T lymphocytes and 
express αβ TCRs that have a very limited diversity. 
On the other hand, some proteins, small phosphorylated proteins and alkyl amines are recognized 
by γδ T cells (Born et al., 2013). γδ T cells are a small population of T cells and the exact 
mechanism of how γδ T cells recognize ligands is still not known. There is evidence that ligand 
recognition does not depend on MHC presentation, but a diversity of cell surface structures were 
shown to be recognized by γδ T cells (Born et al., 2013). 
 
1.3.5 Autophagic Pathways 
Autophagy is a cell intrinsic process by which intracellular constituents are transported to the 
lysosome for degradation. The term autophagy was coined by Christian de Duve, renaming 
autolysis which was used by Ashford and Porter to describe vesicles that contained cellular 
organelles and lysosomal enzymes and connecting it to cellular catabolism (autophagy from the 
Greek “auto” for “self” and “phagein” meaning “to eat”) (Ashford and Porter, 1962; De Duve, 
1963). Until today three types of autophagy have been described – namely, chaperone-mediated 
autophagy, microautophagy and macroautophagy (Figure 1.4). 
 
Chaperone-mediated autophagy (CMA) is a highly selective form of autophagy. During CMA, 
proteins that show a KFERQ-like motif (KFERQ is the one-letter code for the amino acid sequence 
Lys-Phe-Glu-Arg-Gln) are recognized by Hsp70 chaperones (heat shock 70 kDa protein) and 
targeted to the lysosome. The selected protein surpasses the lysosomal membrane by help of the 
Introduction 
 17 
lysosomal membrane-associated protein 2A (LAMP-2A) and is finally degraded in the lysosome. 
(Kaushik and Cuervo, 2012) 
Another form of autophagy is microautophagy, which sequesters portions of the cytoplasm by the 
direct engulfment of the cytoplasm by the membrane of the lysosome or late endosome (mammals) 
or the vacuole (plants and fungi). During this process the cytosol is directly sequestered at the 
surface of the lysosome and no transport vesicles or adaptor proteins are involved. More 
specifically, small soluble substrates are engulfed by tubular invagination, whereas, during the 
process of selective microautophagy (e.g., micropexophagy, microautophagy of the nucleus, 
micromitophagy), the cargo is sequestered by arm-like protrusions. Noteworthy, non-selective 
microautophagy is regularly observed in mammalian cells, while the other three forms of selective 
microautophagy are frequently induced in yeast. Once the invagination is completed, the 
invaginating membrane is choked off and single membrane vesicles are released into the lysosomal 
lumen where the cargo is degraded. (Li et al., 2011b) 
 
 
Figure 1.4: Types of autophagy and the main players in the formation of the macroautophagic isolation membrane. 
During macroautophagy an isolation membrane is formed around cytoplasmatic constituents. After completion of the 
isolation membrane, the autophagosome is formed and fuses with lysosomal vesicles for degradation of cargo. 
Additionally, key autophagy (Atg)-related proteins that are important in the formation of the isolation membrane are 
depicted. Microautophagy is a non-selective process in which the membrane of the lysosome directly engulfes 
cytoplasmic cargo for delivery to the lysosome. CMA is a highly selective pathway in which proteins carrying a KFERQ-
like motif are recognized by Hsp70 chaperones. The targeted protein translocates into the lysosome through the LAMP-
2A transporter. Figure from (Münz, 2009). 
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Macroautophagy is a conserved catabolic process, which is important for the maintenance of 
cellular homeostasis. During the process of macroautophagy, an isolation membrane sequesters a 
portion of the cytoplasm that contains cellular components such as organelles and pathogens as well 
as misfolded or long-lived proteins. The resulting vesicle is called the autophagosome. Once the 
autophagosome is assembled, lysosomal vesicles are recruited to the autophagosome, an 
autophagolysosome is formed and the cargo is degraded in the lysosome. Hereafter, 
macroautophagy will be referred to as autophagy and will be discussed in more detail below. 
 
1.3.6 Autophagy 
Nowadays, it is known that autophagy is involved in many different physiological processes, such 
as: generation of amino acids during starvation, clearing of redundant or nonfunctional proteins, 
regulation of availability of certain substrates, mammalian development as well as degradation of 
pathogens and antigen presentation. (Cecconi and Levine, 2008; Deretic and Levine, 2009; Levine 
and Kroemer, 2008; Menzies et al., 2011; Milo and Kahana, 2010; Mizushima and Levine, 2010; 
Mizushima et al., 2008; Virgin and Levine, 2009; White et al., 2010; Wong and Cuervo, 2010). 
 
1.3.6.1  Regulation of Autophagy 
Under steady state conditions, autophagy works at low levels, but it can be induced by various 
triggers, such as deprivation of nutrients, hormones, and energy (He and Klionsky, 2009). The key 
player in the regulation of autophagy is the mammalian target of rapamycin (mTOR), which is a 
central serine/threonine protein kinase of the nutrient-sensing pathway (Jung et al., 2010). 
Rapamycin can induce autophagy by inhibiting mTOR. Generally, the activity of mTOR is 
regulated by a diversity of signals such as growth factors, amino acids, glucose and energy status of 
the cell (Kim et al., 2002). 
In addition to mTOR, other processes can also influence the level of autophagy. For example, anti-
apoptotic proteins from the B cell lymphoma 2 (BCL-2) family inhibit autophagy (Pattingre et al., 
2005), whereas, withdrawal of growth factors leads to the upregulation of autophagy to ensure 
maintenance of cellular functions (Lum et al., 2005). Autophagy is also upregulated in response to 
cellular stress such as hypoxia (Mazure and Pouysségur, 2010), oxidative stress (Lee et al., 2012), 
or ER stress (Deegan et al., 2013). Latter describes conditions that interfere with the proper function 
of the ER, such as accumulation of unfolded protein aggregates or excessive protein traffic. 
Autophagy also plays an important role in the removal of invading pathogens and the recognition of 
potential pathogens depends on the detection of PAMPs by PRRs such as Toll-like receptors 
(TLRs). For example, viral ssRNA (single-stranded RNA) induces autophagy via TLR7 (Delgado et 
al., 2008), whereas zymosan, a yeast-derived glucan, activates TLR2 and bacterial 
lipopolysaccharide (LPS) induces autophagy by binding to TLR4 (Xu et al., 2007a). 
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1.3.6.2  Assembly of the Autophagosome 
Once autophagy is induced, an isolation membrane (also called phagophore) is formed (Figure 1.5). 
In total more than 30 autophagy-related proteins (Atg, from AuTophaGy) have been described to be 
involved in the formation of the autophagsosome (Mizushima and Komatsu, 2011). 
The first step in the generation of the isolation membrane is the assembly of the ULK1 
(uncoordinated (UNC)-51-like kinase 1) complex at the autophagosome formation site on the 
membrane of, for example, the ER, which is also known as phagophore assembly site or pre-
autophagosomal structure (PAS) (Xie and Klionsky, 2007). The mammalian ULK1 complex 
comprises of the proteins ULK1, Atg13, FIP200 (focal adhesion kinase (FAK) family interacting 
protein of 200 kDa) and Atg101 (Itakura and Mizushima, 2010). Once this first initiation complex is 
assembled, the ULK1 complex induces the assembly of a second initiation complex, namely the 
class III PI3K (Phosphatidylinositide 3-kinase) complex. The latter constitutes of the Vps34 
(vacuolar protein sorting protein 34), Vps15, Beclin1 (B cell lymphoma-2 (Bcl-2) interacting 
coiled-coil protein; also know as Atg6), Atg14(L) and AMBRA1 (activating molecule in Beclin-1-
regulated autophagy protein 1) and is responsible for the production of phosphatidylinositol-3-
phosphate (PI3P) on the membrane. PI3P binds to double FYVE-containing protein 1 (DFCP1) and 
both initiate the formation of the omegasome (Axe et al., 2008). The omegasome is a cup-shaped 
protrusion of the ER that serves as starting point for the generation of the autophagosome. In 
addition to PI3P and DFCP1 also Atg9, WIPIs (WD-repeat protein interacting with 
phosphoinositides) and VMP1 (vacuole membrane protein 1) can be found at this initiation point 
(Mizushima and Komatsu, 2011). 
For the elongation, maturation and closure of the isolation membrane further steps are necessary 
and utilize two ubiquitin-like conjugation systems. The first conjugation system in action is the 
Atg12 conjugation system. To form this protein complex the E1-like enzyme Atg7 and the E2-like 
enzyme Atg10, which are an ubiqutin-activating enzyme and ubiqutin-conjugating enzyme, 
respectively, are necessary (Mizushima et al., 1998). Atg7 and Atg10 are responsible for the 
coupling of Atg12 to Atg5 (Mizushima et al., 1998) and, in a next step, Atg16L1 is also recruited to 
build the Atg5-Atg12/Atg16L1 complex. The Atg5-Atg12/Atg16L1 complex is one of the two 
complexes required for the conjugation of Atg8/LC3 (microtubule-associated protein 1A/1B-light 
chain 3) to phosphatidylethanloamine (PE) to the isolation membrane (Fujita et al., 2008; Hanada et 
al., 2007). The second conjugation system is called Atg8/LC3 conjugation system and consists of 
LC3, Atg4, Atg7 and Atg3. Atg4 is a cysteine protease that cleaves off the five C-terminal amino 
acids (MKLSV) of LC3 and makes its glycine residue accessible. In a next step, LC3 is activated by 
the E1-like enzyme Atg7 and conjugated by the E2-like enzyme Atg3 to PE on the outer and inner 
membrane of the isolation membrane (Ichimura et al., 2000). LC3 is responsible for the fusion of 
membrane vesicles that are of importance during the formation, elongation and closure of the 
isolation membrane (Nakatogawa et al., 2007; Xie et al., 2008). Furthermore, LC3 was described as 
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a receptor or an adaptor protein that is responsible for selective cargo incorporation into the 
autophagosome (Noda et al., 2010). The isolation membrane elongates and, finally, results in a 
double-membrane organelle that is called autophagosome. After the autophagosome is completed, 
LC3 bound to the outer membrane of the autophagosome is released by cleavage by the 
deconjugation enzyme Atg4 (Kirisako et al., 2000). On the other hand, LC3 bound to the inner 
membrane stays attached to it and is degraded together with the autophagosome once it reaches the 
lysosome. 
 
 
Figure 1.5: Formation of the autophagosome. Upon inhibition of mTORC1, autophagy is induced and the ULK1 
complex is assembled and translocated to the ER membrane. The ULK1 complex initiates the assembly of the class III 
PI3K complex that produces PI3P and attaches it to the membrane. PI3P recruits DFCP1 and the formation of the 
omegasome is induced. The Atg5-Atg12/Atg16L1 complex plays an important role in the conjugation of Atg8/LC3 to PE 
and assists in the elongation and closure of the isolation membrane. Figure from (Mizushima and Komatsu, 2011). 
 
The membrane source for the formation of the isolation membrane is still not clearly determined. 
Some of the potential membrane sources are believed to be organelles such as the ER, Golgi 
complex, mitochondria or endosomes, but also de novo synthesis of the membrane seems 
reasonable. And even the plasma membrane or nuclear membrane are considered potential starting 
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points of membrane supply (Tooze and Yoshimori, 2010). 
Classically, autophagy was thought to be important for the degradation of unnecessary proteins and 
random uptake of cytosolic constituents. Meanwhile it was shown that autophagosomes also 
specifically bind to cargo by the assistance of adaptor proteins such as p62/SQSTM1 (sequestosome 
1), NBR1 (neighbor of BRCA1 gene 1), NDP52, optineurin and TAX1BP1. These cargo receptors 
are responsible for the degradation of ubiquitinated substrates (Johansen and Lamark, 2011; Kraft et 
al., 2010). Additionally, it could be demonstrated that autophagy is involved in the selective 
degradation of organelles such as mitochondria (mitophagy) (Kim et al., 2007), peroxisomes 
(pexophagy) (Dunn et al., 2005), ribosomes (ribophagy) (Kraft et al., 2008), ER (reticulophagy) 
(Bernales et al., 2006) and intracellular microbes (xenophagy) (Klionsky et al., 2007). 
 
1.3.6.3  LC3-Associated Phagocytosis 
LC3-associated phagocytosis (LAP) is a newly characterized process that combines features from 
both phagocytosis and autophagy and was first described by Sanjuan et al. in 2007. In this study it 
was shown that a pathogen or particle that engages TLRs on murine macrophages induces 
phagocytosis and the recruitment of elements of the autophagic pathway. Beads that were coated 
with LPS (TLR4 agonist) and pathogen-derived surface molecules such as zymosan (TLR2 agonist) 
co-localized with LC3 on the phagosomal membrane which indicates that LAP is induced when a 
receptor-mediated signaling pathway is engaged (Sanjuan et al., 2007). LAP can be distinguished 
from canonical autophagy with regard to the following characteristics (Figure 1.6): LAP goes back 
to a single-membrane phagosome that can be detected by transmission electron microscopy (TEM), 
LAP causes a more rapid maturation of the phagosome and is independent of the ULK1 pre-
initiation complex. On the other hand, LAP and autophagy show similar characteristics in terms of 
class III PI3K activity, LC3 recruitment and the requirement of Beclin1, Atg5 and Atg7 (Sanjuan et 
al., 2009). 
Additionally, LAP was shown to be triggered by apoptotic cell bodies that display 
phosphatidylserine (PtdSer) on their surface by which they engage the T cell immunoglobulin 
mucin-4 (TIM4) receptor on the phagocytic cell (Martinez et al., 2011). DNA-antibody immune 
complexes that bind to Fc receptors (FcR) are also able to induce LAP (Henault et al., 2012) and 
entotic bodies are able to trigger the recruitment of LC3 in an endothelial cell line. But, in the latter 
case, it still needs to be determined how the engulfment of non-pathogens in the absence of “eat 
me” signals can promote LC3 targeting (Florey et al., 2011). 
 
Introduction 
 
 22 
 
 
Figure 1.6: Comparison of autophagy and LAP. (A) Graphical comparison of autophagy and LAP. Autophagic 
isolation membrane engulfes mitochondrium and protein aggregate, whereas virus and bacterium are engulfed by 
phagocytosis. Red circles: Atg5-Atg12/Atg16L1 complex, green circles: LC3. Figure adopted from (Randow and Münz, 
2012) (B) Comparison of hallmark proteins involved in either autophagy or LAP. Data are based on results from (Florey 
et al., 2011; Martinez et al., 2011; Sanjuan and Green, 2008). 
 
Amongst these well-defined LAP processes, there are additional studies that describe processes that 
could be related to LAP, but are not clearly defined as LAP. One of these potential cellular signals 
are peptidoglycans that bind to NOD-like receptors such as NOD1 and NOD2. In this study it could 
be shown that LC3 and Atg16L are located at the site of the plasma membrane where the bacterium 
Shigella flexneri was engulfed (Travassos et al., 2010). Furthermore, beads coated with human 
immunoglobulin G (IgG) were taken up by RAW 264.7 cells, a murine macrophage-derived cell 
line by FcR-mediated endocytosis and induced the recruitment of LC3 to phasosomes (Huang et al., 
2009). In another study, the autophagy-related proteins Vps34, Vps15 and Beclin1 were recruited to 
phagosomes containing beads that were coated with Escherichia coli  (E. coli) outer membrane 
extract. Based on the fact that the class III PI3K complex (Vps34 Vps15 Beclin1 complex) is 
essential for the formation of the autophagosome, a potential association between the uptake of E. 
coli extract and LAP was suggested (Berger et al., 2010). 
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1.3.6.4  Role of Autophagy in Antigen Presentation, Immunity and Autoimmunity 
Autophagy is known as an „auto-digestive“ process that engulfes intracellular components by an 
autophagosome which transports the cargo to the lysosome for degradation and recycling. 
Additionally, MHC class II molecules were thought to function solely for the presentation of 
exogenous and foreign peptide antigens. But it could actually be shown that MHC class II 
molecules are able to present intracellular antigen (Chicz et al., 1993) and that endogenous viral 
antigens are presented to CD4+ T cells through an intracellular route using the example of measles 
and influenza antigens (Guéguen and Long, 1996). In subsequent years, the involvement of 
autophagy in the presentation of cytosolic model peptides by MHC class II molecules could be 
shown (Dörfel et al., 2005; Nimmerjahn et al., 2003; Paludan et al., 2005). It was demonstrated that 
autophagosomes constitutively form in MHC class II-positive cells - including DCs, B cells and 
epithelial cells. In these cells, autophagosomes continuously fused with multivesicular MIICs and 
targeting of antigen to autophagosomes via fusion to the autophagosome-associated protein 
Atg8/LC3 led to strongly enhanced MHC class II presentation to CD4+ T cells (Schmid et al., 
2007). These data showed that macroautophagy constitutively and efficiently delivers cytosolic 
proteins for MHC class II presentation. Not just intracellular self-antigens are targeted to MHC 
class II presentation, but also bacterial and viral antigens that are present in the cytoplasma can be 
presented on MHC class II molecules (Nimmerjahn et al., 2003; Paludan et al., 2005). In this 
context, it was hypothesized that the presentation of intracellular pathogenic antigen might be 
beneficial for the induction of Th cell functions. 
The presentation of self-peptide on MHC class II molecules by the assistance of autophagy plays 
also an important role in the selection process of thymic CD4+ T cells. In this regard, thymic 
epithelial cells deliver self-peptides via autophagy to MHC class II molecules for positive and 
negative selection in the thymus (Nedjic et al., 2008). Supporting these data, it was shown that 
autophagosomes fuse with MIICs in theses thymic epithelial cells (Kasai et al., 2009). Notably, 
inflammatory stimuli such as pro-inflammatory cytokines and TLR agonists upregulate 
macroautophagy in APCs suggesting that macroautophagy-mediated antigen processing could 
particularly enhance immune responses within inflamed tissues (Münz, 2009). 
Autophagy has also been linked to the development of autoimmunity (Bhattacharya and Eissa, 
2013). One of the autoimmune diseases associated with a deficiency in autophagy is SLE. Genome-
wide associations studies have shown that single-nucleotide polymorphisms (SNPs) in the gene 
encoding the Atg5 protein can be related to SLE susceptibility (Pierdominici et al., 2012). 
Additionally, activation of mTOR was shown in SLE patients which further suggests an association 
between SLE and the autophagy machinery (Pierdominici et al., 2012). In the context of autophagy-
deficiency, it was discussed that one of the potential causes of SLE might be the defective clearance 
of apoptotic cell corpses which might lead to the breakdown of self-tolerance, the activation of 
autoreactive lymphocytes and, finally, to the development of SLE (Gaipl et al., 2006). 
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Furthermore, autophagy was linked to the development of Crohn’s disease (CD) by means of 
genome-wide association studies in which non-synonymous single nucleotide polymorphisms 
(SNP) in the autophagy gene ATG16L1 were associated with the susceptibility to this disease. And 
it was discussed that autophagy might lead to an altered immune response to commensal gut 
bacteria or an insufficient induction of tolerance (Prescott et al., 2007; Rioux et al., 2007). 
A role of autophagy was also considered for the etiology of MS since an elevated expression of 
Atg5 was detected in blood samples of EAE mice (Alirezaei et al., 2009). It is assumed that Atg5 
and IRGM (immunity-related GTPase) might positively effect the survival of mature effector CD4+ 
T cells which might contribute to EAE and/or MS development (Xu et al., 2010). 
 
1.3.6.5  DCs – The Model APC 
 DCs are professional APCs and are, thus, most efficient in the activation of naïve T cells and the 
initiation of T cell responses. DCs were first described by Ralph M. Steinman and Zanvil A. Cohn 
who termed this cell subset „dendritic cell“ because of their tree-like morphology at certain 
development stages (dendrite = δένδρον or déndron being Greek for "tree") (Steinman and Cohn, 
1973). Meanwhile, it is well known that theses cells are the major players in regulating the adaptive 
immune response. 
DCs derive from the bone-marrow and can arise from lymphoid as well as myeloid precursor cells. 
Their precursors migrate from the bone-marrow through the blood to lymphoid organs or to 
peripheral non-lymphoid organs. They are mainly present in all tissues that are in contact with the 
external environment - such as epithelium of the skin, inner lining of the respiratory tract, and 
interstitium of most parenchymal organs. Based on their diverse origin cell-specific surface 
markers, location and immunological functions, three main DC subsets can be distinguished: 
plasmacytoid DCs, conventional DCs and inflammatory DCs. (Satpathy et al., 2012) 
Plasmacytoid DCs (pDCs) show a round and spheric phenotype and need further development in 
order to acquire the dendritic morphology and complete DC function. After stimulating the pDCs 
with microbial or viral antigen, pDCs produce high amounts of type 1 interferon (IFN) and, based 
on this, are also known as „natural interferon-producing cell“. After activation, they also form 
dendritic-like protrusions and gain typical DC-like antigen processing and presentation functions. 
(Liu, 2005) 
Conventional DCs (cDC) are fully differentiated cells and show a dendritic morphology and fully-
operational DC functions under steady state conditions. When they are newly differentiated, they 
show high endocytic activity and low surface expression of MHC class I and II molecules. After 
stimulation of cDCs, the cytoplasm is reorganized and MHC class I and II molecules as well as co-
stimulatory molecules are upregulated. cDCs can be further subdivided into migratory DCs and 
lymphoid tissue-resident DCs. Migratory DCs are the classical textbook DCs which have a high 
capacity of antigen sampling. They migrate through the lymphatic system to the lymph node where 
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they can activate T cells. Examples for migratory cDCs are Langerhans cells in the epidermis, 
dermal DCs located in the dermis or interstitial DCs from the lamina propria of the mucosa. On the 
other hand, lymphoid tissue-resident DCs are stationary in the lymphoid organs and do not migrate 
within the lymphatics, but they do collect and present antigen in lymphoid organs themselves. In the 
mouse system CD8+ and CD8- cDCs can be further distinguished. 
A third major DC subset are the inflammatory DCs that cannot be found under steady state 
conditions. These cells first arise after infection or inflammation and can develop into TipDCs 
(tumour-necrosis factor (TNF) / inducible nitric oxide synthase (iNOS)-producing DCs) that 
produce high amounts of TNF and iNOS (Segura and Amigorena, 2013). 
 
1.4 Working Hypothesis 
The emergence, activation and expansion of autoreactive CD4+ T cells are considered crucial events 
in the development and progression of MS and EAE. Generally, CD4 T+ cells are activated by 
APCs such as DCs and macrophages. The classical way of processing and presenting antigen to 
CD4+ T cells is the MHC class II pathway. But recent studies have identified autophagy as an 
alternative pathway that shuttles intracellular antigens into MIIC for recognition by CD4+ T cells. 
Furthermore, constitutive autophagosome formation in MHC class II-positive cells, including DCs, 
B cells and epithelial cells was demonstrated. In these cells, autophagosomes continuously fused 
with MHC class II-loading compartments and targeting of antigen to autophagosomes strongly 
enhanced MHC class II presentation to CD4+ T cells. Additionally, other studies have shown the 
involvement of the autophagic machinery in processing of even extracellular material. It could be 
shown in two independent studies that autophagy-related proteins are either recruited to latex beads 
coated with TLR-ligands or to phagocytosed apoptotic cells that promote the processing of this 
material. But so far it has not been shown if extracellular self-antigen could be processed by 
involvement of the autophagic machinery. But unpublished data from our laboratory have shown 
that the formation of LC3+ vesicles is markedly induced in CNS-resident APCs, namely activated 
microglia, during autoimmune CNS inflammation in MOG-induced EAE. 
Thus, we hypothesized that an autophagic machinery-dependent presentation of autoantigens by 
DCs facilitates the activation of autoreactive CD4+ T cells within the CNS. To address this question 
we used conditional gene targeting in mice to investigate whether autophagy in DCs influences the 
development and/or progression of EAE. Furthermore, the antigen-presenting capabilities of mouse 
APCs of the self-protein MOG were investigated. 
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2 Material and Methods 
2.1 Materials 
2.1.1 Chemicals and Reagents 
Chemicals and molecular biology reagents were mainly obtained from the companies Sigma-
Aldrich™, Fisher Scientific, Becton Dickinson Biosciences, Invitrogen™ and Fermentas unless 
otherwise mentioned. 
 
2.1.2 Plastic Supplies 
Plastic supplies such as multiwell plates, disposable plastic pipettes and plastic reaction tubes were 
obtained from Becton Dickinson Labware (FALCON®), VWR International®, Costar® and 
NuncTM. 
 
2.1.3 Bacterial Strains 
For the amplification of the plasmid pET-22b(+) (rmMOG1-124) chemocompetent Top 10 bacteria 
and for the overexpression of rmMOG protein, chemocompetent BL21 cells were used that were 
originally purchased from Invitrogen. 
 
2.1.4 MOG35-55 Peptide and rmMOG1-124 Protein 
The MOG35-55 peptide (MOG peptide) was purchased from GenScript, dissolved in PBS at a final 
concentration of 5 mg/ml, filter-sterilized (0.22 µm) and stored at -80°C. The plasmid pET-22b(+) 
(rmMOG1-124) was kindly provided by Burkhard Becher, University of Zurich, Switzerland and 
originates from Steve Anderton, University of Edinburgh, GB. RmMOG1-124 protein (MOG protein) 
was expressed and purified as described in chapter 2.2.11. 
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2.1.5 Buffers and Solutions 
2.1.5.1 Commercial Reagents and Kits 
Reagent / Kit Company Catalog number 
ACK Lysing Buffer Invitrogen A10492-01 
Agarose, LE, analytical grade Promega V3125 
β-mercaptoethanol Gibco 31350-010 
BCA Protein Assay Kit Thermo Scientific 23225 
BD Cytofix/Cytoperm™ Fixation/ 
Permeabilization Solution Kit with BD 
GolgiStop™ 
BD Biosciences 554715 
BD GolgiStop™ (Monensin) BD Biosciences 554715 
BSA, 30% Sigma A9576-50ml 
CFSE eBioscience 65-0850-84 
Collagenase D Roche 11088866001 
cOmplete Protease Inhibitor Cocktail Tablets Roche 11873580001 
DAPI Invitrogen D3571 
DMSO Sigma D2650 
DNA loading dye, 6× Fermentas R0611 
DNase Roche 2600105 
dNTPs, 10 mM Qiagen 124108743 
ECL Western Blotting Substrate Thermo Scientific  32106 
FIREPol, 5× master mix, 7.5 mM LucernaChem 04-12-0015 
Foxp3 Staining Buffer Set eBioscience 00-5523 
GelRedTM Nucleic Acid Gel Stain, 10000× Biotium 41003 
GeneRuler 100 bp DNA Ladder Fermentas SM0243 
Ionomycin Sigma I3909 
LB broth base Invitrogen 12780-029-2.5 kg 
L-Glutamine 200 mM 100× Gibco 25030 
LIVE/DEAD® Fixable Aqua Dead Cell 
Stain Kit 
Invitrogen L34957 
LIVE/DEAD® Fixable Near-IR Dead Cell 
Stain Kit 
Invitrogen L10119 
Normal goat serum Sigma G9023 
PCR reaction buffer with Mg2+ Roche 1127138001 
Penicillin-streptomycin, liquid Invitrogen 15070-063 
Percoll GE Healthcare 17-0891-01 
Pertussis toxin islet activating protein LuBioscience 180 
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PMA Sigma P1585 
ProLong® Gold Antifade Reagent Invitrogen P36934 
Proteinase K Roche 3115879001 
ReBlot Plus Strong Antibody Stripping 
Solution, 10x 
Millipore 2504 
Saponin Fluka 84510 
SDS solution Fluka 5030 – 500 ml 
Taq DNA Polymerase Roche 11435094001 
TaKaRa LA Taq with Mg2+ plus buffer Axonlab RR002M 
TritonTM-X100 Sigma T8532 
TritonTM-X114 Sigma X114-100 ml 
Trypan blue Gibco 15250-061 
Trypsin-EDTA 0.25% Gibco 25200-072 
Tween® 20 Sigma P5927 
 
2.1.5.2  General Use Buffers 
Biopsies lysing buffer 100 mM Tris, pH8.0 
100 mM NaCl 
10 mM EDTA, pH8.0 
0.2% SDS 
0.2 mg/ml proteinase K (added freshly each time) 
 
Cell lysing buffer,  
for Western blot analysis 
 
1% NP-40 
1x protease inhibitor cocktail (thawed on ice) 
In PBS 
 
Digest buffer, spleen 0.4 mg/ml collagenase D 
20 µg/ml DNase 
In PBS 
Freshly prepared each time 
 
Digest buffer, CNS 0.2 mg/ml collagenase D 
20 µg/ml DNAse 
In PBS 
Freshly prepared each time 
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FACS buffer 2% FCS 
0.01% NaN3 
In PBS 
Stored at 4°C 
 
Laemmli buffer 60 mM Tris-Cl, pH6.8 
2% SDS 
10% glycerol 
5% β-mercaptoethanol 
0.01% bromophenol blue 
 
MACS buffer 1% FCS 
2 mM EDTA 
In PBS 
Filter-sterilized with 0.22 µm filter device 
Stored at 4°C 
 
PBS, pH7.4, 10× 1.37 M NaCl 
26.8 mM KCl 
16.2 mM Na2HPO4*7H20 
14.7 mM KH2PO4 
 
Paraformaldehyde, 4% Kantonsapotheke 
 
PTx diluent 0.015 M Tris  
0.5 M NaCl 
0.017% Triton X-100  
Filter-sterilized with 0.22 µm filter device 
Stored at 4°C 
 
TBE, 5× 44.5 mM Trizma base, pH8.5 
44.5 mM Boric acid 
2 mM EDTA 
Materials and Methods 
 31 
2.1.5.3 Cell Culture Medium 
BM-DC medium 
 
RPMI 1640 
10% heat inactivated FCS 
1x penicillin-streptomycin  
1x L-glutamine 
50 µM β-mercaptoethanol 
X-63-GM-CSF cell line supernatant (1 part into 10 parts) 
Filter-sterilized with 0.22 µm filter device 
 
DMEM cell culture medium DMEM medium 
10% heat inactivated FCS 
1x penicillin-streptomycin 
 
Freezing medium 10% DMSO 
In FCS 
 
Medium for primary cells 
 
RPMI 1640 medium 
10% heat inactivated FCS 
1x penicillin-streptomycin  
1x L-glutamine 
50 µM β-mercaptoethanol  
 
RPMI cell culture medium  RPMI 1640 medium 
10% heat inactivated FCS 
1x penicillin-streptomycin 
 
2.1.5.4  Buffers for Immunofluorescence Microscopy 
Blocking buffer 10% normal goat serum 
1% BSA 
In PBS 
 
Dilution buffer 10% normal goat serum 
1% BSA 
0.1% saponin 
In PBS 
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Fixation buffer 3% PFA 
In PBS 
 
Permeabilization buffer 0.1% Triton X-100 
In PBS 
 
Washing buffer 0.01% Saponin 
In PBS 
 
2.1.5.5  Buffers for Purification of MOG Protein 
Volumes in brackets indicate approximate amount needed for each purification procedure. 
 
Arginine buffer (250 ml) 
 
50 mM NaH2PO4 , pH8.0 
2 M L-Arginine 
300 mM NaCl 
50 mM red. glutathione 
 
Dialysis buffer A (2 l) 
 
50 mM NaH2PO4 , pH8.0 
300 mM L-Arginine 
300 mM NaCl 
 
Dialysis buffer B (6 l) 
 
50 mM NaH2PO4 H, pH8.0 
300 mM NaCl 
 
Dialysis buffer C (1× PBS) 
(10 l) 
 
10 mM Na2HPO4, pH7.4 
137 mM NaCl 
2.7 mM KCl 
1.7 mM KH2PO4 
 
Elution buffer (50 ml) 
 
250 mM Imidazole 
In solubilization buffer  
 
Endotoxin-removal buffer 
(350 ml) 
 
0.1% Triton X-114 
In solubilization buffer 
pH was not adjusted 
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Lysis buffer (50 ml) 50 mM Tris, pH8.0 
300 mM NaCl 
25 µg/ml DNAse 
1× Roche cOmplete Protease Inhibitor Cocktail Tablet 
 
Solubilization and running 
buffer (100 ml) 
 
50 mM NaH2PO4 , pH8.0 
6 M GuHCl 
300 mM NaCl 
20 mM Imidazole 
50 mM β-mercaptoethanol 
 
2.1.5.6  Buffers for Western Blot Analysis 
PBS-T buffer 0.1% Tween® 20 
In PBS 
 
Running buffer, 10×  (1 l) 
 
30.3 g Tris base 
144 g Glycine 
10 g SDS (Add SDS after pH adjustment) 
adjust pH to 8.3 (with HCl) 
 
1.5 M Tris pH8.8 (150 ml) 
 
27.23 g Tris base  
add dH2O until ~80 ml 
adjust pH to 8.8 with 6N HCl 
 
1.5 M Tris pH6.8 (100 ml) 
 
18.17 g Tris base 
Add dH2O until ~60 ml and adjust pH to 6.8 with 6N HCl 
 
20% SDS solution Purchased from Fluka (Sigma) 
 
Transfer buffer, 1× 
20% methanol 
 
25 mM Tris base 
192 mM glycine 
20% methanol 
 
Destaining buffer 
 
400 ml H2O 
400 ml methanol 
80 ml acetic acid 
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Coomassie Staining 
 
200 ml methanol 
200 ml H2O 
40 ml acetic acid 
1 spoontip of Coomassie brilliant  blue R250 
 
2.1.6 General Use Material 
Material Company Catalog Number 
Amicon Ultra-15 Centrifugal Filter Units Millipore UFC900324 
CD4 (L3T4) MicroBeads, mouse Mylteni 130-049-201 
CD11c MicroBeads, mouse Mylteni 130-052-001 
Cell culture slide SPL 30108 
Cell freezing container Nalgene - 
ECL films GE Healthcare/VWR 28-9068-37 
Ni-NTA Superflow Qiagen 30410 
Polymer microspheres 3.87 µm Bangs laboratories PS05N/6749 
PureYield™ Plasmid Miniprep System Promega (HELIX) A1223 
PVDF membrane GE Healthcare RPN303F 
Spectra/Por 3 Dialysis Tubing, 3.5K MWCO VWR 734-0686 
QIAprep Spin Miniprep Kit Qiagen 27104 
Whatman blotting papers 3 mm CHR VWR international 588-3186 
 
2.1.7 Cytokines 
Material Company Catalog Number 
GM-CSF Self-made (chapter 2.2.8.5) - 
Mouse IL-23 recombinant protein eBioscience 14-8231 
 
2.1.8 PCR Primers 
Primer Target Sequence (5’-3’) 
CS003 Atg5flox/flox GAATATGAAGGCACACCCCTGAAATG 
CS004 Atg5flox/flox GTACTGCATAATGGTTTAACTCTTGC 
CS005 Atg5flox/flox ACAACGTCGAGCACAGCTGCGCAAGG 
CS006 Atg5flox/flox CAGGGAATGGTGTCTCCCAC 
CS007 CD11c-Cre-GFP GCGGTCTGGCAGTAAAAACTATC 
CS008 CD11c-Cre-GFP GTGAAACAGCATTGCTGTCACTT 
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CS009 
CD11c-Cre-GFP 
(positive control 1) 
CTAGGCCACAGAATTGAAAGATCT 
CS010 
CD11c-Cre-GFP 
(positive control 2) 
GTAGGTGGAAATTCTAGCATCATCC 
CS011 B6-GFP-LC3 ATAACTTGCTGGCCTTTCCACT 
CS012 B6-GFP-LC3 CGGGCCATTTACCGTAAGTTAT 
CS013 B6-GFP-LC3 GCAGCTCATTGCTGTTCCTCAA 
CS014 Atg7flox/flox TGGCTGCTACTTCTGCAATGATGT 
CS015 Atg7flox/flox CAGGACAGAGACCCATCAGCTCCAC 
CS016 Atg7flox/flox TTAGCACAGGGAACAGCGCTCATGG 
 
2.1.9 Antibodies 
2.1.9.1  FACS Antibodies 
2D2 genotyping 
Antigen Fluorochrome Clone Dilution Company 
CD4 APC GK1.5 1:1000 BioLegend 
CD8 PE-Cy7 53-6.7 1:800 BD 
TCR Vb11 PE RR3-15 1:400 BD 
 
BM-DC time course 
Antigen Fluorochrome Clone Dilution Company 
CD11c PE HL3 1:200 BD 
H2-Ab Pacific Blue M5/114.15.2 1:800 BioLegend 
H-2Db  APC KH95 1:200 BioLegend 
 
Cre leakage 
Antigen Fluorochrome Clone Dilution Company 
CD4 APC GK1.5 1:1000 BioLegend 
CD8 PE-Cy7 53-6.7 1:800 BD 
CD11b APC-Cy7 M1/70 1:400 BD 
 
DC:T cell co-culture 
Antigen Fluorochrome Clone Dilution Company 
CD4 Pacific Blue RM4-5 1:1000 BioLegend 
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DC subset analysis 
Antigen Fluorochrome Clone Dilution Company 
CD8a Brilliant violett 570 53-6.7 1:200 BioLegend 
CD11b APC-Cy7 M1/70 1:400 BD 
CD11c PE-Cy7 N418 1:400 eBioscience 
CD45.2 Pacific Blue 104 1:800 BioLegend 
CD86 Alexa Fluor® 700 PO3 1:200 BioLegend 
F4/80 APC BM8 1:200 BioLegend 
H2-Ab Biotinylated AF6-120.1 1:800 BD 
Ly6c PercCP-Cy5.5 HK1.4 1:200 BioLegend 
Siglec-H PE eBio440c 1:800 eBioscience 
Streptavidin  Qdot800 - 1:800 Invitrogen 
 
ICS 
Antigen Fluorochrome Clone Dilution Company 
CD4 APC-Cy7 GK1.5 1:500 BioLegend 
CD8 PerCP-Cy5.5 53-6.7 1:500 BD 
CD11b APC-Cy7 M1/70 1:400 BD 
CD45 Pacific Blue 30-F11 1:800 BioLegend 
IFN-γ PE-Cy7 XMG1.2 1:250 BioLegend 
GM-CSF PE MP1-22E9 1:250 BD 
IL-17A Alexa Fluor® 647 TC11-18H10.f 1:200 eBioscience 
 
Treg analysis 
Antigen Fluorochrome Clone Dilution Company 
CD4 Pacific Blue RM4-5 1:800 BioLegend 
CD25 APC PC61 1:500 BD 
CD45  APC-Cy7 30-F11 1:400 BD 
FoxP3 PE FJK-16s 1:100 eBioscience 
 
2.1.9.2  Anti CD3 and CD28 Antibodies (Co-Culture) 
Antigen Clone Final Concentration Company 
CD3 145-2C11 5 µg/ml BD 
CD28 37.51 5 µg/ml BD 
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2.1.9.3  Antibodies for Immunofluorescence Cytochemistry 
All antibodies used for immunofluorescence cytochemistry were diluted in dilution buffer as 
indicated in the table below. The diluted antibodies were spun for five minutes at 13000 rpm to 
remove precipitated antibodies.  
 
Antibody Company Catalog number Dilution 
1° Antibody 
Rabbit anti-LC3 polyclonal, MBL LabForce PM036 1:100 
2° Antibody 
Goat anti-rabbit IgG (H+L), Alexa 
Fluor® 488 
Invitrogen A-11008 1:500 
 
2.1.9.4 Antibodies for Western Blot Analysis 
Antibody Company Catalog number Dilution 
β-actin antibody [AC-15] 
HRP-conjugated 
Abcam ab49900-100 1:50000 
Atg5 and Atg5-Atg12 complex Biomol 0262-100/ATG5-7C6 1:400 
Atg8/LC3  Biomol 0231-100/LC-3-5F10 1:1000 
Goat anti-mouse IgG, HRP BioRad 170-6516 1:10000 
 
2.1.10 Mice 
Female or male B6 mice were purchased from Janvier or Zuchtbetrieb Fuellinsdorf, Switzerland. 
C57 Bl/6J-Tg(Itgax-cre-EGFP)4097Ach/J were purchased from Charles River. Atg5flox/flox mice 
were a kind gift of Noboru Mizushima (University of Tokyo, Japan). To generate conditional 
knockout (KO) mice lacking macroautophagy in CD11c+ APCs CD11c-Cre-EGFP+/- mice were 
bred with Atg5flox/flox mice to generate Atg5flox/flox CD11c-Cre-EGFP+/- mice (designated DCAtg5KO 
mice). For a more detailed breeding scheme see chapter 3.1. 
MOG-specific TCR transgenic mice C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J (designated 2D2) 
were a kind gift from Burkhard Becher (University of Zurich, Switzerland). Atg7flox/flox mice were a 
kind gift of Masaaki Komatsu (University of Tokyo, Japan). To generate conditional KO mice 
lacking Atg7 in CD11c+ APCs, CD11c-Cre-EGFP+/- mice were bred with Atg7flox/flox mice to 
generate Atg7flox/flox CD11c-Cre-EGFP+/- mice (designated DCAtg7KO mice). DCAtg5KO, DCAtg7KO and 
2D2 mice were bred in-house under specific pathogen-free conditions. Animal experiments were 
approved by the Swiss Veterinary Office (134/2011) and were carried out according to federal and 
institutional guidelines. 
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2.2 Methods 
2.2.1 Genotyping 
2.2.1.1 Preparation of DNA Samples for Genotyping 
Biopsies were taken from either ear or tail (0.3-0.6 cm) and transferred to 1.5 ml tubes. 100 µl of 
tail digestion buffer, which had been completed with proteinase K, was added to each biopsy. The 
digest was performed at 550 rpm, 56°C for four to six hours or overnight. When the digest was 
completed 300 µl of H20 was added to 100 µl of digest buffer. The sample was centrifuged for ten 
minutes at maximum speed in a tabletop centrifuge to pellet cell debris. The supernatant was 
transferred to a fresh tube containing 500 µl of isopropanol and mixed well. The sample was 
centrifuged as described above and the supernatant was removed. The DNA pellet was washed with 
200 µl of ice-cold (-20°C) ethanol 70%. At this step, the DNA was not resuspended, but only rinsed 
with ethanol 70%. Another centrifugation step was performed and the supernatant was discarded. 
The DNA was air-dried for a maximum of 15 minutes. Finally, the DNA was resuspended in 100 µl 
of H20 and used for the genotyping PCR. 
 
2.2.1.2 Genotyping PCR Protocols 
Depending on the allele that had to be screened for, different PCRs were performed. They differed 
in their master mix as well as in the PCR program applied. For further details see protocols below. 
The PCR products were analyzed on a 1% agarose gel in TBE buffer.  
 
Atg5flox/flox Genotyping Protocol 
Regarding the genotyping for the Atg5flox/flox allele either the Taq DNA Polymerase System or the 
FIREPol 5× Master Mix 7.5 mM Ready to Load were used. The expected PCR products were 650 
base pairs (bp) for the Atg5flox allele and 350 bp for the Atg5 wild type (wt) allele. The 
components of the master mix and the PCR program are shown below. 
 
Standard master mix (1×)  FIREPol master mix (1×) 
Reagent Volume (µl)  Reagent Volume (µl) 
DNA 5.0  DNA 2.0 
10× buffer + MgCl2 5.0  5× FIREPol mix 4.0 
Primer CS 003, 10 µM 1.0  Primer CS 003, 10 µM 0.5 
Primer CS 004, 10 µM 1.0  Primer CS 004, 10 µM 0.5 
Primer CS 005, 10 µM 1.0  Primer CS 005, 10 µM 0.5 
Primer CS 006, 10 µM 1.0  Primer CS 006, 10 µM 0.5 
Taq DNA polymerase 0.4  H2O 12.0 
dNTPs 1.0  Total Volume 20.0 
H2O 34.6    
Total Volume 50.0    
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PCR program (standard reaction)  PCR program (FIREPol reagents) 
Temperature  Time   Temperature Time  
95°C 3 min   95°C 10 min  
95°C 30 sec   95°C 30 sec  
60°C 30 sec ×35  60°C 30 sec ×35 
72°C 1 min   72°C 1 min  
72°C 10 min   72°C 10 min  
12°C ∞   12°C ∞  
 
 
Atg7flox/flox Genotyping Protocol 
For the genotyping of the Atg7flox allele the TaKaRa PCR products were used. The expected PCR 
products were 0.5 kilobase pairs (kb) for the Atg7flox allele and 1.5 kb for the Atg7 wild type 
allele. The components of the master mix and the PCR program are shown below. 
 
Standard master mix (1×) 
Reagent Volume (µl) 
DNA 2.0 
10× buffer 2.0 
Primer CS014 0.2 
Primer CS015 0.2 
Taq DNA polymerase  0.2 
dNTPs 3.2 
H2O 12.2 
Total Volume 20.0 
 
PCR program 
Temperature Time  
94°C 5 min  
94°C 30 sec  
65°C 30 sec ×30 
68°C 90 sec  
72°C 10 min  
12°C ∞  
 
 
CD11c-Cre Genotyping Protocol 
Regarding the genotyping for the Cre allele either the Taq DNA Polymerase System or the FIREPol 
“FIREPol 5× Master Mix 7.5 mM Ready to Load were used. The expected PCR products of the Cre 
transgene is 100 bp and those of the internal positive control 324 bp long. Note, that this PCR 
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reaction will not discriminate heterozygous from homozygous transgenic animals. The components 
of the master mix and the PCR program are shown below. 
 
Standard master mix (1×)  FIREPol master mix (1×) 
Reagent Volume (µl)  Reagent Volume (µl) 
DNA 2.0  DNA 2.0 
10× buffer + MgCl2 2.5  5× FIREPol Mix 4.0 
Primer CS 007, 10 µM 1.0  Primer CS 007, 10 µM 0.5 
Primer CS 008, 10 µM 1.0  Primer CS 008, 10 µM 0.5 
Primer CS 009, 10 µM 1.0  Primer CS 009, 10 µM 0.5 
Primer CS 010, 10 µM 1.0  Primer CS 010, 10 µM 0.5 
dNTPs 1.0  H2O 12.0 
Taq DNA polymerase 0.25  Total Volume 20.0 
H2O 15.25    
Total Volume 25.0    
     
PCR program (standard protocol)  PCR program (FIREPol protocol) 
Temperature  Time   Temperature Time  
94°C 3 min   94°C 3 min  
94°C 30 sec   94°C 30 sec  
58°C 1 min ×35  63°C 1 min ×35 
72°C 1 min   72°C 1 min  
72°C 10 min   72°C 5 min  
10°C ∞   12°C ∞  
 
 
2D2 Genotyping Protocol 
2D2 mice that are MOG-specific TCR transgenic mice were genotyped by flow cytometry analysis. 
For this analysis 50 µl of blood were used. The blood was taken by cutting the tip of the tail and 50 
µl of blood were withdrawn and mixed with 5 µl of Heparin. The mixture was transferred to FACS 
tubes and 900 µl of ACK lysing buffer was added. The red blood cell lysis was performed for three 
minutes at room temperature. The cells were washed with PBS and spun for three minutes at 400 × 
g at room temperature. The red blood cell lysis was repeated until all red blood cells had been lysed. 
The cells were finally washed with PBS and subsequently stained with antibody solution (CD4 
Pacific Blue, CD8a FITC, Vβ11 PE) for 30 minutes on ice. The cells were washed twice with 4 ml 
of PBS and fixed with 2% PFA in PBS for ten minutes at room temperature. A final wash with 4 ml 
of PBS was performed and the cells were resuspended in 200 µl of PBS. If cell clumps had been 
formed, cells were filtered prior to flow cytometry analysis. 
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2.2.2 Induction and Scoring of EAE 
2.2.2.1  Induction of Active EAE 
For the induction of EAE at least nine week old mice were used. EAE was either induced with 
MOG35–55 peptide (MOG peptide) or MOG1-124 protein (MOG protein). The MOG peptide or MOG 
protein were prepared in the same way and the preparation is exemplarily described for the MOG35–
55 peptide. Initially, a mixture of MOG35–55 peptide with CFA was prepared and the final 
concentration of MOG peptide was 0.5 µg/µl. If necessary the peptide was diluted in PBS and 
subsequently mixed at a 1:1 ratio with CFA. For the preparation of the MOG peptide:CFA mixture, 
the two fractions were pooled in a 5 ml polypropylene tube with snap caps. The mixture was 
vortexed for 30 minutes at room temperature at medium speed. The MOG peptide:CFA homogenate 
was sonicated on ice five times for 15 seconds each at a power level of 18. Each sonification step 
was interrupted with breaks of 45 seconds. The homogenate was transferred to a 1 ml syringe and 
for the injection a 24G×1’’ needle was used. Finally, at day 0, the mice were immunized with 200 
µl of the MOG peptide:CFA mixture subcutaneously in the left lateral abdomen. At day 7 the 
injection was repeated, but this time the MOG peptide:CFA mixture was applied to the right 
abdomen. Additionally, the mice were injected with 300 ng of PTx. 300 ng of PTx was diluted in 
100 µl of PTx diluent and was administered intra peritoneally (i.p.) on day zero and two. After 
induction of EAE mice were observed daily for weight loss, disability and availability of feed and 
water.  
 
2.2.2.2  Induction of EAE by Adoptive Transfer of Autoreactive CD4+ T Cells 
At least nine week old mice were used. The MOG peptide:CFA emulsion was prepared as described 
above and the final MOG peptide concentration was adjusted to a final concentration of 1 mg/ml. At 
day zero donor mice (either wt or 2D2) were immunized subcutaneously with 100 µl of MOG-CFA 
emulsion into both flanks. Thus, in total each mouse received 200 µl of MOG-CFA emulsion. On 
the same day 300 ng of PTx in 100 µl of PTx diluent was administered i.p. On day seven mice were 
sacrificed and spleens as well as draining axillary lymph nodes were removed. 
Lymphocytes were isolated from spleen and lymph nodes as described in chapter 2.2.3. After the 
isolation of lymphocytes, cells were counted and the cell number was adjusted to 8-10×106 cells/ml 
in culture medium. Culture medium was additionally supplemented with 20 ng/ml of recombinant 
IL-23 and 20 µg/ml of MOG peptide35–55. Cells were transferred to a 10 cm tissue culture-treated 
Petri dish and cultured for two days at 37°C and 5% CO2 in humid atmosphere. Cell blasts were 
visible under the microscope after two days of culture. One day before the transfer of the cells, the 
recipient mice were irradiated with 550 rad (cesium source). At day nine the cultured cells were 
washed with PBS twice and the cell number was adjusted to the desired concentration of 5×106 
cells/400 µl (2D2 as donor) or 10-15×106 cells/ 400 µl (wt as donor). 400 µl of this cell suspension 
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was injected intraperitoneally into the recipient mice. No additional injection of Ptx was performed. 
After induction of EAE mice were observed daily for weight loss, disability and availability of feed 
and water. The disease onset was expected to be two days later than in the active immunization 
procedure. 
 
2.2.2.3  EAE Scoring and Analysis 
After onset of EAE symptoms mice were scored according to the following scoring criteria by a 
grid test: 0: no detectable signs of EAE, 0.5: distal limp tail weakness, 1.0: complete limp tail, 1.5: 
limp tail and hind limb weakness, 2.0: unilateral partial hind limb paralysis, 2.5: bilateral partial 
hind limb paralysis, 3.0: complete bilateral hind limb paralysis, 3.5: complete bilateral hind limb 
paralysis and partial forelimb paralysis, 4.0: moribund (mouse completely paralyzed), score 5.0: 
dead. With an EAE score of 1.0 feed and water needed to be provided to guarantee well-being of 
the mice. Mice were sacrificed if they showed a score of 3.0 for more than seven constitutive days 
or a score of 3.5 for more than three constitutive days, and immediately if they showed a score of 
4.0. Furthermore, mice needed to be sacrificed if they lost more than 30% of their maximum body 
weight. For the analysis, the average day of onset, mean clinical scores and mean maximal scores 
were determined. 
 
2.2.3 Lymphocyte Isolation and Preparation 
2.2.3.1  Lymphocyte Isolation from Mouse Spleen and Lymph Nodes 
T cells and DCs were purified from spleen and/or lymph nodes. For the preparation of DCs from 
organs, a single-cell suspension was prepared by enzymatic disaggregation with collagenase D and 
DNase. On the other hand, for the preparation of T cells this disaggregation step can be omitted. 
Organs were removed from mice, transferred to PBS and kept on ice until further proceeding. In a 
next step, the respective organ was chopped with scissors and digested with spleen digest buffer at 
37°C (5% CO2 in humid atmosphere) for 30 minutes. Afterwards, the tissue was meshed through a 
70 µm nylon mesh by using a syringe punch. The nylon mesh was rinsed with 40 ml of PBS, the 
cells were centrifuged for five minutes at 400 × g and the supernatant was discarded. Additionally, a 
red blood cell lysis was performed by adding 1 ml of ACK red blood cell lysing buffer followed by 
thorough resuspension of the cells. After an incubation time of three minutes at room temperature, 
the cells were washed with PBS as described above. 
 
2.2.3.2  Lymphocyte and Microglia Isolation from Mouse CNS 
Mice were sacrificed with CO2 and perfused with 30-50 ml of ice-cold PBS. The spinal cord was 
flushed out with a 24G×1’’ needle and the brain was removed. The organs were transferred to ice-
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cold PBS and all following steps were performed on ice unless otherwise mentioned. The organs 
were chopped with scissors and digested with 5 ml of digest buffer per brain. The digest was 
performed for 30 minutes at 37°C and mixed every ten minutes with a 1 ml pipette. To stop the 
reaction 10 mM of EDTA was added and incubated for another five minutes at 37°C. The digested 
tissue was meshed through a 70 µm nylon mesh using a syringe punch. The mesh was rinsed with 
40 ml of PBS and the cells were spun for 5 minutes at 400 × g at 4°C. The supernatant was 
discarded and the pellet was resuspended in a 30% percoll solution. The suspension was transferred 
to 16 ml centrifuge tubes and spun at 10’8000 rpm for 30 minutes at 4°C. To not disturb the 
gradient, the centrifuge brakes were set to an acceleration of nine and a disacceleration of one. The 
myelin was sucked off and discarded. The remaining fraction, but not the red blood cells, was 
transferred to a fresh 50 ml tube und filled up with PBS. The cells were spun at 400 × g for five 
minutes at 4°C. The supernatant was discarded and the pellet was resuspended in 1 ml of PBS. At 
the end the cells were counted and used for the desired experiment.  
 
2.2.3.3  Magnetic Activated Cell Sorting 
DCs or T cells were purified by magnetic activated cell sorting (MACS) by using CD11c and CD4 
MicroBeads, respectively, according to MACS Miltenyi Biotec’s recommendations. The procedure 
is briefly summarized here: 
A single-cell suspension was obtained from spleen as described in chapter 2.2.3. Generally, for the 
performance of MACS separation the cells were kept cold during the entire procedure and all 
solutions were pre-cooled. To avoid cell clumps, the suspension was filtered through a 70 µm nylon 
mesh before usage.  
Cells were magnetically labeled by using either CD11c MicroBeads (100 µl of CD11c MicroBeads 
and 400 µl of MACS buffer per 1×108 cells) or CD4 MicroBeads (10 µl of CD4 MicroBeads and 90 
µl of MACS buffer per 1×107 cells). The cells and reagents were mixed thoroughly by pipetting and 
incubated for 15 minutes at 4°C. The cells were washed with MACS buffer (2 ml per 1×107 cells) 
and centrifuged. The cell pellet was resuspended in MACS buffer (500 µl per 1×108 cells) and the 
magnetic separation was performed with the autoMACSTM separator using the “PosselD” program. 
The expected percentage of CD4+ T cells in the spleen is around 20% of total cells, whereas the 
expected number of DCs in the spleen is around 1%. 
 
2.2.4 Flow Cytometric Techniques 
2.2.4.1  Flow Cytometry 
All flow cytometric analyses were performed in PBS without supplements. A list of used antibodies 
and their respective dilution is shown in table 2.1.9.1. The used antibody combinations are 
mentioned with the respective experiment (see results section). For all experiments antibody 
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staining and live/dead staining by use of the LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit were 
performed in parallel. All centrifugation steps were performed for five minutes at 400 × g unless 
otherwise mentioned.  
Generally, 30 to 50 µl of antibody mixture were used to stain roughly 1×106 cells. The cells were 
carefully resuspended and incubated for 20 to 30 minutes at 4°C. The cells were washed twice with 
PBS and centrifuged. The supernatant was discarded and the cells were resuspended in 100 to 200 
µl of PBS, depending on the cell number used. Cells were subsequently analyzed via flow 
cytometry. 
 
2.2.4.2  IFN-γ, IL-17 and GM-CSF Intracellular Cytokine Staining 
A lymphocyte suspension was prepared as described in chapter 2.2.3. To perform an intracellular 
cytokine staining (ICS), 1-2×107 cells per condition were used. The needed cells were resuspended 
in 1 ml of cell culture medium and transferred to sterile FACS tubes. The cells were stimulated in 
vitro by using 50 ng/ml of phorbol ester (PMA) and 500 µg/ml of ionomycin. In order to block the 
intracellular transport processes, additionally, BD GolgiStop™ (Monensin) was added to the cells. 
The subsequent time period of incubation depended on the respective cytokine production (GM-
CSF: 6 hours, IFN-γ: 4-5 hours). The cells were incubated at 37°C for 5 hours. 
In a next step, the surface staining of the cells was performed according to the standard flow 
cytometry staining procedure (chapter 2.2.4.1). After staining for cell surface markers, the cells 
were resuspended with 300 µl of PBS. To stain for intracellular antigens, the cells were fixed and 
permeabilized by use of the BD Cytofix/Cytoperm™ Plus Solution. The cells were pulse vortexed 
after the last washing step and 200 µl of BD Cytofix/Cytoperm™ Buffer was added per sample 
(only 100 µl were used when ICS was performed in a 96-well plate format) and thoroughly vortexed 
again. The cells were incubated for 20 minutes at 4°C and 1 ml of 1× BD Permeabilization/Wash 
Buffer was added. The cells were centrifuged for three minutes at 500 × g and the supernatant was 
discarded. Optionally, the staining procedure was stopped at this step and the cells were stored in 
either 1× BD Permeabilization/Wash Buffer or in FACS buffer at 4°C overnight. In a next step, the 
cell pellet was resuspended in 30 to 50 µl of properly diluted antibody solution that was diluted in 
1× BD Permeabilization/Wash Buffer. The cells were incubated for 20 minutes at 4°C and 1 ml of 
1× BD Permeabilization/Wash Buffer was added. Finally, the cells were centrifuged for three 
minutes at 500 × g and the supernatant was discarded. The cells were resuspended in PBS and 
subsequently analyzed via flow cytometry. 
 
2.2.4.3  Intracellular Staining for Murine FoxP3+ Regulatory T cells 
The Foxp3 Staining Buffer Set from eBioscience was used to perform the intracellular FoxP3 
staining for flow cytometry analysis. Prior to the staining, the eBioscience 
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Fixation/Permeabilization Concentrate (1 part) was diluted into the eBioscience 
Fixation/Permeabilization Diluent  (3 parts) which resulted in the so-called eBioscience 
Fixation/Permeabilization Working Solution (Fix/Perm solution). 
A single cell suspension was prepared as described in chapter 2.2.3 and 1×106 cells in 100 µl were 
used per condition. The surface molecules CD4, CD8 and CD25 were stained according to the 
general flow cytometry procedure (chapter 2.2.4.1). Cells were washed with PBS and the cell pellet 
was resuspended with 500 µl of freshly prepared Fix/Perm solution. In a next step, cells were pulse 
vortexed and incubated at 4°C between 30 minutes and 18 hours in the dark. After this incubation 
time, cells were washed twice by adding 1 ml of 1× eBioscience Permeabilization Buffer (Perm 
buffer) followed by centrifugation and aspiration of the supernatant. 10 µl of anti-FoxP3 antibody 
diluted in 1× Perm buffer was added to the cells. Cells were then incubated at 4°C for at least 30 
minutes in the dark. At the end, cells were washed twice with 2 ml of 1× Perm buffer and 
resuspended in an appropriate volume of PBS and subsequently analyzed by use of flow cytometry. 
 
2.2.4.4  Fluorescent Activated Cell Sorting 
Single cell suspensions were prepared as described in chapter 2.2.3 and the final cell number was 
adjusted to 2×107 cells/ml. DCs were purified by fluorescence activated cell sorting (FACS) based 
on the following markers: CD45+, CD11chigh and H2-Ab high and the desired cell population was 
sorted into 5 ml of complete cell culture medium in 15 ml tubes. The FACS was performed at the 
FACS Aria cell sorter by the technical staff of the Center for Microscopy and Image Analysis at the 
University of Zurich, Switzerland. 
 
2.2.4.5  Flow Cytometry Analysis 
Flow cytometry analyses were either performed on FACSCantoII or LSRII Fortessa provided by the 
Institute of Experimental Immunology, Zurich, Switzerland. Flow cytometry analysis data were 
analyzed by Diva or FlowJo software. 
 
2.2.5 CFSE Labeling 
To uniformly label the cells with carboxyfluorescein succinimidyl ester (CFSE), it was ensured that 
the cells were properly resuspended and not aggregated. The quantity of cells labeled depended on 
the respective experiment. A single-cell suspension of CD4+ T cells was prepared in PBS/0.1% 
BSA at a final concentration of 5×107 cells/ml. CFSE was added to the cells at a final concentration 
of 1 µM and the cells were incubated for 10 minutes at 37°C. In a next step, the cells were quenched 
by adding 5 volumes of ice-cold cell culture medium followed by five minutes incubation on ice. 
Finally, the cells were washed three times with cell culture medium. 
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2.2.6 DC:T Cell Co-Culture 
Isolated (chapter 2.2.3) and MACS-enriched (chapter 2.2.3.3) CD4+ T cells were CFSE-labeled 
(chapter 2.2.5) and co-cultured with FACS-sorted DCs (chapter 2.2.4.4) in RPMI cell culture 
medium supplemented with β-mercaptoethanol. The co-culture was performed in a 96-well round-
bottom plate at a 1:3 effector to target cell ratio (30000 DCs: 100000 T cells). Depending on the 
conditions to be tested either MOG peptide, MOG protein, or beads coated with MOG protein were 
added to the cells in cell culture medium. To control for unspecific proliferation of CD4+ T cells, 
the following negative controls were included: T cells only and DCs plus T cells without further 
additives. As positive control CD4+ T cells were cultured in the presence of an anti-CD3 and anti-
CD28 antibody. The wells were coated with 5 µg/ml of anti-CD3 and anti-CD28 antibody each in 
PBS for five hours at room temperature or overnight at 4°C. Finally, the cells were incubated for 
four days at 37°C and 5% CO2 in a humid atmosphere. To check for CFSE dilution, cultured cells 
were washed twice with PBS and spun at 400 × g for five minutes. The cells were stained with anti-
CD4 and the LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit was used. CFSE dilution was 
analyzed via flow cytometry analysis and assessed by CFSE dilution. For the analysis of T cell 
proliferation, only those samples were analyzed that showed 1% live cells (AmCyan- cells) of the 
starting cell number (starting cell number 100000 T cells). Furthermore, all CFSEdim/low cells were 
considered as proliferated T cells and the percentage of this cell number was used. 
 
2.2.7 Coating of Polystyrene Beads with MOG Protein 
The coating procedure of polystyrene beads is based on recommendations form Technote 204 from 
Bangs laboratories. The polystyrene beads were coated with 50 µg of MOG protein per 1×108 
beads. For the coating, 1×108 beads were taken and washed with 1 ml of PBS. In a next step, beads 
were centrifuged at 600 × g for five minutes and the supernatant was discarded. The washing step 
was repeated once more and the beads were resuspended in 950 µl of PBS. The beads were added to 
50 µl of MOG protein (stock 1 mg/ml) and mixed by pipetting. The coating was performed for one 
to two hours at room temperature and, additionally, overnight in the cold room on a rotator. On the 
next day, the beads were washed 5 times with PBS and counted. In the experimental setup of a co-
culture experiment (chapter 2.2.6), the beads were used at a bead to DC ratio of 8:1, 4:1, 2:1 and 
1:1. 
 
2.2.8 Cell Culture 
All cell lines or primary cells were cultured at 37°C in a humid atmosphere of 5% CO2 in air. The 
different cell lines were cultured in medium specifically designed for their respective nutritional and 
survival factor characteristics. Glass bottles, pipette tips, PBS and endotoxin-free Milli-Q water 
were sterilized by autoclaving before usage. Culture plates, flasks and further plastic supplies used 
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for cell culture were purchased from SPL Life Sciences. Cell culture work was performed under 
sterile conditions in a biological safety cabinet. All centrifugation steps of cells were performed 
with the Multipurpose Centrifuge 5810 R from Eppendorf ® at 400 × g for five minutes at 4°C, 
unless otherwise mentioned. 
 
2.2.8.1  Determination of Cell Concentration 
Cells were counted by using a Neubauer-counting chamber (Fisher Scientific), also known as 
hemocytometer. To distinguish viable from dead cells, a trypan blue staining was performed by 
mixing the cell suspension and trypan blue at a 1:1 ratio. Dead cells are stained by trypan blue 
whereas live cells do not take up the trypan blue dye. The viability and cell numbers were 
determined by use of a Leica DMIL microscope.  
 
2.2.8.2  Cell Passaging of Adherent Cells 
Adherent cells were kept at a cell density of 20-90%. For detachment of cells, cell medium was 
removed and cells were rinsed with PBS. Trypsin-EDTA 0.25% was added to the cells and 
incubated for one minute at room temperature to assure a quick and efficient detachment of the 
cells. During the incubation time the flask was frequently tapped to facilitate detachment. The cells 
were washed with PBS and resuspended in complete cell culture medium and plated into new tissue 
culture flasks. If Trypsin was to be avoided, adherent cells were detached by use of a cell scraper 
instead. 
 
2.2.8.3  Freezing and Thawing of Cells 
Cells to be frozen were washed with medium and resuspended in freezing medium. Cells were 
transferred to cryo tubes and and slowly frozen using a cell freezing container. On the next day, 
cells were transferred to liquid nitrogen for long-term storage. 
To thaw cells, a frozen aliquot of cells was thawed quickly in a 37°C water bath and cells were 
immediately transferred to complete medium to dilute the DMSO and minimize osmotic shock. 
Cells were spun, supernatant discarded, and the cell pellet resuspended in fresh complete medium 
and plated. As soon as the cells appeared healthy and started to grow exponentially they were 
maintained as normal and could be used for experiments. 
 
2.2.8.4  Culturing of Primary Mouse Cells 
Single cell suspensions were obtained as described in chapter 2.2.3. The cells of interest were 
cultured under general cell culture conditions as described above. 
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2.2.8.5  Cell Line X-63-GM-CSF 
The X-63-GM-CSF cell line is a mouse myeloma cell line served as a source for GM-CSF and the 
supernatant of the X-63-GM-CSF cell culture was used to generate bone marrow-derived DCs. The 
cell line X-63-GM-CSF was cultured in complete DMEM medium. To start with, X-63-GM-CSF 
cells were cultured under selective conditions to select for the GM-CSF gene. The antibiotic G418 
was added at a final concentration of 500 µg/ml and G418 selection was performed for 10 to 14 
days. After successful selection, the cells were washed and seeded at a final density of 3×105 
cells/ml of complete medium without G418 in a 10 cm cell culture dish. This equals approximately 
6.5×106 cells/ per 30 ml in a 175 cm2 dish. The cells were kept in culture for a week or until the pH 
indicator in the medium turned yellow indicating acidity. At the end, the medium was harvested and 
spun at 500 × g for five minutes. The supernatant was kept, sterile filtered with a 0.22 µm mesh, 
aliquoted and stored at -20°C until further usage. 
 
2.2.8.6  Generation of Bone Marrow-Derived DCs 
For isolation of progenitor DCs from the bone marrow (BM), BM-donors were euthanized and skin 
and muscles from pelvis, femur and tibia were removed. Bones were transferred to PBS and stored 
on ice. Later on, the bones were cut with scissors in half and flushed with PBS by use of a 30G1/2’’ 
needle. The cells were forced through a 70 µm cell strainer and topped with PBS. In a next step, the 
cells were centrifuged at 400 × g for five minutes and the supernatant was discarded. For red blood 
cell lysis, the cell pellet was resuspended in 3 ml of ACK red blood cell lysing buffer and incubated 
for three minutes at room temperature. The lysis was stopped by adding 50 ml of PBS and the cells 
were centrifuged. The supernatant was discarded and the cell number was adjusted to a final cell 
concentration of 2-2.5×106 cells/ml in complete BM-DC medium. The cells were finally cultured in 
a total volume of 10 ml (2-2.5×107 total cells) in a 10 cm non-tissue culture treated petri dish. A full 
medium change was performed every other day by collecting the floating cells, spinning them and 
resuspending the resulting pellet in fresh BM-DC medium. The cells were then placed back to the 
original dish. In total, the cells were cultured for eight to ten days to assure proper differentiation 
into a DC-like phenotype. At the last day of culture, the complete medium was removed and the 
adherent cells were removed by either trypsinization or scraping them off with a cell scraper. The 
purity and maturation status of the cells was confirmed by flow cytometry analysis. Generally, a 
purity of 80% of CD11c+ DCs could be achieved. 
 
2.2.9 Immunofluorescence Microscopy 
2.2.9.1  Preparation of Cells for Immunofluorescence Microscopy 
To study the localization of LC3+ autophagosomes after the treatment of BM-DCs with MOG 
protein-coated beads, immunofluorescence microscopy was performed. BM-DCs were generated as 
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described in chapter 2.2.8.6 and at day ten of culture, BM-DCs were seeded in a cell culture slide 
and only the adherent BM-DCs were taken for each experiment. In total, 7.5×104 BM-DCs were 
plated into each well of the cell culture slide and cells were left in the chamber slide overnight in 
order to attach properly. In parallel, the polystyrene beads were coated with MOG protein as 
described in chapter 2.2.7. On the next day, the BM-DCs were cultured under various conditions for 
four hours at 37°C. 
 
2.2.9.2  Immunofluorescence Staining for Microscopy 
For the immunofluorescence staining, the cells were washed by drawing off the medium with a 
sucking device and adding 200 µl of PBS to each well. The PBS was left on the cells for three 
minutes and was then sucked off again. All washing steps described in the following section were 
performed in this way and all staining steps were performed as room temperature – unless otherwise 
mentioned. The cells were fixed with 200 µl of 3% PFA per well and incubated for 15 minutes to 
then be washed twice with PBS. In a next step, the cells were permeabilized with 0.1% Triton-X in 
PBS. To do so, 200 µl of 0.1% Triton-X in PBS was added to each well and incubated for five 
minutes. Another washing step was performed and the cells were blocked for 30 minutes with 100 
µl of blocking buffer per well. Next, the desired primary antibody was diluted in dilution buffer and 
100 µl of the antibody was added to the cells and incubated for one hour. In a next step, the primary 
antibody was removed and cells were washed twice with washing buffer. The secondary antibody 
was prepared as described before and 100 µl of secondary antibody was added to the cells for 45 
minutes. After the incubation, the cells were washed twice with washing buffer. Finally, the cell 
nucleus was stained with 200 µl of DAPI (dilution 1:5000 in PBS) for two minutes. The cells were 
washed twice with washing buffer and once with PBS. Afterwards the slides were mounted with 
ProLong® Gold Antifade Reagent and the sample was topped with a cover slide (1.5 thickness). To 
let the mounting medium harden, the slides were let sit for 24 hours in the dark, and were then 
transfered to 4°C for long-term storage. 
 
2.2.9.3  Analysis of Immunofluorescence Cytochemistry 
The analysis of the immunofluorescence cytochemistry stainings was performed using the inverted 
CLSM Leica SP5 Mid-UV confocal microscope at the ZMB (Zentrum für Mikroskopie und 
Bildanalyse, University of Zurich, Switzerland). Acquisition of the data was performed using the 
LAS Leica Application Imaging software and the graphical analysis was performed with ImageJ. 
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2.2.10 Protein Analysis 
2.2.10.1  Cell Lysis for Western Blot 
For the entire procedure, the cells were kept on ice to prohibit stress-related responses during the 
preparation of the cells. The medium of the cells was removed and washed once with PBS. To 
detach the adherent cells, the cells were either trypsinized or scraped off. The cells were mixed well 
and a single cell suspension was prepared. The cells were transferred to a 15 ml tube and washed 
with 10 ml PBS. The cells were spun at 400 × g for five minutes at 4°C, the supernatant was 
discarded and the cell pellet was resuspended in 1 ml of PBS and transferred to 1.5 ml tubes. The 
cells were spun another time and the supernatant was completely removed. At this point the cells 
can be stored at -80°C for later usage. The cell pellet was resuspended in lysis buffer (50 µl lysis 
buffer per 1×106 cells) by pipetting the cells up and down vigorously until the suspension was 
homogenous. The cells were incubated on ice for 20 minutes and vortexed for 15 seconds. The 
lysed cells were centrifuged at maximum speed in a table top centrifuge for ten minutes at 4°C to 
separate cell lysate from cell debris. The supernatant was transferred to a fresh 1.5 ml tube and 
small aliquots were removed for BCA protein quantification (chapter 2.2.10.2). The cell lysates 
were snap frozen and stored at -80°C. 
 
2.2.10.2  BCA Assay for Protein Quantification 
Protein quantification was performed using the bicinchoninic acid (BCA) Protein Assay Kit 
according to manufacturer’s recommendations. First, a bovine serum albumin BSA standard was 
prepared in PBS. The final BSA concentration ranged from 2000 µg/ml to 25 µg/ml. The working 
reagent provided by the BCA Protein Assay Kit was prepared as recommended. Since the sample 
size was limited, the “microplate procedure” was applied. In this procedure, 10 µl of each sample 
and standard were used and pipetted into a flat bottom 96-well plate. In a next step, 200 µl of the 
working reagent were added to each well and was mixed with the sample. The plate was closed with 
adhesive tape to prevent evaporation of the sample and the mixture was incubated at 37°C for 30 
minutes. After this incubation time, the plate was cooled to room temperature and the absorbance 
was measured at a wavelength of 540 nm on an ELISA plate reader. 
 
2.2.10.3  Western Blot Procedure 
Depending on the purpose of the Western blot, different protein samples were analyzed. If not 
mentioned differently, the samples were prepared according the protocol provided in chapter 
2.2.10.1. The samples were prepared in Laemmli buffer and boiled at 95°C for five minutes to 
denature the proteins. Generally, a 12.5% SDS-PAGE of 0.75 to 1.5 mm thickness was prepared in 
a BioRad stacking system. The samples were applied to the wells and the gel was run at 85 V for 
two to three hours or until the protein front reached the very bottom of the gel. The protein transfer 
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was carried out using a semi-dry blotting system. The Whatman paper was equilibrated with 
transfer buffer and, in parallel, the PVDF membrane was activated for five minutes with 100% 
Methanol and then also equilibrated with transfer buffer. The transfer unit was assembled and the 
transfer was performed for one hour at 10 V. Next, the membrane was blocked with blocking 
solution for one hour at room temperature while gently shifting. All further steps were also 
performed at room temperature on a shaker. The primary antibody was added in 5% skimmed milk 
in PBS-T buffer and incubated for one hour at room temperature or overnight at 4°C. Next, the 
membrane was washed once for 15 minutes and three times for five minutes with PBS-T. The 
secondary antibody was prepared in the same way as the primary antibody and the membrane was 
incubated for one hour. The membrane was washed as described above and a final washing step was 
performed by washing twice with PBS for five minutes each. The membrane was developed using 
the Pierce ECL Western Blotting Substrate. Membranes were developed on ECL films for different 
timings to visualize protein levels. Actin detection was used as a loading control to normalize LC3, 
Atg5, and Atg7 levels. 
 
2.2.10.4  Stripping of Western Blot Membrane 
The PVDF membrane was washed twice for five minutes with PBS-T and twice for five minutes 
with H2O. The water was removed and 5 ml of ReBlot System Strong Solution was added. The 
membrane was incubated for 30 minutes at room temperature while gently shifting on a shaker. To 
remove residues of the stripping solution, the membrane was washed twice for five minutes with 
H2O and in a next step twice with PBS-T. To repeat the detection procedure, the membrane was 
blocked with 5% skimmed milk powder in PBS-T and the normal detection procedure was 
continued. 
 
2.2.11 Overexpression and Purification of MOG Protein 
2.2.11.1 Transformation of Chemocompetent Bacteria 
For the amplification of the plasmid pET-22b(+) (mMOG1-124) chemocompetent Top 10 bacteria 
were transformed. On the other hand, for the overexpression of rmMOG protein1-124 
chemocompetent BL21 cells were used. Both bacterial strains were transformed by using the 
following protocol: 
Bacteria were thawed on ice and 1 µl of plasmid DNA (stock 40 ng/µl) was added to the bacteria. 
The bacteria were incubated on ice for 30 minutes and a heat shock was performed for 30 seconds 
at 42°C. The bacteria were put back on ice for five minutes and 1 ml of LB medium without 
additives were added. The cells were incubated for 45 minutes at 37°C and 220 rpm. All bacteria 
were plated on 1 LB Amp+ plate and incubated overnight at 37°C in inverted position. On the next 
day, a colony was picked and transferred to 5 ml of LB Amp+ medium and incubated overnight at 
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37°C and 220 rpm. A glycerol stock of both bacterial strains was prepared by mixing the bacterial 
culture and 100% glycerol at a 1:1 ratio. The glycerol stock was transferred to cryo tubes and stored 
at -80°C. 
 
2.2.11.2 DNA Plasmid Purification and Sequencing 
DNA plasmids were purified by a PureYield™ Plasmid Miniprep System from Promega. The 
bacterial lysate was prepared by adding 600 µl of bacterial culture to a 1.5 ml microcentrifuge tube. 
100 µl of Cell Lysis Buffer was additionally added to the tube and mixed by inverting the tube. 
Furthermore, 350 µl of cold Neutralization Solution was added and mixed by inverting the tube. 
The suspension was centrifuged at maximum speed in a table-top centrifuge for three minutes. The 
supernatant was transferred to a PureYield Minicolumn and the column was placed into a fresh 
tube. Another centrifugation step was performed at maximum speed for 15 seconds. The flow 
through was discarded and the column was placed back into the same tube. The column was washed 
by adding 200 µl of Endotoxin Removal Wash and a centrifugation step was performed as described 
above. After this step, 400 µl of Column Wash Solution was added to the column and centrifuged 
for 30 seconds. To elute the DNA, the column was transferred to a clean 1.5 ml reaction tube and 30 
µl of Elution Buffer or nuclease-free water were directly applied to the column matrix. The column 
was incubated or one minute at room temperature and was then centrifuged for 15 seconds to elute 
the plasmid DNA. The eluted plasmid DNA was stored at -20°C. 
The plasmid DNA was sequenced by the sequencing service of Microsynth AG, Switzerland. 
 
2.2.11.3 Overexpression of MOG Protein 
On the day before the actual overexpression of MOG protein, 50 ml of LB medium supplemented 
with ampicillin (final concentration 100 µg/ml) were inoculated with the bacterial glycerol stock 
BL21 mMOG1-124. This culture was incubated overnight at 37°C and 220 rpm. On the next day, 2 l 
of LB medium (supplemented with 100 µg/ml ampicillin, 0.1% glucose and 1 mM MgCl2) were 
inoculated with ~10 ml of the overnight culture to reach a starting OD600 of 0.1. At an OD600 of 0.7 
the protein overexpression was induced by adding 1 mM of IPTG and incubated for three more 
hours. The suspension was centrifuged at 3000 × g for 20 minutes at 4°C and the pellets were 
collected and pooled. The pellet can be stored at -20°C for long-term storage. 
 
2.2.11.4 Purification of MOG Protein 
For the purification of MOG protein, all steps were performed at room temperature unless otherwise 
mentioned. The bacterial pellet was resuspended in 30 ml of lysis buffer and the bacteria were 
disrupted via French press by applying a pressure of 900-1100 PSI. This step was repeated three to 
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four times. The bacterial lysate was centrifuged at 30000 × g for 30 minutes at room temperature. 
The supernatant was decanted and the inclusion body pellet was resuspended in 30 ml of lysis 
buffer by use of a spatula. This centrifugation step was repeated once more. The pellet was 
resuspended in ~50 ml of solubilization buffer to solubilize the inclusion bodies. The tube was 
closed with PARAFILMTM and incubated overnight at room temperature while spinning to entirely 
dissolve the inclusion body pellet. The solved inclusion bodies were filtered with a 0.45 µm filter 
device. The Ni-NTA Superflow column (column volume 3 ml) was equilibrated with running buffer 
and the protein suspension was loaded onto this column. The flow through was reloaded three more 
times to increase binding efficiency. The column was washed with 20 column volumes (CV) of 
solubilization buffer and afterwards with 200 CV of endotoxin-removal buffer. The protein was 
eluted batch-wise with four CV of elution buffer. The protein concentration was determined with 
the nano drop (chapter 2.2.11.5) and the concentration was adjusted to 3 mg/ml with the 
solubilization buffer in order to reduce the amount of imidazole before dialysis. 
The protein was further diluted 1:3 with arginine buffer and transferred to a 3000 MWCO dialysis 
membrane tube. The dialysis was performed for 24 hours against dialysis buffer A (15× volume). 
During the dialysis, the volume increased threefold. A second dialysis was performed for three 
hours against dialysis buffer B (15x volume). The dialysis against buffer B was repeated for 12 
hours (50x volume). To finish, the sample was dialysed three times against 5 l of of dialysis buffer 
C (125000x volume). 
To concentrate the sample, a 3000 MWCO Millipore concentrator was used. The final concentration 
was adjusted to 1-2 mg/ml. The MOG protein1-124 was snap-frozen in liquid nitrogen and stored at -
80°C. To thaw the protein, the solution was thawed quickly at 37°C in order to avoid precipitation 
of protein.  
 
2.2.11.5 Nanodrop 
The Nanodrop ND-1000 (Thermo Scientific) is a microvolume UV-Vis spectrophotometer that can 
be used to analyze DNA, RNA and proteins. It was used to determine the protein concentration of 
purified MOG protein. The absorption of purified MOG protein at 280 nm 0.1% (=1 g/l) was 1.344. 
 
2.2.11.6 Statistical analysis 
For clinical EAE scores, differences between groups were evaluated by two-way analysis of 
variance (ANOVA) with Bonferroni’s post-test. For cell subsets and cytokine expression, 
differences between two cell populations were evaluated by the two-tailed Student's t-test. P values 
of less than 0.05 were considered significant. 
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3 Results 
We hypothesized that autophagy in CD11c-expressing cells accelerates EAE development and 
progression due to increased loading of self-antigen onto MHC class II molecules. To test this 
hypothesis, we generated a knock out (KO) mouse system in which one of the hallmark proteins of 
autophagy is conditionally deleted in CD11c+ cells by use of the Cre/loxP recombination system. 
This recombination system enables the targeted deletion of a gene of interest. Principally, in the 
Cre/loxP recombination system, two recombination sites, called loxP sites, flank the gene of 
interest. A loxP-flanked DNA sequence is also described as “floxed” (abbreviated as flox or fl). An 
enzyme, named Cre (cyclization or causes recombination enzyme), catalyzes the homologous 
recombination between the two loxP sites and, consequently, the floxed gene is removed (Bouvier 
and Cheng, 2009; Mortensen, 2001). In order to conditionally eliminate autophagy from CD11c+ 
cells, the Atg5 protein was targeted in a Cre/loxP recombination system. Atg5 is a protein essential 
for autophagosome formation whose complex with Atg12 and Atg16L mediates ligation of Atg8 to 
the autophagosomal membrane for vesicle expansion and substrate recruitment. Accordingly, Atg5-
deficient cells do not show autophagic activity. Thus, CD11c Cre/loxP-deleter transgenic mice 
allow us to study the development of EAE in the absence of autophagic activity in CD11c+ APCs, 
mainly DCs, compared to control (CTRL) littermates. 
 
3.1 Breeding of the Conditional KO Mouse 
In order to generate mice that are deficient in Atg5 in CD11c+ cells, multiple breeding steps were 
necessary (breeding scheme shown in Figure 3.1). The first step was to cross CD11c-Cre-/- 
Atg5fl/oxflox mice with CD11c-Cre+/- Atg5wt/wt mice. This breeding step produced, amongst others, 
mice of the CD11c-Cre+/- Atg5flox/wt genotype. These mice, in the next breeding step, were bred to 
CD11c-Cre-/- Atg5flox/flox mice. In the last step, CD11c-Cre-/- Atg5flox/flox mice were crossed with 
CD11c-Cre+/- Atg5flox/flox and this, finally, resulted in mice with the genotype of interest. For all 
experiments, control mice that do not lack the atg5 gene in CD11c+ cells (CD11c-Cre-/- Atg5flox/flox, 
designated DCAtg5CTRL mice) and mice that conditionally lack the atg5 gene in CD11c+ cells 
(CD11c-Cre+/- Atg5flox/flox, designated DCAtg5KO mice) were compared. 
The desired genotypes were confirmed by genotyping PCR. To screen for Cre and the Atg5floxed 
transgene, two different genotyping PCRs were performed. The CD11c-Cre genotyping reaction 
yielded a band of 324 bp, which represents an internal positive control and a band of 100 bp 
representing the Cre transgene. On the other hand, depending on the genotype of the respective 
mouse, the Atg5 floxed genotyping PCR reaction was supposed to give a 650 bp band (floxed 
gene), a band of 350 bp (Atg5 wild type) and a third band of 300 bp (Atg5floxed deleted when Cre 
is also positive). Exemplarily, one agarose gel depicting a genotyping result is shown in Figure 3.1. 
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Figure 3.1: Schematic flow sheet representing the breeding strategy for the generation of DCAtg5KO and DCAtg5CTRL 
mice and representative genotyping results. (A) Breeding was performed according to this scheme. The upper row in 
each box represents the cre allele, and the lower row represents the atg5 allele. The offspring of interest is CD11c-Cre+/- 
Atg5flox/flox (DCAtg5KO) and CD11c-Cre-/- Atg5flox/flox (DCAtg5CTRL). (B) Agarose gel showing genotyping results of 
atg5floxed and CD11c-Cre genotyping PCR. Left: Results of the atg5floxed genotyping. Expected bands: 650 bp=floxed 
gene, 350 bp=Atg5 wild type, 300 bp=atg5floxed deleted when cre is also positive. Right: Results of the CD11c-Cre 
genotyping. Expected bands: 324 bp=internal positive control, 100 bp=cre transgene. The results of mice number 46 to 50 
are exemplarily shown. 
 
3.2 Characterization of DCAtg5KO and DCAtg5CTRL Mice 
The use of the Cre/loxP recombination system implies that most tissue-specific promoters do not 
work absolutely tissue-specific. This might result in the ectopic expression of Cre and, thus, lead to 
unintended gene deletion in other cell types. Additionally, the random genomic insertion of Cre is 
able to cause transgene silencing with uncontrollable effects on cell proliferation and viability and 
might also show toxic effects on cells in vitro and in vivo. Furthermore, the targeted promoter needs 
to reach a high level of activity to ensure a complete excision of the target gene. 
In consideration of this knowledge and despite the fact that our mouse system had been already 
described for even DC migration, activation marker expression and cytokine secretion in DCAtg5KO 
and DCAtg5CTRL mice (Lee et al., 2010), we wanted to confirm these data with regard to cell 
frequencies. We evaluated the specific Cre expression and unspecific Cre leakage as well as the 
frequency of cell subsets such as DCs, macrophages and T cells under steady state conditions. 
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3.2.1 Cre Expression by CD11c+ Cells in DCAtg5KO and DCAtg5CTRL Mice 
In order to confirm specific Cre expression in CD11c+ cells, cells from spleen and CNS, which 
derived from either DCAtg5KO or DCAtg5CTRL mice, were analyzed by flow cytometry. Cells were 
analyzed according to their forward scatter (FSC) and side scatter (SSC) characterictics. And the 
subsequent analysis was based on their CD45, H2-Ab and CD11c expression and the Cre expression 
on H2-Ab+ CD11c+ double positive cells. 
As shown in Figure 3.2, Cre expression was assessed by the relative expression of the conjugate 
Cre-EGFP and it could be shown that Cre-EGFP is expressed in CD11c+ cells from DCAtg5KO, but 
not from DCAtg5CTRL mice. This result held true for H2-Ab+ CD11c+ cells from both spleen and CNS. 
 
 
 
Figure 3.2: Comparison of Cre expression of CD11c+ cells originated from spleen and CNS of DCAtg5KO and 
DCAtg5CTRL mice. Cells from spleen and CNS from DCAtg5KO and DCAtg5CTRL mice were stained with CD45, CD11c and 
H2-Ab antibodies conjugated with fluorochromes. Cells of interest (CD45+ CD11c+ H2-Ab+) were analyzed by flow 
cytometry and Cre expression levels were assessed by EGFP expression. Gating strategy for the analyses is shown for (A) 
spleen and (B) CNS. (C) Histogram illustrating Cre expression of CD45+ CD11c+ H2-Ab+ cells in spleen and CNS of 
DCAtg5CTRL (black line) and DCAtg5KO (red line) mice. 
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3.2.2 Cre Expression in CD4+, CD8+ and CD11b+ Cells 
As shown in Figure 3.2, Cre is expressed by H2-Ab+ CD11c+ cells that were derived from DCAtg5KO 
mice, but not by H2-Ab+ CD11c+ cells that were derived from DCAtg5CTRL mice. To further confirm 
that Cre expression is specific to CD11c+ cells and does not affect unspecifically other cell types, 
Cre-EGFP expression by CD4+, CD8+ and CD11b+ cells was also assessed by flow cytometry 
(Figure 3.3). Five DCAtg5CTRL mice and four DCAtg5KO mice were compared to one B/6 wildtype 
mouse. CD4+, CD8+ and CD11b+ cells do not express Cre-EGFP and, thus, an effect based on Cre 
leakage into these cell compartments could be excluded in future experiments. 
 
Figure 3.3: Analysis of unspecific Cre-leakage into CD4+, CD8+ and CD11b+ cells. Splenocytes from DCAtg5CTRL and 
DCAtg5KO mice were stained with CD4, CD8 and CD11b antibodies conjugated with fluorochromes. Cells of interest 
(CD4+ T cells, CD8+ T cells and CD11b+ cells) were analyzed by flow cytometry and Cre expression levels were assessed 
by EGFP expression. Flow cytometry analysis of splenic CD4+, CD8+ T cells and CD11b+ cells originated from (A) 
DCAtg5CTRL and (B) DCAtg5KO mice. 
 
3.2.3 APC Frequencies in DCAtg5CTRL and DCAtg5KO Mice 
Since the Cre/loxP recombination system used in this study targets the CD11c+ cell compartment 
and, thus, mainly CD11c+ DCs were targeted for Atg5-deficiency, we were eager to investigate the 
APC frequencies under steady state conditions. In this regard, the splenic frequency of CD11c+ H2-
Ab+ cells, CD11c+ CD8+ CD11b+ CD8 DCs, CD11c+ SiglecH+ pDCs and CD11c- CD11b+ F4/80+ 
macrophages was determined under steady state condition. The gating strategy as well as APC 
frequencies are shown in Figure 3.4. The percentage of CD11c+ H2-Ab+ was higher in DCAtg5CTRL 
than in DCAtg5KO mice, but the other APC frequencies did no show a significant difference in 
DCAtg5CTRL and DCAtg5KO mice. The one outlier seen under almost all conditions goes back to one 
single mouse. 
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Figure 3.4: APC frequencies in DCAtg5KO and DCAtg5CTRL mice. Splenocytes from DCAtg5CTRL and DCAtg5KO mice were 
stained with antibodies anti CD45, CD11c, CD11b, H2-Ab, SiglecH, CD8, Ly6c, F4/80. Cells were analyzed by flow 
cytometry based on their FSC and SSC characteristics as well as for APC-specific markers. (A) Top row: Gating strategy 
of flow cytometry analysis is exemplarily shown. Bottom row: Scatter plots to illustrate percentage of CD11c+ H2-Ab+ 
cells, CD11c+ CD8+ CD11b+ CD8 DCs, CD11c+ SiglecH+ pDCs and CD11c- CD11b+ F4/80+ macrophages. (B) 
Assessment of Cre expression levels by EGFP expression in CD11c+ H2-Ab+ splenocytes originated from DCATG5KO and 
DCATG5CTRL mice. (C) Percentage of single, live CD45+ APC subsets. Each symbol represents one mouse, and horizontal 
lines indicate the mean with SEM. 
 
3.2.4 T Cell Frequencies in DCAtg5KO and DCAtg5CTRL Mice 
Next, T cell frequencies in DCAtg5KO and DCAtg5CTRL mice were investigated. Hence, splenocytes 
originating from each mouse strain were analyzed by flow cytometry for T cell markers such as 
CD4 and CD8, but also more specifically for the production of IFNγ (Τh1 cells), IL-17 (Th17 cells) 
and GM-CSF (GM-CSF-producing Th cells) after PMA/ionomycin treatment.  
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Figure 3.5: Investigation of CD4+ and CD8+ T cell fractions in DCAtg5KO and DCAtg5CTRL mice. Splenocytes from 
DCAtg5CTRL and DCAtg5KO mice were stained with CD45, CD8, CD4, IFNγ, IL-17 and GM-CSF antibodies. Cells were 
analyzed by flow cytometry based on their FSC and SSC characteristics as well as for T cell-specific markers. (A) Gating 
strategy of flow cytometry analysis is exemplarily shown. Scatter plots to illustrate percentage of (B) CD4+ T cells, CD8+ 
T cells and CD4/CD8 ratio and (C) IL-17, IFN-γ and GM-CSF-producing CD4+ T cells. (B+C) Each symbol represents 
one mouse, and horizontal lines indicate the mean with SEM. 
 
Splenocytes were analyzed according to their FSC and SSC characterictics, as well as to their 
CD45, CD4 and CD8 expression. The gating strategy applied to analyze these cell subsets is shown 
in Figure 3.5A. The percentage of CD4+ and CD8+ T cells is shown in Figure 3.5B, whereas the 
percentage of CD4+ T cells that produce IL-17, IFNγ, IL-17 and IFNγ, or GM-CSF is illustrated in 
Figure 3.5C. Comparing all T cell subsets from DCAtg5KO and DCAtg5CTRL mice, it was shown that the 
percentage of CD8+ T cells in DCAtg5CTRL mice was increased compared to DCAtg5KO mice. But the 
percentage of CD4+ T cells and the level of cytokine production, such as IFNγ, IL-17 and GM-CSF, 
did not yield a significant difference. 
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As for the analysis of CD4+ and CD8+ T cells, a similar analysis was performed with regard to the 
frequency of Tregs in DCAtg5KO and DCAtg5CTRL mice. In this context, Tregs were defined as CD4+ 
CD25+ and Foxp3+ and were analyzed by flow cytometry. 
The gating strategy in the context of this experimental setup and the percentage of Tregs in the 
spleen of DCAtg5KO and DCAtg5CTRL mice is shown in Figure 3.6. It could be shown that there was no 
difference in Treg frequencies between DCAtg5KO and DCAtg5CTRL mice. Contrary the results shown in 
Figure 3.5, in this independent experiment, no statistical difference in the percentage of CD8+ T 
cells could be demonstrated. 
Since the statistical significance of CD8+ T cells in the first experiment was rather low (P value 
0.0244) and there was no statistical difference in the second experiment, it was concluded the 
analyzed T cell subsets under steady state conditions show a similar percentage in both groups and 
that it should not be of any influence during the functional studies performed. 
 
 
Figure 3.6: Investigation of the percentage of Tregs in DCAtg5KO and DCAtg5CTRL mice. Splenocytes from DCAtg5CTRL 
and DCAtg5KO mice were stained with CD8, CD4, CD25 and Foxp3 antibodies. Cells were analyzed by flow cytometry 
based on their FSC and SSC characteristics. Splenic Tregs (CD4+ CD25+ Foxp3+) were analyzed by flow cytometry 
analysis. (A) Gating strategy of flow cytometry analysis is exemplarily shown. Percentage of (B) Tregs, (C) CD4+ T cells 
and (D) CD8+ T cells are shown as scatter plots. (B-D) Each symbol represents one mouse, and horizontal lines indicate 
the mean with SEM. 
 
3.3 Active EAE in DCAtg5KO and DCAtg5CTRL Mice 
3.3.1 Induction of Active EAE with MOG Peptide 
In order to investigate the susceptibility and disease severity in DCAtg5KO mice in comparison to 
DCAtg5CTRL mice, EAE was actively induced in these two mouse strains. Mice were injected 
subcutaneously with 100 µg of MOG35-55 peptide (MOG peptide) in an emulsion with CFA at days 0 
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and 7. Additionally, PTx was applied at day 0 and 2 intraperitoneally. In total, three independent 
experiments were performed and each of them is shown in Figure 3.7. 
 
 
Figure 3.7: MOG peptide-induced EAE in DCAtg5KO and DCAtg5CTRL mice. Mice were immunized with double 
injections of 100 µg of MOG peptide. In total three independent experiments were performed (A-C) and the pooled data 
of these experiments are shown in (D). Black dots represent DCAtg5CTRL and red dots DCAtg5KO mice. For each experiment 
female/male ratio, mean maximum severity, mean day of onset and disease incidence are summarized in table form. § 
Mean maximum severity and mean day of onset are based on diseased mice. Statistical analysis: ns = not significant, *P < 
0.05, **P < 0.01 and ***P < 0.001 two-way analysis of variance (ANOVA) with Bonferroni’s post-test. Clinical disease 
was monitored daily and mice were scored according to the guidelines specified in the material and methods section. 
 
Results 
 63 
Comparing the clinical EAE course of the three independent experiments, heterogenous results were 
observed. DCAtg5KO mice showed a more severe disease course than DCAtg5CTRL mice in two 
experiments, whereas in one experiment the opposite trend was documented. Overall, no difference 
in EAE score could be shown. For all experiments, the clinical disease course was correlated to the 
percentage of body weight change. In each experiment a clear correlation between disease course 
and weight loss could be shown. This reflects the observed EAE scores. 
 
3.3.2 Induction of Active EAE with MOG Protein 
No difference in disease severity could be seen when EAE was induced with MOG peptide in 
DCAtg5CTRL and DCAtg5KO mice. Since it might be that MOG peptide bypasses the requirement for 
antigen processing, it was reasoned that EAE induction with MOG protein instead of MOG peptide 
might require the LAP machinery. Accordingly, we hypothesized, that LAP would not be induced 
in DCAtg5KO mice by the induction of EAE with MOG protein, which might be reflected in a 
difference in EAE course. To proof this hypothesis, EAE was induced as described above, but with 
MOG protein instead of MOG peptide. The clinical disease course of three independent 
experiments as well as the pooled data are depicted in Figure 3.8. 
Evaluating the EAE data shown in Figure 3.8, inconsistent results were obtained. In two 
experiments DCAtg5KO mice showed a more severe disease course than DCAtg5CTRL mice, where in 
one experiment the opposite trend could be seen. In summary, also under these conditions, no 
difference in EAE severity could be shown. These results were reflected by the change of body 
weight. 
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Figure 3.8: MOG protein-induced EAE in DCAtg5KO and DCAtg5CTRL mice. Mice were immunized with double 
injections of 100 µg of MOG protein. In total three independent experiments were performed (A-C) and the pooled data of 
these experiments are shown in (D). Black dots represent DCAtg5CTRL and red dots DCAtg5KO mice. For each experiment 
female/male ratio, mean maximum severity, mean day of onset and disease incidence are summarized in table form. § 
Mean maximum severity and mean day of onset are based on diseased mice. Statistical analysis: ns = not significant, *P < 
0.05, **P < 0.01 and ***P < 0.001 two-way ANOVA with Bonferroni’s post-test. Clinical disease was monitored daily 
and mice were scored according to the guidelines specified in the material and methods section. 
 
3.3.3 Induction of Active EAE with Different Concentrations of MOG protein 
When EAE was induced with either MOG peptide or MOG protein, no difference in disease course 
or severity could be shown when DCAtg5CTRL and DCAtg5KO mice were compared (Figure 3.7 and 
3.8). Based on these results, it was assumed that the high amount of MOG peptide or MOG protein 
and CFA might have caused such a strong immune response that potential differences between the 
two experimental groups were masked. Accordingly, it was considered that a decrease in antigenic 
load might lead to a better-controlled immune response that might result in more consistent results. 
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In the experimental setup, DCAtg5KO and DCAtg5CTRL mice were injected with either 50 µg or 20 µg of 
MOG protein. The amount of CFA was kept at a constant level and only the amount of MOG 
protein was decreased. 
 
 
 
Figure 3.9: Titration of MOG protein during the induction of active EAE in DCAtg5KO and DCAtg5CTRL mice. Active 
EAE was induced with double injections of (A) 100 µg, (B) 50 µg or (C) 20 µg of MOG protein. Results are shown in line 
graphs where black dots represent DCAtg5CTRL mice and red dots DCAtg5KO mice. For each experiment female/male ratio, 
mean maximum severity, mean day of onset and disease incidence are summarized in table form. § Mean maximum 
severity and mean day of onset are based on diseased mice. Statistical analysis: ns = not significant, *P < 0.05, **P < 0.01 
and ***P < 0.001 two-way ANOVA with Bonferroni’s post-test. Clinical disease was monitored daily and mice were 
scored according to the guidelines specified in the material and methods section. 
 
When DCAtg5KO and DCAtg5CTRL mice were injected with different amounts of MOG protein, it could 
be shown that disease incidence decreases with lower amounts of MOG protein injected. The lower 
disease incidence is reflected in a lower clinical EAE score. This holds true for both experimental 
groups and no difference between groups could be shown. 
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3.3.4 Induction of Active EAE in DCAtg7KO and DCAtg7CTRL Mice with MOG protein 
In one of the intermediate steps of autophagosomal formation, Atg12 is first ligated to Atg5 by 
assistance of the E1-like enzyme Atg7. In a next step, this conjugate forms a complex with Atg16L1 
which results in a complex named Atg5-Atg12/Atg16L1. This protein complex is essential for the 
ligation of Atg8 to the autophagosomal membrane. Conclusively, Atg5 as well as Atg7 are similarly 
essential for the formation of the autophagosome. Since Atg5 is also described to be of importance 
in autophagy-unrelated processes such as regulation of apoptosis, exocytosis and innate antiviral 
immune signalling (Subramani and Malhotra, 2013), we wanted to control for an autophagy-
specific effect in our model by using a control mouse strain, namely Atg7flox/flox CD11c-Cre-/- 
(DCAtg7CTRL mice) and Atg7flox/flox CD11c-Cre+/- (DCAtg7KO mice). This mouse system is based on the 
same principal as for the Atg5 KO system, but lacks Atg7 instead of Atg5 in the CD11c+ cell 
compartment. To control for the autophagy-specific effect in the EAE model, DCAtg7KO and 
DCAtg7CTRL mice were injected with double injections of 100 µg of MOG protein as described above. 
The results of three independent experiments are shown in Figure 3.10. 
In all three experiments both experimental groups showed a similar course of disease and 
percentage of body weight change. Furthermore, mean maximmum score and mean day of onset as 
well as the disease incidence did not differ between groups. 
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Figure 3.10: MOG protein-induced EAE in DCAtg7KO and DCAtg7CTRL mice. Mice were immunized with double 
injections of 100 µg of MOG peptide. In total three independent experiments were performed (A-C) and the pooled data 
of these experiments are shown in (D). Black dots represent DCAtg7CTRL and red dots DCAtg7KO mice. For each experiment 
female/male ratio, mean maximum severity, mean day of onset and disease incidence are summarized in table form. § 
Mean maximum severity and mean day of onset are based on diseased mice. Statistical analysis: ns = not significant, *P < 
0.05, **P < 0.01 and ***P < 0.001 two-way ANOVA with Bonferroni’s post-test. Clinical disease was monitored daily 
and mice were scored according to the guidelines specified in the material and methods section. 
 
3.4 Adoptive transfer EAE in DCAtg5KO and DCAtg5CTRL Mice 
Actively induced EAE by the injection of either MOG peptide or MOG protein did not yield any 
differences between DCAtg5KO and DCAtg5CTRL mice in terms of EAE severity (Figure 3.7 and 3.8). 
As mentioned earlier, a possible reason for the absence of a phenotype could be the fact that MOG 
peptide and MOG protein might not be processed in the context of LAP or macroautophagy. It was 
further reasoned that particulate antigen might be necessary to induce this pathway in the context of 
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EAE since it had been already shown that LAP can be induced by the uptake of dead cells 
(Martinez et al., 2011) or even live cells by entosis (Florey et al., 2011). 
In the adoptive transfer model of EAE, in contrast to the active induction of EAE, transferred 
myelin-reactive T cells encounter the self-antigen in the recipient mouse for the first time when it is 
presented by local APCs in the CNS. This self-antigen, in the form of cells or cell debris, needs to 
be processed and presented. Atg5-deficient CD11c+ cells might not be able to process the self-
antigen properly and, thus, might not be competent in reactivating infiltrating myelin-reactive T 
cells. Accordingly, EAE was induced by adoptive transfer of auotreactive T cells in DCAtg5KO and 
DCAtg5CTRL mice. 2D2 transgenic mice, that carry a MOG-specific TCR, were injected with MOG 
peptide. Seven days later, splenocytes and cells from axillary and inguinal lymph nodes were 
isolated, re-stimulated in the presence of MOG peptide and IL-23 and, finally, adoptively 
transferred to DCAtg5KO and DCAtg5CTRL recipient mice. The results from this experiment are depicted 
in Figure 3.11. 
So far, three independent experiments have been performed. It could be demonstrated that almost 
none of the DCAtg5KO mice developed EAE symptoms or showed a change in body weight. Whereas, 
DCAtg5CTRL mice showed a comparable course of disease as in the experiments described above. 
That means that DCAtg5CTRL mice showed a similar disease onset at day 15.4 (±	 2.7 days), mean 
maximum severity of 3.6 (±	 0.7) and a disease incidence of 80.0% when compared to the mice 
described in earlier experiments (Figure 3.7 and 3.8). 
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Figure 3.11: Adoptive transfer EAE experiment with DCAtg5KO and DCAtg5CTRL mice. 2D2 mice were immunized with 
MOG peptide and at day seven splenocytes were removed. Splenocytes were cultured for two days in the presence of 
MOG peptide and IL-23 and then transferred into sublethally irradiated recipient DCAtg5KO and DCAtg5CTRL mice. In total 
three independent experiments were performed (A-C) and clinical EAE score as well as change in body weight are shown. 
The pooled data of these experiments are shown in (D). Black dots represent DCAtg5CTRL and red dots DCAtg5KO mice. For 
each experiment gender, mean maximum severity, mean day of onset and disease incidence are summarized in table form. 
§ Mean maximum severity and mean day of onset are based on diseased mice. Statistical analysis: ns = not significant, *P 
< 0.05, **P < 0.01 and ***P < 0.001 two-way ANOVA with Bonferroni’s post-test. Clinical disease was monitored daily 
and mice were scored according to the guidelines specified in the material and methods section. 
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3.5 In Vitro Studies of Antigen Processing and Presentation 
Based on the results of the in vivo EAE experiments presented in chapter 3.4, the deficiency of Atg5 
in CD11c+ APCs does have an effect on the development and progression of adoptive transfer EAE. 
In order to investigate the processes that lead to this effect, we were eager to perform in vitro 
studies to define the underlying mechanism. 
 
3.5.1 Antigen Presentation Assay 
Antigen processing and presenting capabilities of DCs were assessed by co-cultures with T cells. 
DCs from spleen of either DCAtg5CTRL or DCAtg5KO mice were isolated by MACS (CD11c+ selection) 
and FACS (CD45+ CD11c+ H2-Ab+). In parallel, MOG-specific CD4+ T cells were isolated from 
spleen from 2D2 mice by positive MACS isolation (CD4+ selection) and were CFSE-labelled in a 
final step. DCs and T cells were co-cultured at a ratio of 1:3 in the presence of MOG peptide, MOG 
protein or polystyrene beads coated with MOG protein. Beads were added to the co-culture at 
different beads to DC ratios ranging from 0.5:1, 1:1, 2:1, 4:1 to 8:1. Cells were co-cultured for four 
days and T cell proliferation was assessed by CFSE dilution. As positive control, T cells were 
incubated with anti CD3 and anti CD28 plate-bound antibodies. As negative control, T cells were 
cultured alone or in the presence of DCs only. 
The pooled results of three independent experiments are shown in Figure 3.12. T cells in presence 
of CD3/CD28 and T cells co-cultured with DCs in the presence of MOG peptide showed a blasted 
phenotype based on their FSC and SSC characteristics. In contrast, T cells alone did not blast at all. 
T cell proliferation was assessed by CFSE dilution. 
Because of the variations between experiments in terms of T cell survival and T cell proliferation, 
each experiment was normalized to the condition Atg5CTRL DCs and T cells in the presence of 1 
µM of MOG peptide. T cell proliferation in the presence of DCs derived from either DCAtg5KO or 
DCAtg5CTRL mice was higher in the presence of Atg5-deficient DCs when MOG protein or beads 
coated with MOG protein were present. Even under conditions under which statistical difference 
could not be reached the same trend held true. 
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Figure 3.12: DC:T cell co-culture to study the antigen presentation capabilities of primary DCs. Splenic DCs 
(CD11c+ H2-Ab+) originated from either DCAtg5CTRL or DCAtg5KO mice were MACS and FACS-isolated and co-cultured 
with MOG-specific CD4+ CFSE+ T cells in the presence of antigen for four days. As antigen 1 µM of MOG peptide or 
protein and beads coated with MOG protein were used. Beads were incubated with the cells at a bead to DC ratio of 0.5:1, 
1:1, 2:2, 4:1 and 8:1. As positive control T cells were stimulated by anti-CD3 and CD28 treatment. As a read-out for 
antigen presentation, T cell proliferation was assessed by a CFSE dilution assay. (A) Gating strategy to determine 
percentage of proliferated T cells (CD4+ CFSElow). Three experimental setups are shown. Top: CD3/CD28 stimulation as 
positive control, middle: T cells and DCs withouth stimulus, bottom: T cells and DCs in the presence of 1 µM MOG 
peptide. (B) Left: Percentage of proliferated T cells in the presence of various stimuli (see above). Right: Same 
experimental setup as on left, but data were normalized. The percentage of DCAtg5CTRL DCs in the 1 µM MOG peptide 
condition was set to 1. Black symbols: DCs originated from DCAtg5CTRL mice. Red symbols: DCs originated from 
DCAtg5KO mice. Pooled data of three independent experiments are shown. 
 
3.5.2 Phagocytosis Assay 
3.5.2.1  Characterization of BM-DCs as an In Vitro Model  
To study phagocytic capabilities of DCs, the in vitro model of our choice was bone marrow-derived 
dendritic cells (BM-DCs). BM-DCs are widely used as a model for APCs and show the classical 
characteristics of an APC such as antigen processing and presentation competences as well as T cell 
activating capabilities. 
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Figure 3.13: Investigation of mouse BM-DCs for CD11c, H2-Ab and H2-Kb expression and Atg5-deficiency in a 
time-dependent manner. BM-DCs were differentiated from mouse bone marrow of DCAtg5CTRL and DCAtg5KO mice in the 
presence of GM-CSF. (A+B) At day 6, 8 and 10 BM-DCs were stained with CD11c, H2-Ab and H2-Kb antibodies. (A) 
FSC and SSC characteristics of BM-DCS at day 6. (B) Analysis of cell surface expression of CD11c, H2-Ab and H2-Kb 
by flow cytometry at day 6, 8 and 10. (C) At day 6, 8 and 10 BM-DCs were also analyzed by anti-Atg5 Western blot for 
Atg5-deficiency. Anti-β-actin was used as a loading control and Precision Plus Protein Standard from BioRad was used to 
estimate protein size. 
 
For the purpose of our studies, BM-DCs derived from bone marrow were differentiated in the 
presence of GM-CSF. It is noted that BM-DCs differentiated in the presence of GM-CSF are 
distinct from BM-DCs differentiated in the presence of Flt3L. More specifically, BM-DCs 
differentiated in the presence of GM-CSF resemble the inflammatory or TipDC type, whereas BM-
DCs differentiated in the presence of Flt3L show more features of cDCs and pDCs (Harding et al., 
2001; Xu et al., 2007b). 
BM-DCs originated from either DCAtg5CTRL or DCAtg5KO mice were used. To ensure the same 
phenotypic features of these two cell lineages, BM-DCs from DCAtg5CTRL and DCAtg5KO mouse origin 
were analyzed for CD11c, H2-Ab and H2-Kb expression at days 6, 8 and 10 by flow cytometry. 
Histograms illustrating the relative expression of these cell surface molecules are shown in Figure 
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3.13B. Furthermore, Atg5-deficiency of these BM-DCs was investigated by anti-Atg5 Western blot. 
The results of this Western blot are shown in Figure 3.13C. 
The cell surface expression of CD11c, H2-Ab and H2-Kb on BM-DCs was documented over time. 
All three markers were upregulated over time and no differences between cells from DCAtg5CTRL and 
DCAtg5KO mice were detected. Furthermore, Atg5 expression by theses BM-DCs were checked on 
day six, seven and ten by Western blot analysis. A decrease of Atg5 in BM-DCs from DCAtg5KO 
mice was detected over time and reached a total ablation at day ten. In contrast, Atg5 was present in 
BM-DCs of DCAtg5CTRL mice at all time points tested. 
 
3.5.2.2  Phagocytosis of Beads by BM-DCs 
We next investigated the antigen uptake of the self-antigen MOG protein. Classically, small soluble 
peptides and proteins are taken-up by fluid-phase endocytosis, also known as macropinocytosis 
(Blum et al., 2013). So far, LAP has been associated with the degradation of intracellular pathogens 
such as bacteria (Gong et al., 2011; Lam et al., 2013), particles associated with ligands for TLR2, 4 
or 6 (Sanjuan et al., 2007), the detection of apoptotic cells by their exposure of phophatidylserine 
and their recognition by T cell immunoglobulin mucin-4 (TIM-4) (Martinez et al., 2011) as well as 
the uptake of live cells by entosis (Florey et al., 2011). However, LAP has not been described in the 
context of macropinocytosis. Conclusively, the soluble self-antigen MOG protein it-self is most 
likely not targeted by LAP. 
In order to study antigen uptake in the context of LAP, we were eager to find a method that induces 
LAP-associated uptake of self-protein. It had been already shown in other autophagy studies, that 
extracellular antigen coated to beads can be taken up and degraded in the context of LAP (Sanjuan 
et al., 2007). Based on those studies and unpublished data from our laboratory (Susana  de Freitas 
Romão, personal communication), MOG protein was coupled to polystyrene beads and incubated 
with BM-DCs. Beads and BM-DCs were cultured at a ratio of 10:1 for a time span of four hours. In 
a next step, phagocytic uptake was assessed by fluorescent microscopy where beads were identified 
as round black wholes with a diameter of roughly 3.9 µm. LAP was visualized by anti-LC3 
staining. A representative immunocytochemistry picture is shown in Figure 3.13. No LAP 
formation could be detected when beads were coated with MOG protein. Since MOG protein is a 
self-protein and is not supposed to trigger pattern recognition receptors, which are known to induce 
LAP, it was reasoned to induce LAP by a known trigger. An already described trigger of LAP is 
Pam3CSK4 - a synthetic triacylated lipoprotein that mimics bacterial lipoproteins (Sanjuan et al., 
2007). Accordingly, polystyrene beads were coated with Pam3CSK4 or, in an independent setup, 
with Pam3CSK4 and MOG protein. The analyses of these experimental setups are summarized in 
Figure 3.13. 
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Figure 3.14: Phagocytic uptake of beads by BM-DCs measured by microscopy. BM-DCs were differentiated from 
DCAtg5KO and DCAtg5CTRL mice in the presence of GM-CSF over a time period of 10 days. At day 10 adherent BM-DCs 
were harvested and incubated for 4 hours with beads that were coated with the following stimuli: no additive, MOG 
protein, Pam3CSK4 and MOG protein plus Pam3CSK4. BM-DCs were incubated with coated beads at a ratio of 1:10. (A) 
Representative images of BM-DCs that phagocytosed beads coated with different coatings. Phagocytic capacity was 
determined by (B) counting the number of beads per cell and (C) the percentage of cells that phagoytosed beads. 
 
The phagocytic uptake of beads, which were coated with different antigen, by BM-DCs was 
assessed by fluorescent microscopy. BM-DCs did phagocytose beads, but no unambiguous 
formation of LC3-associated phagosomes could be detected in any of the conditions tested. To 
check if there are differences of phagocytic uptake of BM-DCs either derived from DCAtg5CTRL or 
DCAtg5KO mice, the number of beads per cell was quantified for the conditions “beads only”, “MOG 
protein”, “Pam3CSK4” and “MOG protein plus Pam3CSK4”. Compared to the condition “beads 
only”, the number of beads per cell increased when the beads were coated with Pam3CSK4 only, 
but even decreased when MOG protein was coated on the beads. Furthermore, the supplementation 
of MOG protein with Pam3CSK4 did not induce LAP - contrary, this supplementation even 
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decreased the amount of beads in the cell in comparison to the Pam3CSK4 only condition. This 
might be due to the fact that MOG protein might compete with Pam3CSK4 for binding sides on the 
beads and, thus, decreases phagocytic uptake. Comparing the phagocytoc capacity of BM-DCs that 
were either originated from DCAtg5CTRL or DCAtg5KO mice, no difference could be found. 
As an alternative read-out, the percentage of cells that contained beads was quantified. A smiliar 
trend as for the analysis of beads per cells was observed and no difference between Atg5KO BM-
DCs and Atg5CTRL BM-DCs could be shown. 
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4 Discussion 
Autoreactive CD4+ T cells are crucial for the development of MS and its animal model EAE. So far, 
the mechanisms mediating the activation of autoreactive CD4+ T cells in the development of this 
autoimmune disease are incompletely characterized. We hypothesized that Atg5-dependent 
presentation of autoantigens by CD11c+ cells facilitates the activation of autoreactive T cells and, 
conclusively, might have an impact on the development of EAE. 
To address this question we investigated whether Atg5-deficiency in CD11c+ cells influences the 
development of EAE. We showed that Atg5-deficiency in CD11c+ does have an impact on the 
development of adoptive transfer EAE, but not on the development of active EAE. So far antigen 
presentation and phagocytosis assays revealed no conclusive results with regard to antigen 
processing and presenting capabilities of MOG peptide, MOG protein and beads coated with MOG 
protein by CD11c+ cells or BM-DCs. 
 
4.1 MS, EAE, Autophagy and CD11c+ Cells – The Rationale 
4.1.1 The Role of CD4+ T Cells in the Development of MS 
MS is an inflammatory autoimmune disease that affects the myelin sheath around the axons in the 
CNS (Sospedra and Martin, 2005). The exact etiology of this disease is still under debate, but 
genetic as well as environmental factors are considered crucial for the development of MS. Also the 
starting point of inflammation, which, eventually, leads to first disease symptoms, is still 
incompletely understood. Environmental factors such as viral infections are the most favourable 
suspects that cause initiation of the disease (Ascherio et al., 2012). 
MS and EAE are considered mainly CD4+ T cell-driven diseases. The strongest genetic risk factor 
that determines the susceptibility to suffer from MS is associated with the HLA-DRB1*1501 allele 
(Schmidt et al., 2007). The HLA-DRB1*1501 allele encodes for MHC class II molecules and, thus, 
mediates presentation of antigens to CD4+ T cells. This allele is known to increase the risk of 
developing MS by threefold in heterozygous carriers and by sixfold in homozygous carriers 
(Sadovnick, 2012). During the course of MS, the main lymphocytic infiltrates comprise of CD4+ 
and CD8+ T cells and both cell types are ascribed pathogenic functions during the development of 
MS and EAE (Fletcher et al., 2010). A diversity of immunotherapeutic drugs has been approved and 
was shown to reduce disease activity and progression (Buck and Hemmer, 2011). 
 
4.1.2 Antigen Processing during CNS Autoimmunity 
Antigen processing and presentation is an essential step during the activation process of CD4+ T 
cells. Antigens need to be taken up by an APC, degraded by the lysosomal machinery and loaded 
onto MHC class II molecules for presentation to CD4+ T cells. There are two main pathways that 
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are ascribed to the processing and presentation of antigen on MHC class II molecules – namely, the 
classical MHC class II antigen processing pathway (Neefjes et al., 2011) and the autophagic 
pathway (Levine and Deretic, 2007). There is a third, but lesser known, pathway that also 
contributes antigens to the MHC class II pathway - namely LAP. In the context of EAE or MS, 
there have been no studies that investigated which one of these pathways is exactly responsible for 
the processing and presentation of extracellular material in order to stimulate encephalitogenic 
CD4+ T cells. 
Since DCs are known to play the major role in antigen presentation in the priming and restimulation 
phase of EAE (Greter et al., 2005), we were eager to investigate which role autophagy or LAP 
might play in the presentation of extracellular self-antigen. We made use of a Cre/loxP-deleter 
transgenic mouse system in which Atg5 was conditionally deleted in CD11c+ APCs which mainly 
include DCs. Atg5 is a protein essential for autophagosome formation whose complex with Atg12 
and Atg16L1 mediates ligation of Atg8 to the autophagosomal membrane for vesicle expansion and 
substrate recruitment. Conclusively, if Atg5 is missing in CD11c+ cells neither autophagosomes nor 
LC3-associated phagosomes can be formed and both of theses pathways are abolished. With this 
mouse system we were able to study the development of EAE in the absence of Atg5 in CD11c+ 
APCs compared to control littermates. According to our aims, we hypothesized that autophagy in 
CD11c-expressing cells accelerates EAE development and progression due to increased loading of 
self-antigen onto MHC class II molecules. 
 
4.1.3 Potential Role of Autophagy in Autoimmune Diseases 
Autophagy has been described to be involved in the pathogenesis of various autoimmune diseases. 
Generally, there are different roles of autophagy that are ascribed to cause autoimmunity (Lleo et 
al., 2007). For instance, autophagy is known to eliminate intracellular pathogens (Kuballa et al., 
2012) which might lead to presentation of autoantigens on the cell surface or to molecular mimicry. 
But not only pathogen-related antigens are processed via autophagy, also intracellular self-antigens 
are presented via MHC class II molecules which might lead to the activation of autoreactive CD4+ 
T cells (Dengjel et al., 2005). 
Autophagy is associated with the most frequent form of inflammatory bowel diseases, namely 
Crohn’s disease. In the context of this disease a defect in autophagy leads to an increase in IL1-β 
secretion and, consequently, to the generation of an inflammatory milieu. For more information 
regarding the connection between polymorphisms in autophagy genes and Crohn’s disease see 
(Plantinga et al., 2012). Furthemore, genetic studies have shown that polymorphisms in genes 
encoding the autophagy-regulating protein IRGM and the Atg16L1 protein, that is part of the Atg5-
Atg12/Atg16L1 complex, provide evidence that autophagy is related to Crohn’s disease. Even 
though a functional link between autophagy and the susceptibility to Crohn’s disease has not been 
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established, it is hypothesized that autophagy plays a role in an uncontrolled immune response 
against commensal gut bacteria or a deficiency in removing of bacteria (Levine and Deretic, 2007). 
Furthermore, autophagy and SLE are potentially interconnected since it was shown that some 
autophagic genes, such as genes encoding for Atg5 and Beclin-1, are known to be involed in the 
removal of dead bodies. A model for the connection of autophagy and SLE envisions that the lack 
of Atg5 and Beclin-1 results in the absence of “eat me signals” such as the exposure of 
phosphatidylserine on the cell surface or the deficient release of the “come-get-me” signal 
lysophosphatidylcholine. These circumstances might lead to an impaired clearance of dead cells 
and, finally, to the production of autoantibodies against cell debris (Pierdominici et al., 2012). 
 
4.1.4 Potential Role of Autophagy in the Development of MS and EAE 
Amongst other characteristics, autophagy is involved in the cellular degradation of unnecessary or 
dysfunctional cellular components such as protein aggregates. Studies of spinal cords of mice with 
EAE revealed an increased level of oxidized protein aggregates that went along with a reduced level 
of LC3. Latter was accounted to be the reason for the accumulation of aggresomes, even though a 
functional mechanism between the presence of aggresome and disease was not shown (Dasgupta et 
al., 2013). Furthermore, LC3 level in spinal cord of EAE mice at day 21 post EAE induction was 
increased in comparison to sham controls. It was concluded that autophagy may be beneficial for 
the removal of degraded or damaged intracellular organelles within the spinal cord during EAE 
(Choi et al., 2013). Alirezaei et al. investigated if Atg5 levels are modified in T cells in a T cell-
mediated autoimmune disease. In this context, a correlation between Atg5 expression in T cells and 
disease severity could be shown by quantitative PCR and Western blot analysis of blood from mice 
with EAE and individuals with active RR-MS in comparison to heathly controls. It was concluded 
that increased levels of Atg5 might promote T cell survival and proliferation during disease 
progression (Alirezaei et al., 2009). And finally, investigating the role of autophagy in CNS-
resident APCs, such as microglia, revealed an upregulation of LC3+ puncta at the peak of disease 
(unpublished data). 
 
4.2 Effect of Atg5-Deficiency in CD11c+ Cells on EAE Development 
4.2.1 Breeding and Characterization of DCAtg5KO Mice 
In order to study the role of LAP in the development and progression of EAE, DCAtg5CTRL (CD11c-
Cre-/- Atg5flox/flox genotype) and DCAtg5KO mice (CD11c-Cre+/- Atg5flox/flox genotype) were generated. 
Due to the known side-effects of the Cre/loxP-deleter transgenic mouse system, such as unspecific 
activity of promotors (Cre leakage), gene silencing due to random genomic inserton of Cre or 
incomplete excision of the target gene, a basic characterization of the DCAtg5KO and DCAtg5CTRL 
mouse was performed. First of all, Cre-EGFP expression was demonstrated in CD11c+ H2-Ab+ cells 
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originated from either CNS or spleen of DCAtg5KO mice in comparison to DCAtg5CTRL mice. The 
unspecific Cre expression in CD4+, CD8+ and CD11b+ cells was excluded by flow cytometry and 
only a low level of unspecific Cre expression was observed in one out of four DCAtg5KO mice in the 
CD11b+ compartment. 
Atg5 is known to also have autophagy-unrelated functions such as negative regulation of innate 
antiviral immune signals or pro-apoptotic functions (Subramani and Malhotra, 2013). To ensure an 
uneffected T cell and DC subset repertoire in both DCAtg5CTRL and DCAtg5KO mice, the percentage of 
CD4+ and CD8+ T cell and Treg fractions as well as DC subsets was investigated. A similar 
percentage of all afore mentioned cell types was shown by flow cytometry analysis. 
 
4.2.2 Induction of Active EAE with MOG Peptide or Protein 
For the induction of EAE, autoreactive CD4+ T cells need to be activated by myelin-specific antigen 
that is presented by APCs. In the model of active EAE, this self-antigen is given to the mice by 
injection of a MOG peptide/protein:CFA emulsion. APCs take up the antigen by endocytosis and 
transport it to the lysosome for degradation and loading onto MHC class II molecules. The exact 
route of the self-antigen from the phagosome to the MIIC has not been described yet and it could 
traffic via the classical MHC class II presentation pathway, the LAP pathway or an alternative, so 
far undescribed, pathway. 
In order to study Atg5-dependent antigen processing in the context of EAE development, we 
induced active EAE in DCAtg5KO and DCAtg5CTRL mice by the injection of MOG peptide in three 
independent experiments. The pooled data of theses experiments showed no difference between 
DCAtg5KO and DCAtg5CTRL mice in terms of clinical EAE score or body weight change. One potential 
explanation for the absence of a phenoytpe might be that MOG peptide can bind to empty MHC 
class II molecules on the cell surface without being processed. This scenario is rather unlikely since 
the HLA-DM molecule is responsible for the peptide editing process during which loosely bound 
peptides are removed. This way it is ensured that only stable peptide:MHC class II molecules exist 
on the cell surface (Neefjes et al., 2011). Despite these precautions, it might happen that empty 
MHC class II molecules occur on the cell surface. But, since these empty MHC class II molecules 
are unstable in their conformation, they aggregate immediately, are internalised and degraded 
which, again, prevents the binding of unwanted peptides on the cell surface. An alternative 
explanation for the absence of a phenoytpe might be that MOG peptide does not trigger LAP due to 
its minor size of 20 amino acids. 
To investigate if the injection of MOG protein causes a difference between groups, EAE was 
actively induced by the injection of MOG protein in CFA. Also under these conditions no 
difference in disease course or severity could be shown. Consequently, it was considered if MOG 
protein might also be able to bind onto MHC class II molecules without beeing processed or via 
bypassing the LAP pathway. Classically, proteins need to be processed before being loaded onto 
Discussion 
 81 
MHC class II molecules. But, actually, quite contrary views on the necessity of myelin antigen 
processing were found. For example, Cross et al. showed that both, MBP and peptide, need to be 
processed for antigen presentation (Cross et al., 1990). In contrast, Friedman et al. claims that even 
unprocessed MBP can induce the proliferation of T cell lines and, additionally, that MBP-activated 
T cell lines are able to induce EAE in recipient mice (Friedman et al., 1992). The former study is 
supported by newer investigations that demonstrated that antigen processing and presentation is 
necessary when EAE is elaborated in C57BL/6 mice by MOG peptide injection (Slavin et al., 2001; 
Tompkins et al., 2002). 
Additionally, it was considered that the active induction of EAE in the presence of the strong 
adjuvant CFA might cause such a strong immune response that a potentially minor effect due to the 
absence of Atg5 in CD11c+ cells on EAE development might be mimicked. In order to reduce this 
rather harsh treatment, MOG protein and CFA were diluted. But also under these conditions no 
difference between experimental groups could be found. 
To ensure LAP-specific effects and exclude non-canonical autophagy related functions of Atg5, the 
same experiments were performed with DCAtg7CTRL and DCAtg7KO mice. The active immunization 
protocol, with injection of MOG peptide and MOG protein, resulted in no differences between the 
two experimental groups. 
 
4.2.3 Impact of Atg5-Deficiency in CD11c+ Cells on Adoptive Transfer EAE 
The induction of active EAE did not yield a difference between experimental groups, and it could 
not be determined as to which extend MOG peptide or protein were processed by the Atg5-
dependent antigen processing pathway. Therefore we made use of the adoptive transfer EAE model. 
The main difference between these two models is that in the adoptive transfer model, already 
primed autoreactive CD4+ T cells encounter the self-antigen in the recipient mouse the first time 
when presented by local APCs in the CNS. This ensures that CNS antigen needs to be phagocytosed 
and presented by local APCs. 
Furthermore, the adoptive transfer EAE model is considered being a less strong immune activator - 
due to the absence of the strong adjuvant CFA and PTx. For reasons already elucidated above, 
adoptive transfer EAE might be beneficial in revealing minor differences. Contrary to the results 
gained with the active immunization model, in the adoptive transfer EAE model DCAtg5KO mice did 
not develop any EAE symptoms whereas DCAtg5CTRL mice developed normal EAE symptoms. 
 
4.3 Role of APCs During the Priming and Effector Phase 
4.3.1 Priming of Autoreactive CD4+ T cells 
Active EAE is induced by subcutaneous injection of CFA and MOG antigen. In order to induce 
EAE, MOG antigen needs to be processed by APCs and presented to autoreactive T cells. It has 
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long been accepted that DCs play an important role in linking innate and adoptive immune 
responses, that they are the main players in raising primary T cell responses and that other 
professional APCs contribute less to this process (Inaba et al., 1990; Macatonia et al., 1989). Even 
though DCs are the model APC, unambigous studies showing their role in the first priming of 
peripheral autoreactive CD4+ T cells during EAE development are still missing. For this reason 
different types of APCs and their role in peripheral activation of autoreactive CD4+ T cells will be 
discussed below. 
One type of APC that resides in the skin and could be responsible for the antigenic uptake during 
active EAE are migratory DCs. Migatory DCs belong to the class of cDCs and can be further 
subdivided into Langerhans cells (CD11c+ CD207+ CD103-) and dermal DCs (CD11b- CD103+ or 
CD11b+ CD103- dermal DCs) (Ginhoux et al., 2007; Henri et al., 2010). One study making use of 
the model antigen chicken ovalbumin (OVA) showed that migratory and lymphoid-resident DCs are 
required to initiate T cell responses after subcutaneous injection of OVA antigen (Allenspach et al., 
2008). Further studies by King et al. supported those data by demonstrating that CD103+ dermal 
DCs are of major importance for the development of EAE since they are responsible for the priming 
of encephalitogenic CD4+ T cells (King et al., 2010). Nevertheless, these data were challenged by a 
study demonstrating that Batf3-/- mice, which lack all peripheral CD11b- CD103+ DCs (Edelson et 
al., 2010), show a similar course of disease as C57BL/6 wildtype mice (Edelson et al., 2011). Batf3 
is a transcription factor that is required for the development of lymphoid-tissue resident CD8a+ 
cDCs and CD103+ non-lymphoid DCs as well as dermal Langerin+ CD103+ DCs. In a third study, 
the role of migratory DCs in inducing tolerance was investigated. The self-antigen MOG was 
targeted to cell surface receptors on specific DC populations and the tolerogenic effect was studied 
in vivo by use of the EAE model. Migratory DCs were shown to generate Tregs and alleviate EAE 
symptoms (Idoyaga et al., 2013). Even though these results might be conflictive with the data 
shown by King et al., the authors argue that, under steady state conditions, migratory DCs promote 
Tregs and peripheral tolerance, whereas, under inflammatory conditions, they promote effector Th1 
and Th17 cells (Idoyaga et al., 2013). 
Another question still being unanswered is if DCs alone are sufficient to raise an immune response. 
In a mouse study in which MHC class II expression was restricted to DCs only, mice showed a 
milder course of disease when EAE was actively induced with MOG protein but not with MOG 
peptide. This indicates that DCs alone are not sufficient in inducing EAE (Wu et al., 2011). Two 
recent papers rolled up the field of DC immunology and claimed that DCs are completely 
dispensable for EAE development (Isaksson et al., 2012; Yogev et al., 2012). Isaksson et al. made 
use of a CD11c-DTR system in which CD11chigh DCs can be conditionally deleted by the injection 
of diphteria toxin, but not pDCs, macrophages and B cells (Jung et al., 2002). Successful DC 
depletion was estimated by FACS analysis and it could be shown that dermal Langerin- DCs and 
CD11chigh MHC class II+ mDCs from skin-draining LNs and spleen were efficiently depleted 
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whereas 50% of CD11cint MHC class II+ inflammatory DCs could not be deleted successfully. And, 
at peak of disease a large amount of mDCs as well as inflammatory DCs were present in the so-
called DC-deficient mice as well as control mice. Using these mice it was demonstrated that 
priming of encephalitogenic T cells and the development of EAE were not affected in this CD11c-
DTR system (Isaksson et al., 2012). In an independent study two different mouse models were used 
to conditionally ablate DCs and to study their in vivo functions during EAE development – namely, 
the inducible diphtheria toxin receptor (iDTR) model (Buch et al., 2005) and CD11c-DTR mice 
(Jung et al., 2002). Also in this study DCs were not absolutely depleted and there were always DCs 
remaining. Despite this flaw, it was claimed that ablation of DCs did not lead to an impairment but 
actually worsening of EAE symptoms (Yogev et al., 2012). Even though results from both studies 
go into the same direction, it remains questionable if the remaining DCs might be sufficient in 
priming autoreactive T cells as it was shown that a low number of peptide:MHC complexes can 
trigger a high number of TCRs (Valitutti et al., 1995). 
But if it was true that DCs are not necessary in priming of T cells, another cell subsets needs to be 
determined for being responsible. Aside from DCs, the group of professional APCs also includes B 
cells and macrophages. But also monocytes that differentiate into inflammatory/monocyte-derived 
DCs (moDCs) might be potential candidates for professional APC functions. 
B cells have a diversity of known functions that contribute to the pathogenesis of EAE – namely, 
secretion of autoantibodies that activate complement and cause demyelination (Lassmann et al., 
1988; Linington and Lassmann, 1987; Schluesener et al., 1987), presentation of myelin antigens 
(Morlacchi et al., 2011) and release of cytokines (Fillatreau et al., 2002; Matsushita et al., 2008). It 
is noted that not only pathogenic features are ascribed to B cells, but also regulatory functions 
(Mann et al., 2012). Even though a clear role for B cells in EAE has been demonstrated, it seems as 
if they were redundant for EAE induction since even B cell-deficient mice develop a severe form of 
EAE (Dittel et al., 2000; Hjelmström et al., 1998; Wolf et al., 1996). 
Despite latter data, Yogev et al. investigated the role of B cells in the priming phase of EAE. Mice 
were immunized with beads that had been treated with CFA, and, in a next step, cells from lymph 
nodes were checked for uptake of beads. It was shown that both, B cells and macrophages were able 
to ingest the beads. To further invest the role of B cells, B cells and DCs were ablated in parallel, 
but no effect on EAE development was shown. Yogev et al. suggested that macrophages might be 
the primarily responsible cell type to prime autoreactive T cells (Yogev et al., 2012). The potential 
role of macrophages in the development of EAE was investigated by deletion of peripheral 
macrophages by Cl2MDP-mnL (mannosylated liposomes containing dichloromethylene 
diphosphonate) injection (Tran et al., 1998) or by the inhibition of macrophage activation and 
proinflammatory cytokine production by injection of a therapeutic called CNI-1493 (Martiney et al., 
1998). In both studies it could be shown that the absence of macropahges prevented EAE and it 
indicates that at least peripheral macrophages are essential for the development of EAE. 
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Monocytes, which are classically defined as the progenitors of macrophages, can also differentiate 
into inflammatory/monocyte-derived DCs (moDCs; defined as beeing CD11cint, MHC II+, CD11b+, 
Ly6C+, CCR5+) (Domínguez and Ardavín, 2010). In the context of Leishmania and respiratory 
fungal infection models, it could be shown that moDCs do have the capability of T cell priming 
(Hohl et al., 2009; León et al., 2007). In a study describing the fate of Ly6Chigh monocytes during 
EAE, it was shown that theses cells are recruited to the spinal cord and differentiate into iNOS-
producing cells that might be an equivilant to TipDCs (King et al., 2009), but it has not been 
investigated if these cells are also present during the initial priming phase of T cells. Due to the 
intermediate expression of CD11c by moDCs and their fast turnover rate, it might be that moDCs 
during the peripheral inflammation in the skin might not be Atg5-deficient. Conclusively, moDCs 
might be fully capable of MOG peptide and protein presentation to autoreactive CD4+ T cells. 
Assuming that moDCs were the driving force in active EAE development and Atg5 was still 
present, no difference in EAE symptoms is to be expected.  
Considering the diversity of cell types that have the capability to present self-antigens during the 
priming phase of EAE, it might very well be that other CD11c- APCs might counterbalance the 
potential effect of Atg5-deficiency in CD11c+ cells during active EAE and that the Atg5-deficiency 
in CD11c+ cells has no effect on EAE development in active EAE. 
 
4.3.2 Brain Resident Cells and Their Potential Role in EAE 
Once autoreactive CD4+ T cells are present in the periphery, they migrate to the CNS where they 
need to be reactivated by local APCs (Slavin et al., 2001). Principally, there are two anatomical 
locations where T cells can encounter their endogenous antigen. Firstly, myelin debris might 
accumulate in peripheral lymphoid organs such as spleen and deep cervical lymph nodes (de Vos et 
al., 2002; Ling et al., 2003). Secondly, myelin antigen is presented by resident local APCs in the 
CNS itself. 
Neuroglia, or also called glia cells, are all non-neuronal cells present in the CNS. Neuroglia are 
responsible for the maintenance of the CNS and functionally there are different responsibilities 
assigned to them: support and protection of neurons, supply of the neurons with nutrients and 
oxygen, insulation of neurons and the removal of pathogens and dead cells. In the mammalian 
system, neuroglia are subclassified into peripheral nervous system (PNS) glia and CNS glia. The 
CNS neuroglia cells include macroglia (astroglia, oligodendroglia, NG2 glia) and microglia, 
whereas the PNS neuroglia cells include Schwann cells, olfactory ensheathing cells, satellite glial 
cells and enteric cells. 
Oligodendrocytes have cellular portrusions that form the myelin sheath around the axons of nerve 
cells to insulate latter and support the conduction of electonical signals. During the course of EAE 
oligodendrocytes are the main target of the imune attack against myelin components. But since they 
do not express MHC class II molecules (Lee and Raine, 1989; Wong et al., 1984) they cannot serve 
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as local APC for the reactivation of T cells. 
Astrocytes form the majority of glial cells in the CNS. Their main functions are the provision of 
neurons with nutrients, maintenance of extracellular ion balance, maintenance of the BBB and 
repair and scarring processes in the brain. Astrocytes are described to express MHC class II 
molecules and to activate CD4+ T cells in the context of EAE (Becher et al., 2000; Chastain et al., 
2011; Fierz et al., 1985). 
Microglia are the macrophage-like cells of the CNS and reside in the parenchymal tissue (Raivich 
and Banati, 2004). They act as APC, belong to the arm of the innate immune system and detect 
pathological events in the CNS. Since the CNS is considered as an immune-priviliged organ, mature 
resident microglia provide surveillance of the CNS – they respond to tissue injury, recognize and 
eliminate pathogenic substances and are important defenders against a diversity of 
neurodegenerative diseases (Kreutzberg, 1996). Due to their location in the CNS and the fact that 
microglia do not only have homeostatic functions, but are also able to interact with cells of the 
immune system, microglia are thought to play a key role in the initiation of immune responses in 
the CNS during EAE in mice and MS in humans where they could be found at inflammatory loci 
(Carson, 2002; Raivich and Banati, 2004). It was further shown that in EAE, under inflammatory 
conditions, microglia upregulated cell surface markers such as CD45, MHC class II and CD11c 
which gave them a macrophage and/or DC-like phenotype (Ponomarev et al., 2005). Thus, the role 
of microglia in the development of EAE in Atg5-deficient mice might also be taken into 
consideration. 
Which one of the two cell types, microglia or DCs, are the major player during the CNS 
inflammation, still needs to be determined. In this context, one study showed that the abolishment 
of microglia cells leads to attenuation of EAE disease symptoms (Heppner et al., 2005) whereas two 
other studies favoured DCs to be the main APC for T cell activation (Greter et al., 2005; McMahon 
et al., 2005; Platten and Steinman, 2005). It was concluded that CNS-resident DCs are the most 
important APCs in the reactivation of transferred myelin-specific CD4+ T cells and that resident 
microglia or infiltrating macrophages are negligible. In newer studies, researchers’ attention was 
turned to the role of monoctyes during EAE since they are recruited to the CNS under inflammatory 
condtions. Once in the inflamed CNS, monocytes differentiate into moDCs and might function as 
the main APC during CNS inflammation (King et al., 2009; Mildner et al., 2009). 
But, for microglia as well as for moDCs, it remains elusive if these cell subsets are immediately 
Atg5-deficient after upregulation of CD11c. Studies, investigating the half-life of proteins involved 
in autophagy, revealed that Atg5 has an approximate half-life of 48 hours after small interfering 
RNA (siRNA) transfection (Deretic, 2010). Additionally, we have shown that Atg5-deficiency 
during BM-DC differentiation is most efficient after 10 days of culture. Hence, microglia and 
moDCs might not be Atg5-deficient when reactivating myelin-specific CD4+ T cells. 
This suggests that, in the adoptive transfer EAE model, CNS-resident CD11c+ APCs are the main 
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players in reactivating transferred myelin-specific CD4+ T cells and that Atg5-deficient CD11c+ 
APCs are not able to successfully present myelin antigen due to the absence of the Atg5-dependent 
antigen processing machinery. Whereas, in active EAE this effect is masked since other CD11c- 
APCs might overrule the reactivation process of CD4+ T cells in presence of the pronounced 
proinflammatory milieu during active EAE. 
 
4.4 Potential Role of Atg5 in Antigen Presentation During EAE 
4.4.1 Antigen Presentation Capabilities of Atg5-Deficient DCs 
The antigen presentation capabilities of Atg5-deficient DCs were first assessed in a co-culture 
setup. Splenic primary DCs originating from DCAtg5CTRL or DCAtg5KO mice were co-cultured with 
MOG-specific CD4+ T cells in the presence of MOG peptide, MOG protein or polystyrene beads 
coated with MOG protein. Antigen presentation capabilities were studied by assessing CD4+ T cell 
proliferation by means of a CFSE dilution assay. In this experimental setup, CD4+ T cells 
proliferated more in the presence of Atg CTRL DCs than in the presence of Atg5 KO DCs. This is 
in contrast to the in vivo data that demonstrated that EAE symptoms are almost completely 
abolished when Atg5-dependent antigen processing pathways are blocked – indicating that 
reactivation of autoreactive CD4+ T cells by Atg5-deficient CD11c+ cells is impaired. In order to 
further investigate these findings, an additional phagocytosis assay was performed and will be 
discussed in the next section. 
 
4.4.2 TLR-Dependent Atg5-Associated Phagocytosis 
The question arises if MOG peptide/protein or MOG protein-coated beads can soleyly trigger LAP 
or if additional triggers are necessary. For instance, classical autophagy was described to be 
triggered by PAMPs and danger-associated molecular pattern (DAMPs) (Tang et al., 2012), 
whereas LAP was described to be triggered by receptor mediated signaling pathways such as TLRs 
(Sanjuan et al., 2007), FcRs (Henault et al., 2012) and PtdSerR (Martinez et al., 2013) or even by 
the uptake of live cells (entosis) (Florey et al., 2011). 
To address this question and the issue raised in the latter chapter, the phagocytic capacity of Atg5-
deficient BM-DCs in comparison to control DCs was studied in a bead phagocytosis assay in the 
presence of Pam3CSK4. Pam3CSK4 is a synthetic bacterial triacylated lipopeptide (LP) and 
interatcs with TLR1 and TLR2. In this experiment, beads were coated with MOG protein, 
Pam3CSK4 or MOG protein plus Pam3CSK4 and added to BM-DCs for four hours. The phagocytic 
uptake was estimated by determining the number of beads per cell or, alternativley, as the 
percentage of cells that phagocytosed any number of beads. Even in the presence of a TLR agonist, 
no LC3-associated phagosomes could be detected and no difference in the phagocytic uptake of 
beads could be demonstrated. These negative results, even in the presence of Pam3CSK4, might be 
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attributed to unsuccessful binding of the compounds to the beads, suboptimal incubation time of 
cells together with beads or a general incapability of mouse BM-DCs to form LC3-associated 
phagosomes after Pam3CSK4 stimulation. 
Since LPS (TLR4 agonist) also induces LAP (Sanjuan et al., 2007), it was reasoned that MOG 
protein or peptide should be supplemented with LPS to achieve better results. It needs to be taken 
into consideration that the recombinant MOG protein used in our assays was purified by use of a 
crude preparation procedure after which a high amount of endotoxin was still present (data not 
shown). Consequently, the purified recombinant MOG protein, which was most likely associated 
with LPS, was used in the above-mentioned assays and it was not sufficient to induce LAP. 
Alternatively, zymosan, which is a β-glucan mannan-rich particle found on the cell surfaces of yeast 
and interacts with TLR2, could be added to the in vitro cultures. But since zymosan is expressed by 
yeast cells and yeast is not known to be of influence during EAE or MS, it might be far-fetched to 
set zymosan into the context of CNS autoimmunity. Furthermore, zymosan has an ameliorating 
effect on the development of EAE (Li et al., 2013), which would argue against the role of zymosan 
in disease induction. 
Investigating other TLRs in the context of EAE, TLR9 (Prinz et al., 2006) and, to some extend, 
TLR2 signaling mediates the pathogenicity of EAE, whereas TLR1, 4 and 6-deficiency in mice did 
not have an impact on the development of active EAE (Miranda-Hernandez et al., 2011). 
Additionally, both studies showed that MyD88 deficiency abrogates disease. For a summary of the 
role of TLRs in autoimmunity compare (Mills, 2011). Additionally, it was shown that FcγRs are 
responsible for the internalization of DNA-immuno complexes (DNA-IC) and that this 
internalization induced the recruitment of TLR9 to the phagosome and the secretion of TNFα. 
Based on these data, it was proposed by the authors that LAP is responsible for the convergence of 
the phagocytic and autophagic pathway (Henault et al., 2012). Conclusively, it might be wortwhile 
to test TLR9 agonists in the context of our in vitro studies. 
 
4.4.3 FcR-Mediated Phagocytosis 
LAP has been described to be induced by FcR engagement (Henault et al., 2012). Noteworthy, a 
connection between B cells, plasma cells, and the presence of antibodies against myelin antigen and 
the development of MS is established. Furthermore, one hallmark for the diagnostic of MS is the 
presence of oligoclonal Igs and plasma cells in the cerebrospinal fluid (Esiri, 1977; Ziemssen and 
Ziemssen, 2005). The role of B cells has also been described in the EAE model and pathogenic as 
well as regulatory functions were attributed to them (Mann et al., 2012). Despite the intense 
investigation of the role of B cells during EAE, contradictory results were shown. On the one hand 
it was shown that antibodies have the capacity to promote the phagocytosis of myelin and 
contribute to the inflammation and demyelination in the CNS (Linington et al., 1988; Morris-
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Downes et al., 2002). But on the other hand it was also shown that mice that are deficient in B cells 
still develop EAE (Dittel et al., 2000; Hjelmström et al., 1998; Wolf et al., 1996). Even though B 
cells might be dispensable during the development of EAE, it is out of question that B cells do 
infiltrate into inflammatory lesions and that autoantibodies targeting myelin antigens are released 
during MS (Genain et al., 1999). 
There are different ways of how B cells might exert their effector functions during demyelination 
(Weber et al., 2011). Amongst various mechanisms, opsonization of target cells and subsequent 
phagocytosis of the opsonized cells are noteworthy in the context of this study. FcRs, which are 
expressed on APCs, recognize the opsonized target and phagocytose it, which, finally, leads to 
destruction of tissue. Generally, the internalization of IgG-opsonized particles by phagocytosis is 
best described for Fcγ receptors (FcγR) (Flannagan et al., 2012). And, in the context of EAE, it 
seems as if macrophages play a major role in phagocytosing antibody-opsonized myelin and, 
eventually, causing demyelination and tissue damage (Sadler et al., 1991; Trotter et al., 1986). But 
also microglia, the resident “macrophages” within the CNS are associtaed with neuronal damage by 
phagocytosis (Bauer et al., 1994; Cash et al., 1993; Huizinga et al., 2012). Mouse DCs, which are 
thought to be the main APC during EAE, express both FcγRIII (activating) and FcγRIIb (inhibitory) 
on their surface (Regnault et al., 1999). The expression of FcγRIII and FcγRIIb would give DCs the 
potential to bind to the Fc part of an antibody and phagocytose opsonized myelin-expressing 
oligodendrocytes. So far there are only few studies describing the role of DCs in the phagocytosis 
of myelin-antigen or oligodendrocytes. Investigating human MS lesions it was demonstrated that 
DC-SIGN+ DCs do contain myelin debris when present in the perivascular spaces of active MS 
lesions (Serafini et al., 2006). In the context of another study, it was investigated how the 
phagocytosis of human myelin influences the activation state of human moDCs. It was shown that 
myelin-laden DCs actually suppress the proliferation of T cells, whereas the secretion of TGF-β 
was increased and the migratory capacity of myelin-treated DCs was decreased (Gredler et al., 
2010). These results might argue that DCs play a primary role in controlling immunity and 
tolerance, but it does not exclude the fact that FcR-mediated phagocytosis of antibody-opsonized 
oligodendrocytes is important for the development of EAE. And if there was a hypothetical 
association between FcR-mediated phagocytosis and LAP, the lack of LAP in CNS-resident DCs 
might lead to an insufficient restimulation of infiltrating autoreactive T cells. This hypothesis would 
be supported by studies in SLE in which it was shown that DCs preferrably phagocytose apoptotic 
bodies opsonized by autoantibodies and apoptotic bodies or blebs displaying “eat me signals” 
(Frisoni et al., 2005). 
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4.4.4 Phagocytosis of Apoptotic Cells and Self-Antigen 
The uptake of dying cells is importat to maintain homeostasis in the body what otherwise might 
result in SLE (Shao and Cohen, 2011). In this context, LAP was described to be induced by 
phagocytosis of apoptotic, necrotic, and RIPK3-dependent necrotic cells (Martinez et al., 2011) or, 
alternatively, by the uptake of live cells (entosis) (Florey et al., 2011). Martinez et al. showed that 
PtdSer on the surface of dying cells is recognized by the PtdSer receptor TIM4 that triggers the 
recruitment of autophagy-related proteins to the dead cell-containing phagosome (Martinez et al., 
2011). Conclusively, it could be that the presence of apoptotic cells might trigger LAP in BM-DCs 
or primary splenic DCs. To investigate this, target cells like an apoptotic or necrotic MOG-
expressing oligodendrocyte cell line could be co-cultured with Atg5-deficient cells to check for 
phagocytic uptake by the engagement of LAP or T cell stimulation in the CFSE dilution assay. 
 
4.4.5 Non-Antigen Processing-Related Functions of Atg5 
The lack of EAE symptoms in the DCAtg5KO mouse group in the adoptive transfer experiments might 
also go back to non-autophagy related functions of Atg5 (Subramani and Malhotra, 2013). For 
instance, one non-autophagy related function of Atg5 is that the Atg12-Atg5 complex negatively 
regulates innate antiviral immune signalling by secluding CARD proteins (Jounai et al., 2007; 
Takeshita et al., 2008). Additionally, Atg16L1 and Atg5 have a beneficial role in the secretion of 
antimicrobial peptides through exocytosis by Paneth cells (Cadwell et al., 2008); and Atg5 and Atg7 
are necessary for the polarized secretion of cathepsin K by osteclasts at the ruffled border of the cell 
(DeSelm et al., 2011). Atg5 makes cells more susceptible towards apoptotic stimuli as it was shown 
that Atg5 cleaved by calpain-mediated caspase activation and, thus, apoptotic cell death (Yousefi et 
al., 2006). 
Regarding the diversity of non-canonical autophagy functions of Atg5, only some of the functions 
outlined above might be applicable to our model. Firstly, Atg5 negatively regulates type I IFN 
secretion (Jounai et al., 2007; Takeshita et al., 2008). Type I IFNs are mainly secreted by pDCs 
after triggerung of TLRs and viral infections (Colonna et al., 2004) and, in the context of EAE, are 
known to have protective characteristics in MS and EAE (Kalinke and Prinz, 2012). This is in line 
with the fact that IFN-β KO mice show exacerbated disease symptoms and more severe 
neurological symptoms compared to the control group (Teige et al., 2003). As per our model, Atg5 
is deleted in CD11c+ cells and this could theoretically result in more type I IFN secretion and, thus, 
in a mildened disease course. This would fit the results of the adoptive transfer EAE model, but 
with regard to the active EAE model, the question arises why this effect is missing – especially, 
since latter system provides a high amount of TLR agonists in form of CFA and PTx that should 
lead to an increase in type I IFN secretion. 
A second non-canonical autophagy function of Atg5 that might be of importance during EAE 
development is that Atg5 makes cells more prone to apoptosis (Yousefi et al., 2006). This effect has 
Discussion 
 
 90 
only been shown for T cells, so that it is hard to judge how Atg5-deficiency might influence 
apoptosis in CD11c+ cells. One could assume that Atg5-deficiency in CD11c+ cells would lead to a 
higher survival rate of CD11c+ cells. Hence, more CD11c+ cells should be present to process and 
present antigen and, thus, more myelin-specific CD4+ T cells should be activated and should cause 
more severe EAE symptoms. This is contrary to our observed results, but further investigations will 
be necessary to ensure the antigen-processing role of Atg5 in our model. 
 
4.5 Active vs. Adoptive Transfer EAE Model 
The pathogenic steps of active and adoptive transfer EAE are similar and can be subdivided into 
distinct phases (Stromnes and Goverman, 2006a; 2006b). Myelin-specific CD4+ T cells that escaped 
tolerogenic mechanisms are activated in the periphery (Seamons et al., 2003) and migrate via the 
BBB into the CNS (Brabb et al., 2000; Hickey, 1991; Wekerle et al., 1986). Infiltrating cells are 
reactivated by local or infiltrating APCs that present myelin antigen on their surface in the context 
of co-stimulatory molecules (Kawakami et al., 2004; McMahon et al., 2005; Tompkins et al., 2002). 
This leads to a cascade of inflammatory events during which cytokines are secreted and 
macrophages and other APCs are recruited. Macrophages secrete additional pro-inflamatory 
cytokines such as TNF-α and IL-1 which contribute to tissue damage in the CNS (Kuchroo et al., 
2002). The tissue damage causes an additional infiltration of T cells, B cells and APCs. By 
executing their inflammatory effector functions, demyelination is caused and focal plaques in the 
CNS are formed, which, eventually, results in the emergence of disease symptoms (Sospedra and 
Martin, 2005). With regard to clinical disease symptoms, adoptive transfer EAE might yield in 
higher disease severity, a higher rate of incidence and a more synchronous course of disease. But in 
terms of clinical and histological aspects, both models show the same features and characteristics 
(Miller et al., 2010). 
Despite the similarities between active and adoptive transfer EAE, the adoptive transfer EAE model 
brings along some advantages. In adoptive transfer EAE, the effector phase is induced exactly at the 
moment when the already primed autoreactive CD4+ T cells are injected into the recipient mouse. 
This is of particular interest when the infiltration of cells into the CNS is to be investigated. 
Additionally, each pathophysiological step, such as CD4+ T cell priming in the donor, activation 
and expansion of CD4+ T cells in vitro and the effector phase in the recipient mouse, can be 
investigated and manipulated one by one. This progressive analysis enables the separation of 
induction and effector phases. Depending on the in vitro settings used, the effector phenotypes of 
the different T helper subsets can be dissected, which might be beneficial for the characterization of 
T cell effector functions in the CNS. Furthermore, cells to be transferred can be labeled in vitro and, 
thus, tracked in vivo in order to locate and investigate their activities in the recipient. In adoptive 
transfer EAE, there is no antigen depot given that might lead to continuos de novo activation of 
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naïve T cells. (McCarthy et al., 2012; Racke, 2001; Rao and Segal, 2012; Stromnes and Goverman, 
2006a) 
4.5.1 Adjuvant Effect 
4.5.1.1  MOG:CFA Antigen Depot 
In adoptive transfer EAE, autoreactive CD4+ T cells are primed in a donor mouse, restimulated in 
vitro and transferred to a naïve recipient mouse. From the site of injection, the T cells migrate to the 
CNS where they are restimulated by local self-antigen presented on MHC class II molecules. 
During this entire process no peripheral source of CNS antigen is present. On the other hand, in 
active EAE, a peripheral antigen depot constisting the self-antigen, namely MOG peptide or protein, 
is present during the entire experiment. This antigen depot potentially enables continuos de novo 
activation of naïve T cells and might even support migration of T cells back and forth from the 
antigen depot to the CNS. Additionally, the antigen depot allows continuos transport of self-antigen 
to the lymphatic system. 
The antigen depot also contains CFA, which consists of heat-killed Mycobacterium tuberculosis 
that stimulates the innate immune response. CFA is indespensable for the induction of EAE since 
Mycobacterium tuberculosis carries PAMPs that bind TLRs and, in turn, trigger immune responses 
which finally lead to EAE (Marta et al., 2009). Furthermore, CFA greatly affects APCs, which, in 
turn, might also affect all other cells of the immune system and which might have an impact on 
EAE development in this particular mouse system. 
 
4.5.1.2  Presence of Pertussis Toxin 
Another factor that differs between active and adoptive EAE is the use of PTx in the active EAE 
model. PTx’s exact mechanism of action is still unknown, but it is thought to have an impact on 
increasing the BBB permeability and, thus, supporting the migration of effector cells into the CNS 
as it was first described by Linthicum (Linthicum et al., 1982). The theory that PTx may lead to an 
increased permeability of the BBB is further supported by a recent study that showed that PTx 
supports angiogenesis in microvascular endothelial cells of the brain (Lu et al., 2008). Additionally, 
patrolling phagocytes interact with brain capillaries by binding of integrin aM (ITGaM) to 
intercellular adhesion molecule 1 (ICAM1) which is expressed at low levels on capillary surfaces 
under steady state conditions, but is upregulated in response to PTx (Richard et al., 2011). 
Besides of this classical view of action, PTx has also been described as an inhibitor of lymphocyte 
recirculation – involving their inability to localize to lymph nodes or Peyer’s patches (Spangrude et 
al., 1984). When PTx is coinjected with an antigen, it strengthens Th1 and Th2 responses, which 
was shown by increased secretion of IFN-γ and IL-2 by naïve T cells, respectively (Ryan et al., 
1998), and also the induction of high frequencies of peptide-specific Th1 cells (Hofstetter et al., 
2002). Furthermore, PTx has a negative impact on the induction of peripheral T cell anergy and 
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even though one might assume that PTx acts as a superantigen, this assumption could be disproven 
(Kamradt et al., 1991). PTx blocks trafficking of single positive thymocytes via the 
corticomedullary junction, which, ultimately, leads to a disturbed thymocyte distribution in the 
thymus (Suzuki et al., 1999). In terms of regulatory mechanisms during the course of EAE, PTx 
reduces the number of CD4+ CD25+ Tregs and their regulatory capabilities in vivo (Cassan et al., 
2006; Chen et al., 2006). On the other hand, PTx generates IL-17-producing CD4+ cells in an IL-6-
dependent manner (Chen et al., 2007) and promotes the maturation of APCs measured by surface 
expression of MHC class II, CD80, CD86, CD40, and DEC205 and a higher functional capacity 
shown by an increased capacity to stimulate T cells proliferation (Hou et al., 2003). 
The above-mentioned effects of PTx on the immune system illustrate in how many aspects PTx 
might influence the outcome of active and adoptive transfer EAE. Nevertheless, it is rather elusive 
how PTx might mask the effect of Atg5-deficiency in CD11c+ cells in active EAE whereas the 
effect is so prominent in adoptive transfer EAE. 
 
4.6 Future Investigations 
In order to address the question why Atg5-deficiency does have an impact on adoptive transfer 
EAE, but not on active EAE, further in vivo studies need to be performed. To begin with, 
infiltrating T cells in the CNS need to be investigated. A central question is, if T cells do infiltrate at 
comparable levels and which T cell effector functions they feature. In case T cells do not infiltrate 
into the CNS, it might be worth knowing to which organ they do home instead or where they 
accumulate. 
With regard to DCs, it needs to be studied, which DC subsets are present in the CNS, if there is a 
difference between DCAtg5CTRL and DCAtg5KO mice and if DCs got activated at the same level in the 
two different strains. Once the percentage of infiltrating DCs is determined, it would be also 
interesting to specify what their phagocytic and presenting features ex vivo might be. In this context, 
a similar experimental setup as the in vitro co-culture experiments is to be considered. 
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Figure 4.1: Model for the potential role of Atg5 in the development of EAE. Top: Comparison of the factors that 
differ in the induction of active and adoptive transfer EAE in the periphery. The most prominent factors are the presence 
of peripheral antigen and the injection of Ptx during the induction of active EAE. In adoptive transfer EAE, donor mice 
are immunized with MOG peptide and seven days later autoreactive CD4+ T cells are transferred to recipient mice. 
Bottom: Potential mechanisms that might cause the induction of phagocytosis of self-antigen. Processes envolved might 
be entosis, phagocytosis of apoptotic material, FcR-mediated phagocytosis or PAMP/DAMP-mediated phagocytosis or 
other non-antigen processing-related functions of Atg5. Figure based on elements from (Steinman, 2009). 
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